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Abstract 
Plant-derived extracts have been used as folk remedies for Type 2 diabetes mellitus 
(T2DM) for many centuries, and offer the potential of cheap and readily available 
alternatives to conventional pharmaceuticals in developing countries.  Extracts of 
Gymnema sylvestre (GS) and Costus pictus (CP) are reported to have antidiabetic 
activity in vivo. The exact molecular mode of action(s) of GS and CP is unclear but 
the antihyperglycemic effect seen in animal studies was associated with dramatic 
increases in insulin secretion so in my thesis I have examined the effect of alcoholic 
aqueous GS extract, named OSA®, on blood glucose and plasma insulin levels in vivo 
from animals and humans with T2DM and I have measured the effect of GS aqueous 
alcoholic and CP methanolic extracts on insulin secretion in vitro from the MIN6 β-
cell line and isolated mouse and human islets. The in vivo data showed that OSA® 
increased insulin levels and reduced blood glucose in patients with T2DM and 
ameliorated glucose intolerance in animal model of diabetes. The in vitro data 
demonstrated that OSA® and CP have a direct stimulatory effect on insulin 
secretion which was not associated with compromised membrane integrity or 
decreased β-cell viability. OSA®-, but not CP-, induced insulin secretion was 
coupled with elevations in insulin gene expression suggesting that GS may reserve 
β-cell insulin store following chronic stimulation of insulin. 
Single cell calcium microfluorimetry measurements showed that OSA® and CP 
elevated intracellular Ca2+ concentrations ([Ca2+]i) in Fura-2-loaded β-cell, an effect 
which was completely abolished by the removal of extracellular Ca2+ or blockade of 
voltage-gated Ca2+ channels (VGCC). These in vitro observations suggest that one 
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mode of action of OSA® and CP is through stimulating insulin secretion which may 
be mediated, in part, by the ability of OSA® and CP to increase [Ca2+]i levels through 
VGCC. In addition, OSA®-induced insulin secretion was partially associated with 
protein kinase activation and was independent of classical PKC, CaMKII or cAMP 
activation. 
OSA® was also found to protect β-cells from cytokine-induced apoptosis. Our 
measurement of caspase-3 and -7 production showed partial reduction in OSA®-
treated MIN6 cells and mouse islets following cytokines exposure. These data were 
further supported by our microarray analysis of mouse islets when challenged with 
cytokines in the presence of OSA®. Enrichment analysis indicated that OSA® 
reduced caspase-3 gene expression most likely through activation of PI3K/AKT 
pathway and subsequent downstream effectors including MnSOD. 
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SNARE Soluble N-Ethylmaleimide-Sensitive Factor Attachment 
Protein Receptor 
ss    Single stranded 
  List of abbreviations 
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STAT    Signal transducer and activator of transcription 
STZ    Streptozotocin 
SUR    Sulphonylurea receptor 
SUs    Sulphonylureas 
T1DM    Type 1 diabetes mellitus 
T2DM    Type 2 diabetes mellitus 
TBM    Tetramethylbenzidine 
TCF7L2   Transcription factor 7-like 2 (T cell specific) gene 
TG    Triglyceride 
Thr    Threonine 
Tnfaip    Tumor necrosis factor, alpha-induced protein 
TNFR    TNF receptor 
TNF-α    Tumor necrosis factor-α 
Traf    TNF receptor associated factor 
TRAIL    TNF-related apoptosis-inducing ligand 
Trp73    Transformation related protein 73 
Val    Valine 
VAMP    Vesicle-associated membrane protein 
  List of abbreviations 
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VGCC    Voltage gated Ca2+ channels 
VIP    Vasoactive intestinal polypeptide 
WFS1    Wolfram syndrome 1 gene 
WHO    World Health Organization 
Xaf1    XIAP associated factor 1 
Xiap    X-linked inhibitor of apoptosis 
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1.1 History 
It is believed that diabetes mellitus (DM) was known as a disease in as early as 
Egyptian times (1500 BC). However, it was not until the 1st & 2nd centuries when the 
Greeks used the term “Diabetes” to describe the disorder. Diabetes was derived 
from the Greek ward “diabainein” which means “passing through”. The name 
referred to the excessive passing of urine. Although the symptoms of diabetes have 
been further studied in the middle age by Arabs, the “sweetness of urine” was only 
noticed and investigated in the mid of 17th century by Thomas Willis. The early 
classification of diabetes into diabetes mellitus and diabetes insipidus has been 
introduced in the 18th century (Schadewaldt, 1989). In 1869, the islets were 
discovered by Paul Langerhans but the association between these islets and DM 
was first noticed in 1889 when Von Mering and Minkowski induced DM by 
pancreatimizing dogs. After approximately 35 years, a break-through in science was 
made by Banting and Best in collaboration with Macleod and Collip when they were 
able to treat diabetic dogs by administering pancreatic extract which when purified 
led to the discovery of insulin (Pratt, 1989). With the advances in technology, many 
discoveries regarding insulin structure, gene sequence, and diabetes have been 
made. Introducing insulin as a potential treatment of DM in the late 1920 saved 
patients lives. Shortly afterward, the therapy of diabetes was further advanced with 
the introduction of sulphonylurea class of drugs to treat DM especially type 2 DM. 
To date, many other treatments have been introduced for a complete cure and 
management of diabetes. 
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1.2 Structure of the pancreas 
The adult pancreas consists of two parts: exocrine tissue which comprises the 
majority (98-99%) of the pancreas and involves in carbohydrate digestion and 
enzyme secretion and islets of Langerhans which make up only 1-2% of the total 
volume of the pancreas and form part of the endocrine system. Islets of Langerhans 
are composed of at least 5 different types of cells. The size of an islet ranges from 
100-500μM and each islet has 1000-3000 cells. In rodent islets, β-cells, which 
comprise at least 60-80% of islet volume, are located in the center of the islet and 
secrete mainly insulin. Glucagon and somatostatin-secreting cells are called α and δ-
cells, respectively. Both types of cells are localized in the mantle of the islet and 
comprise 10-20% of total cell number. The last two cell types are γ and ε-cells. They 
comprise collectively 1-2% of cell volume. γ-Cells secrete pancreatic polypeptide 
but the exact function of this peptide is unknown (Goodman, 2003, Pipeleers et al., 
1992). Recently, ε-cells have been identified and they secrete ghrelin. Ghrelin may 
be involved in the regulation of insulin release and action. However, the 
physiological role of ghrelin on glucose homeostasis needs to be fully elucidated 
(Tritos and Kokkotou, 2006). In human islets, however; the composition and 
architecture of the islets are different than that of the rodent ones. β-Cells are less 
abundant (48-59%) while α-cells can reach 33-46%. The number of other cells is 
similar to that seen in rodent islets. The distribution of these cells follows random 
patterns with the majority of β-cells are in contact with non-β-cells (In't Veld and 
Marichal, 2010). The pancreatic islets are highly vascularized receiving 
approximately 10-20% of cardiac output through pancreatic afferent arterioles. 
This to ensure a rapid sensing of blood glucose and thus allows for appropriate 
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secretory responses and tight regulation of glucose homeostasis (Ballian and 
Brunicardi, 2007). Cells within islets communicate with each other either through 
gap junctions as seen in β-β cells communication or by releasing hormones locally 
(autocrine and paracrine regulation). 
1.3 Insulin gene and structure 
The insulin gene sequence is highly conserved among higher vertebrates (Table 
1.1) (Harris et al., 1956, Nicol and Smith, 1960). In these species, except rodents, 
insulin is encoded by a single gene (3 exons and 2 introns) and located at short arm 
of chromosome 11. In rat and mouse, insulin is encoded by two genes, insulin I 
where intron 1 is absent, and insulin II. While the rat insulin I and II are colocalized 
on chromosome 1, the mouse insulin I and II are located on two different 
chromosomes. Mouse insulin I is on chromosome 19 and mouse insulin II is on 
chromosome 7. In the presence of an appropriate stimulus, the insulin gene is 
transcribed to preproinsulin (Clark and docherty, 1992). The factors associated 
with the regulation of the transcription of the insulin gene are not completely 
understood but some transcription and growth factors have been implicated in the 
regulation. The transcription to preproinsulin is largely regulated by a highly 
conserved region approximately 36 bp upstream of the initiation start of 
transcription called the insulin promoter. This region is a target of many 
transcription factors including pancreatic/duodenal homeobox 1 (Pdx-1), MafA/L-
Maf and beta2/NeuroD (B2) (Andrali et al., 2008, Poitout et al., 2006). These factors 
are also involved in normal pancreatic development because their total deletions 
result in pancreatic agenesis (Babu et al., 2007). Although these factors have shown 
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to modulate the rate of insulin transcription and stability of insulin mRNA, the 
mechanisms underlying these actions are yet to be determined. 
 
1.4 Insulin synthesis 
Insulin is 5.8 KDa protein consisting of two polypeptides, chain A and chain B, 
which are connected by two disulphide bonds at (A7-B7) and (A20-B-19) with one 
intra bond within A chain at (A6-11) (Goodman, 2003). The structure of insulin is 
shown in Figure 1.1. Insulin is produced by sequential proteolytic cleavage of its 
two precursors: preproinsulin and proinsulin. Preproinsulin is 11.5 KDa and has at 
its N-terminal a 24 aa signal peptide followed by B-chain of 30 aa, an Arg-Arg 
sequence, C-peptide of 31 aa, a lys-Arg sequence and finally A-chain of 21 aa. The 
major function of the signal peptide is to translocate preproinsulin to endoplasmic 
reticulum (ER). In ER, the signal peptide is cleaved by signal peptidase. Proinsulin is 
formed by the removal of the signal peptide and the appearance of disulphide 
bridges. Once proinsulin is formed, it is transported to Golgi apparatus and packed 
in Clatherin-rich vesicles which bud from the trans cisternae of Golgi. During 
maturation, the pH of the vesicle lumen becomes acidic triggering the activation of 
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endopeptidases which are involved in the final cleavage of proinsulin to insulin 
(Bailey et al., 1992, Dodson and Steiner, 1998). Proinsulin conversion to insulin is 
triggered by the removal of C-peptide by the actions of two Ca2+-dependent 
endopeptidases (PC 1/3 and PC 2). PC 1/3 and PC 2 cleave C-peptide at Arg 31-32 
(B-C junction) and lys64-Arg 65 (C-A junction), respectively, generating insulin with 
flanking dibasic residues that are removed by zinc-dependent carboxypeptidase H 
(Smeekens et al., 1992). In the presence of zinc, insulin forms hexamers and 
presents with equimolar concentration with C-peptide. Until recently, C-peptide 
had no known function and was used only as a marker for insulin release but 
accumulating evidence has showed that C-peptide is involved in enhancing glucose 
disposal and improving some of diabetes complications such as neuropathy and 
nephropathy in type 1 diabetes mellitus animal models and patients (Hills and 
Brunskill, 2008, Hills and Brunskill, 2009). In response to appropriate stimuli, 
insulin and C-peptide are released by exocytosis along with residual proinsulin, 
intermediate peptides and peptidases. Insulin is secreted into islet extracellular 
space before being drained into efferent arterioles and the portal vein. Insulin is 
rapidly cleared from the circulation by a specific enzyme called insulinase, which 
can be found in liver (major degradation site), kidney, muscle and other tissues, and 
hence its short half-life (4-5 minutes) (Dodson and Steiner, 1998, Bailey et al., 
1992). 
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1.5 Insulin actions 
Insulin plays a very important role in maintaining energy homeostasis. It primarily 
affects carbohydrate, protein, and lipid metabolism in insulin-sensitive tissues such 
as liver, muscle and adipose tissue. Insulin stimulates glucose uptake into fat and 
muscle tissues via glucose transporter 4 (GLUT4) and promotes the storage of 
glucose and fatty acids as glycogen and triglycerides in muscle and adipose tissues. 
Furthermore, insulin enhances glycogen synthesis by enhancing glycogen synthase 
activity and suppresses the release and production of glucose from the liver via 
inhibiting glycogenolysis and gluconeogenesis (Newsholme et al., 1992, Rang et al., 
2003). The physiological actions of insulin are summarized in Table 1.2. Insulin also 
promotes cell growth, differentiation and survival as part of its mitogenic activities.  
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Recently, insulin has been implicated in maintaining the function of various organs 
of the body including the CNS, heart and kidney (Bertrand et al., 2008, Champe et 
al., 2005, Plum et al., 2006). For example in CNS, insulin regulates energy 
expenditure, peripheral glucose utilization, memory formation and information 
processing (Porte et al., 2005, Plum et al., 2006). 
 
1.6 Mechanism of insulin secretion 
Insulin secretion is primarily regulated by nutrient secretagogues such as glucose, 
free fatty acids and some amino acids. However, it can be largely modified by non-
nutrient secretagogues. The nutrient-induced pattern of insulin secretion consists 
of two phases. The peak of the first phase occurs within 2-5 minutes of glucose 
ingestion and lasts for approximately 10 minutes. This phase involves the release of 
readily releasable pool of secretory granules through the action of KATP channel-
dependent pathway, also known as triggering pathway, in pancreatic β-cells. On the 
other hand, the second phase of insulin release starts shortly after glucose 
administration and is maintained for as long as the glucose level is elevated. This 
phase is associated with the translocation of secretory granules from reserve pools 
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to the readily releasable pool. Many of these granules contain newly synthesized 
insulin. This phase involves the action of KATP channel-independent pathway, also 
known as amplifying pathway (Henquin et al., 2002, Gilon et al., 2002, Bratanova-
Tochkova et al., 2002). 
1.6.1 Nutrient metabolism by β-cells 
Glucose is the major nutrient to stimulate insulin release and glucose metabolism 
within β-cells play a key role in initiating insulin secretion. Glucose enters β-cells by 
facilitated diffusion through specific glucose transporter, GLUT2 in rodents and 
GLUT1, 2 and 3 in human (Bailey et al., 1992, MacDonald et al., 2005). Once glucose 
enters the cells, it is converted to glucose-6-phosphate then to pyruvate by the 
process of glycolysis in nine enzymatic step reactions. Glucose phosphorylation in 
β-cells is governed by high affinity hexokinase (Km ∼ 0.1 mM) and low affinity 
glucokinase (Km ∼ 10 mM). Hexokinase (type 1) is fully saturated and therefore 
fully activated at all physiological glucose concentration, so it does not play an 
important role in glucose metabolism. Unlike hexokinases, glucokinase (formally 
known as hexokinase type 4) is highly specific and fully activated only at 
physiological concentrations of glucose (5-10mM) and thus represents the main 
glucose-sensing component and the rate-limiting step in glycolysis. Although ATP is 
generated at this point, the majority of energy is produced in the mitochondria by 
pyruvate oxidation. Pyruvate is converted to acetyl-CoA which is then oxidized to 
CoA by the citric acid cycle. The pyridine nucleotides, mainly NADH produced from 
citric acid cycle, are oxidized to ATP by the electron transport chain coupled to 
oxidative phosphorylation (Bailey et al., 1992, MacDonald et al., 2005). In addition 
to glucose, free fatty acids (FFAs) and some amino acids (aa) mainly arginine and 
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leucine, also stimulate insulin secretion. FFAs are generated as acetyl-CoA 
derivatives which in the mitochondria are converted to acetyl-CoA and normal 
citric acid cycle and oxidative phosphorylation ensue. On the other hand, amino 
acids undergo transamination to 2-keto acid which enters citric acid cycle to 
provide either precursors or intermediates for oxidation and generation of ATP 
(Bailey et al., 1992, Van Schaftingen and Schuit, 1999). 
1.6.2 β-Cell electrical activity 
β-Cells are highly electrically excitable cells and an important feature of these cells 
is that their electrical activity is linked to the metabolic status of the cells. 
Electrophysiological measurements have specified that the resting membrane 
potential of β-cells is about -70mV. At basal physiological glucose concentration 
(5mM), the resting membrane potential is predominantly dominated by K+ efflux 
through the activity of KATP-channels and Na+/K+-ATPase. Increasing glucose 
concentration causes gradual depolarization to more positive potential (-60--
50mV). When glucose levels (∼ 7mM) exceed the threshold potential, rapid 
depolarization occurs reaching a plateau potential of -40--30mV. The plateau 
potential is characterized by an increase Ca2+ conductance mainly though voltage 
gated Ca2+ channels (VGCC). Repolarization of β-cells to resting potential is achieved 
by promoting K+ efflux though voltage-gated K+ channels and decreasing Ca2+ influx 
by two major ways: accelerating the uptake of Ca2+ into ER through the action of 
Ca2+- pumps and increasing Ca2+ efflux in exchange for Na+ or K+ by the activity of 
Na+/Ca2+ exchanger and Ca2+-K+ channels, respectively. The action potential of β-
cells is characterized by two major aspects. First, once β-cells repolarize, they 
undergo a gradual depolarization forming recurrent cycles of depolarization and 
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repolarization which are better known as slow waves or bursts. Second, the plateau 
potential which is maintained by Ca2+ influx though VGCC superimpose the 
recurrent depolarization spikes that occur at -20 to -10mV (Ashcroft and Rorsman, 
1989, Ashcroft and Ashcroft, 1992, Palti et al., 1996).  
1.6.3 Role of KATP-channels in insulin secretion 
Glucose entry and metabolism within β-cells increase ATP concentration and 
ATP/ADP ratio. Changes in ATP/ADP ratio closes KATP-channels and causes 
depolarization of β-cell membranes. KATP-channels were firstly identified by Cook 
and Hales in 1984 (Cook and Hales, 1984). The functional KATP-channels consist of 
octamer of two different subunits, sulphonylurea receptor (SUR) and inward-
rectifying K+ channel (KIR). SUR is a member of ATP-binding cassette (ABC) 
superfamily. It is encoded by two genes SUR1 and SUR2. SUR1 is mainly expressed 
in β-cells and brain while SUR2, which is further spliced to SUR2A and SUR2B, is 
found in cardiac, skeletal and vascular smooth muscle. The SUR1 represents the 
major site of action of sulphonylurea (SU) drugs. KIR has two splice variant (6.1 and 
6.2). In β-cells, KIR 6.2 forms the ion transport pore (Miki et al., 1999). Depolarization 
of β-cells following KATP-channels closure activates opening of VGCC and Ca2+ influx 
leading to insulin exocytosis and release. This pathway is known as the KATP 
channel-dependent pathway. 
1.6.4 Role of intracellular Ca2+ in insulin secretion 
Ca2+ is a key element in stimulus-secretion coupling in β-cells. The importance of 
Ca2+ stems from the fact that 1) removal of extracellular Ca2+ or blocking of Ca2+ 
channels abolishes glucose-induced insulin secretion; 2) increasing Ca2+ 
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concentration in the incubation medium of permeabilized islet cells is sufficient to 
induce exocytosis of insulin and 3) simultaneous measurement of intracellular Ca2+ 
concentration ([Ca2+]i) and insulin release shows spatial correlation. The basal 
[Ca2+]i is about 50-100nM which increases to 10μM following metabolic activation 
of β-cells, opening of VGCC and entry of Ca2+ down its concentration gradient. 
Opening of VGCC is intermittent causing [Ca2+]i oscillations and pulsatile insulin 
secretion (Ashcroft and Ashcroft, 1992). Five types of VGCC have been identified so 
far (L, T, R, N and P/Q) (Islam, 2010). The L-type VGCC is the major channel 
responsible for Ca2+ entry in both human and rodent while the P/Q-type VGCC is 
also involved in Ca2+-induced exocytosis in human (Braun et al., 2008). Ca2+ itself 
acts as a second messenger. Increasing [Ca2+]i causes further Ca2+ release from ER 
and activation of protein kinases and lipases which largely modulate insulin 
secretion (Howell et al., 1994). 
1.6.5 Role of protein phosphorylation and insulin secretion 
The modification of the availability and concentration of intracellular β-cell second 
messengers such as Ca2+, cyclic nucleotide and products of phospholipids hydrolysis 
by nutrients and non-nutrients secretagogues can induce insulin secretion (Howell 
et al., 1994). These mediators are involved in the activation of several intracellular 
transduction cascades such as Ca2+-calmodulin-dependent kinases (CaMKs) (Figure 
1.2), protein kinase C (PKC) (Figure 1.2), mitogen activated protein kinases 
(MAPKs) (Figure 1.2), protein kinase A (PKA) (Figure 1.3) and arachidonic acid 
(AA) (Figure 1.4) (Jones et al., 1999). 
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1.6.5.1 Ca2+-Calmodulin dependent kinases (CaMKs) 
Ca2+-calmodulin dependent kinases (CaMKs) are a 550 KDa protein composed of 8-
10 subunits. Each subunit has regulatory and catalytic components. They are 
activated by Ca2+ in the presence of Ca2+-binding protein (calmodulin) and 
represent a family of three types of kinases; myosin-light chain kinase (MLCK), 
CaMK II and CaMK III (Jones and Persaud, 1998). Accumulating evidence has 
indicated that CaMK II in particular has a role in initiating and potentiating insulin 
secretion (Figure 1.2). Increased CaMK II activity and phosphorylation of 
endogenous substrates correlate well with increased cytosolic Ca2+ and insulin 
secretion following β-cell exposure to either nutrient or non-nutrient 
secretagogues. Although the endogenous substrates of CaMK II involved in CaMK II-
stimulated insulin secretion are not fully elucidated, CaMK II may trigger exocytosis 
by phosphorylating granule-associated synapsin protein (Easom, 1999, Tabuchi, 
2000). 
1.6.5.2 Protein kinase C 
Protein kinase C (PKC) is found in all cell types and is widely involved in cell 
signaling. It is classified into three major classes according to their sensitivity to 
Ca2+ and diacylglycerol (DAG): 1) typical PKC (α, β, γ) are Ca2+ and DAG dependent, 
2) novel PKC (δ, ε, η, θ) are Ca2+-independent but DAG dependent and 3) atypical 
PKC (ζ, ι/λ, μ) are Ca2+ and DAG-independent (Zhang et al., 2004). The expression 
profiling of PKC isoforms in β-cells has generated conflicting data. However, PKCα, 
βII, δ, ε, ζ, λ/ι and μ have been reported to be present in β-cell lines (Jones and 
Persaud, 1998). Under basal conditions, the typical isoforms of PKC are confined to 
the cytosol but following activation by either cytosolic Ca2+ or DAG levels or both, 
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PKC isoforms are translocated into the plasma membrane or membrane-associated 
organelles (Knutson and Hoenig, 1994). DAG is generated from the breakdown of 
phosphatidylinositol bis phosphate (PIP2) by the action of phospholipase Cβ (PLCβ) 
enzyme. Another by-product of PIP2 is phosphatidylinositol tri-phosphate (IP3) 
which binds to IP3 receptors on ER causing Ca2+ release from intracellular stores 
which further increases cytosolic Ca2+ (Zawalich and Zawalich, 1996). The 
contribution of PKC in overall secretory response to either nutrients or non-
nutrients is well established; however, the exact nature of which PKC isoform is 
involved is still debatable. Activation of PKC augments insulin secretion and the 
downstream effectors may include ion channels and secretory granules (Figure 1.2) 
(Jones and Persaud, 1998). 
1.6.5.3 Mitogen-activated protein kinases (MAPKs) 
MAPKs are ubiquitous enzymes and are activated by dual phosphorylation on 
threonine and tyrosine residues. As the name implies, they are mainly involved in 
mitogenesis and proliferation of cells; however, a non-mitogenic short term effect 
on insulin secretion has been reported. MAPKs are superfamily of kinases divided 
into 1) p42/44 MAPK or ERK, 2) p38 MAPK and 3) stress-activated protein kinase 
(SAP kinase) (Jones and Persaud, 1998). They are activated by a series of upstream 
kinases including Ras, Raf and MAPK kinase. MAPKs especially ERK play a 
permissive role in glucose-induced insulin secretion by phosphorylating certain 
proteins involved in exocytosis machinery (Figure 1.2) (Longuet et al., 2005). 
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1.6.6 Role of cyclic adenylate monophosphate (cAMP) in insulin secretion 
cAMP is an important physiological regulator of β-cell function. It is generated from 
ATP by the action of adenylate cyclase (AC). To date, nine isoforms of AC have been 
identified (AC1-AC9), with type 2 and 3-7 being expressed in rat islets (Leech et al., 
1999). AC isoforms differ in their regulation by α and βγ subunit of GTP-binding 
protein, Ca2+/calmodulin and protein kinases (Table 1.3) (Leech et al., 1999, 
Simonds, 1999, Tian and Laychock, 2001). Elevation of cAMP following glucose or 
receptor operated agonists augments glucose-stimulated insulin secretion at 
several sites in the secretory pathways though protein kinase A (PKA)-dependent 
and independent signaling (Figure 1.3) (Ammala et al., 1993, Christie and Ashcroft, 
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1984, Dachicourt et al., 1996, Thams et al., 2005). PKA is a serine/threonine kinase 
which has two regulatory and two catalytic domains. Two cAMP molecules are 
required to bind to each regulatory domain to release the catalytic activities of PKA. 
The targets of PKA include ion channels, enzymes and exocytosis machinery (Jones 
and Persaud, 1998). Apart from PKA-dependent actions of cAMP, PKA-independent 
activities though Epac molecules also contribute to the cAMP-induced insulin 
secretion. Epac (exchange proteins activated by cAMP) mediates the PKA-
independent actions of cAMP (Shibasaki et al., 2004). In mammals, two variants 
have been identified, Epac 1 and Epac 2, with the latter being the predominant 
isoform in pancreatic β-cells (Leech et al., 2000). cAMP-activated Epac 2 enhances 
insulin secretion through 1) inhibition of KATP-channels leading to depolarization of 
β-cells, 2) activation and phosphorylation of IP3 receptors causing acceleration of 
Ca2+-induced Ca2+ release, 3) stimulation of novel PLC (PLCε) triggering 
phospholipids hydrolysis and formation of DAG and IP3 and 4) activation of small 
GTPase proteins from Ras family (Rab 1 and Rab 2) resulting in exocytosis of insulin 
(Eliasson, 2003, Furman et al., 2010, Hinke, 2009, Kang et al., 2006, Kang et al., 
2008). In addition to the acute effects of cAMP on insulin secretion, cAMP also 
chronically promotes β-cell proliferation and survival mostly through activation of 
MAPKs (mainly ERK) and transcription factors such as cAMP-response element 
binding proteins (CREB) and cAMP-response element modulators (CREM) (Costes 
et al., 2006, Rabinovitch et al., 1980).  
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1.6.7 Role of Arachidonic acid in insulin secretion 
Arachidonic acid (AA) is a product of phospholipid hydrolysis and is generated by 
the action of phospholipase A2 (PLA2) and DAG lipase on phosphatidylcholine and 
DAG, respectively. The majority of AA is produced through PLA2 pathway. There are 
at least three different types of PLA2 expressed in islets: 1) cytosolic PLA2 (type IV), 
Ca2+-independent PLA2 (type VI) and secretory PLA2 (type I and II) (Persaud et al., 
2007). In addition to Ca2+, AA may also act as a second messenger and thus 
regulates insulin secretion in response to nutrient or non-nutrient secretagogues. 
AA may increase insulin secretion by a combination of the following mechanisms 
(Figure 1.4): 1) increasing Ca2+ influx through VGCC, 2) mobilization of Ca2+ from 
intracellular stores and 3) activation of protein kinases, 4) facilitating secretory 
granules fusion and exocytosis (Jones and Persaud, 1993). 
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1.6.8 Mechanism of exocytosis 
Exocytosis is the end-stage of insulin secretion. The process of exocytosis includes 
docking, priming and fusion of secretory vesicles to the plasma membrane to 
release insulin molecules (Regazzi, 1999). Increasing glucose concentrations are 
associated with increased [Ca2+]i and exocytosis of insulin granules. Each β-cell has 
10,000-13,000 insulin-containing granules and each secretory granule contains 
approximately 106 molecules of insulin in addition to other polypeptides, low 
molecular weight molecules such as ATP, GABA, 5-HT and glutamate and high 
amounts of metal ions such as Zn+ and Ca2+ (Eliasson et al., 2008). The factors 
regulating exocytosis of secretory vesicles are not completely understood but may 
involve β-cell cytoskeleton, small GTPases and SNARE proteins (Wang and 
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Thurmond, 2009). These three elements interact to provide optimal responses to 
stimulus-induced insulin secretion. β-cells have dense web of actin filaments and 
microtubules. Glucose, for example, induces actin reorganization and microtubules 
remodeling allowing granules movement and mobilization. Granule docking is also 
enhanced by the action of small GTPases such as Rho, Rab and Ras families. 
However, the regulation of these GTPases is still unclear. Once the granules are 
docked by the action of cytoskeleton and small GTPases, the fusion of secretory 
vesicles to plasma membrane is facilitated by the interaction of vesicle-associated 
membrane protein (VAMP) or v-SNARE and plasma membrane-associated protein 
(SNAP-25 and syntaxin) or t-SNARE. This interaction allows the formation of the 
SNARE core complex and thus fusion pores are formed to release the content of the 
granules. The pores are of different sizes allowing differential release of the granule 
content (Eliasson et al., 2008, Kasai et al., 2010, Regazzi, 1999, Wang and 
Thurmond, 2009). 
1.6.9 Regulation of insulin secretion 
Insulin secretion is tightly regulated by complex of autocrine/paracrine, neurocrine 
and endocrine factors. These factors either potentiate or inhibit glucose-induced 
insulin secretion (Ahren, 1999). Table 1.4 and Figure 1.5 summarize the major 
modulators with their possible mechanism of actions on insulin secretion. 
1.6.9.1 Autocrine/paracrine regulation 
Autocrine regulation of insulin secretion involves insulin itself and polypeptides co-
released with insulin. The released insulin provides a negative feedback mechanism 
and inhibits further insulin release (Persaud et al., 2002). Islet amyloid polypeptide 
(IAPP) and chromogranin A peptides are co-released with insulin from β-cells and 
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considered to be inhibitors of insulin secretion. Although the mechanism of action 
of these polypeptides is not fully elucidated, they may facilitate the opening of KATP-
channels and the inactivation of VGCC (Ahren, 1999). In addition to autocrine 
regulation, paracrine modulation from neighbouring cells has been documented. 
Glucagon stimulates while somatostatin inhibits insulin release through activation 
of G-protein coupled receptor linked to either Gαs (glucagon) or Gαi (somatostatin) 
to increase or decrease cAMP levels, respectively (Porte et al., 1976). 
1.6.9.2 Neuronal regulation 
Insulin secretion is largely modulated by neurotransmitters as islets are highly 
innervated by sympathetic, parasympathetic and sensory nerves (Ahren, 2000). 
Three major neurotransmitters are localized in the sympathetic nerves and are 
released upon activation. They are noradrenaline (NA), galanin and neuropeptide Y 
(NPY). In general, activation of sympathetic nerves inhibits glucose-induced insulin 
secretion. However, the action of noradrenaline on insulin release is species 
dependent. Insulin release is either inhibited (in rodent) or stimulated (in human) 
by noradrenaline acting on α2 or β2 adrenoceptors, respectively. Parasympathetic 
nerves release mainly four mediators upon the activation of the vagus nerve. They 
are acetylcholine (Ach), gastrin releasing peptide (GRP), vasoactive intestinal 
polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). 
Unlike the sympathetic nervous system, parasympathetic activation augments 
insulin secretion induced by glucose. The insulinotropic actions of these 
neurotransmitters are mediated by G-protein coupled receptors linked to either 
activation of phospholipid hydrolysis though PLC (Ach and GRP) and PLD (GRP) 
and elevation of cAMP levels (VIP and PACAP). Sensory neurons also secrete 
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neurotransmitters involved in insulin release modulation. Calcitonin gene-related 
polypeptide from sensory nerves has inhibitory action on insulin secretion through 
reduction of cAMP levels. Nerve fibers other than sympathetic, parasympathetic 
and sensory nerves have also been involved in islet function. The stimulatory action 
of cholecystokinin (CCK) released from islet nerves is mediated through CCK-A 
receptor linked to PLC and PLA2 activation (Ahren, 1999, Ahren, 2000, Porte et al., 
1976).  
1.6.9.3 Endocrine regulation 
Endocrine regulation of insulin secretion is mediated by incretin family of gut 
hormones. The incretin effect is based on the observations that insulin responses 
following oral glucose loads are markedly elevated over the IV-administered 
glucose with similar effect on blood glucose levels. Glucagon-like peptide-1 (GLP-1), 
gastric inhibitory polypeptide (GIP) and CCK are gut hormones secreted from L, K 
and T-cells, respectively, located in the duodenum and jejunum. The potent 
stimulation of insulin secretion induced by these hormones is mediated by 
increased cAMP levels (GLP-1 and GIP) or phospholipid hydrolysis (CCK) (Ahren, 
1999, Granner, 2000). 
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1.7 Diabetes mellitus 
Diabetes mellitus (DM) is the fifth leading cause of death in the world (Roglic et al., 
2005). It is defined as a chronic metabolic disorder characterized by an elevated 
plasma glucose level due to either deficiency in insulin secretion or action or both 
(Williams and Pickup, 2004). The number of people with diabetes is increasing 
dramatically and it is estimated that by the year 2030, 440 million people will be 
affected by diabetes worldwide (Internaional Diabetes Federation, 2009). 
According to the World Health Organization (WHO), three clinical diagnostic 
criteria are recommended. These criteria are as follows: 1) symptoms of diabetes 
plus plasma glucose of 11.1 mmol/L or greater or 2) fasting plasma glucose of 7.0 
Chapter 1  Introduction 
The role of plant extracts on islet function in vivo & in vitro Page | 52  
 
mmol/L or greater or 3) plasma glucose of 11.1 mmol/L or greater at two hours 
following a 75-gram glucose load (World Health organization, 2006). 
Diabetes is divided according to etiology, pathogenesis and treatment into two main 
types: type 1 diabetes mellitus and type 2 diabetes mellitus. Diabetes is a polygenic 
disease; however, monogenic diabetes can affect small percentage of people 
(Turner and Neil, 1992). Monogenic diabetes results from either dominant or 
recessive inheritance of mutation(s) in a single gene. The most well known forms of 
monogenic diabetes are neonatal diabetes and maturity onset diabetes of the young 
(MODY). Neonatal diabetes develops mainly from a mutation in KATP-channel 
subunit, KIR 6.2 gene (KCNJ11), although recently other gene mutations have been 
identified (Nichols and Koster, 2002). On the other hand, the most common causes 
of MODY are mutations in either hepatic nuclear factor isoforms such as HNF-1α 
and HNF-4α or the metabolic enzyme glucokinase (Matschinsky et al., 1993, 
Yamagata, 2003). 
1.7.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM) results from an autoimmune destruction of 
insulin-producing cells leading to a massive reduction in β-cells and insulin 
deficiency. It occurs in 5-10% of all diabetic cases and usually affects children or 
adolescents (Gillespie, 2006). This disease is characterized by the presence of 
humoral (B-cells) and cellular (T-cells) responses against islet antigen (Ag). Thus, 
autoantibodies directed against insulin, glutamatic acid decarboxylase (GAD) and 
protein-tyrosine phosphatase-related molecules have been detected in patients 
with T1DM, in addition to infiltration of islets by CD4+ and CD8+ T-cells (Christie, 
1992, Narendran et al., 2005). T1DM affect people with genetic predisposition to 
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the disease. The major susceptibility genes lie within the human leukocyte Ag (HLA) 
region which is located on short arm of chromosome 6. HLA contributes to ∼ 50% 
of genetic susceptibility to T1DM. These genes encode cell surface protein, major 
histocompatibility complex (MHC), which are responsible for Ag presentation and 
involved in interactions with other immune cells and activation of T-cells. 90% of 
children who develop T1DM early in life have two combinations of HLA genes (DR4-
DQ8 or DR3-DQ2) (Dorman and Bunker, 2000, Wassmuth et al., 1992). Another risk 
locus contributing to 10% of all genetic susceptibility to T1DM is in the insulin gene 
promoter (Knip, 2005, Narendran et al., 2005). 
Twin studies of mono and dizygotes have shown a concordance of 50% and 10%, 
respectively. Thus, environmental factors may also have an influential role in the 
development of the disease because a concordance of 100% would be expected if 
genetic factors were the solely causative factor (Wassmuth et al., 1992). Viral 
infections, especially with rhino virus, may precipitate and aggravate autoimmune 
reaction in genetically susceptible individuals. Other environmental factors have 
been also reported, including cow’s milk and other dietary supplements but the 
data are still not conclusive.(Achenbach et al., 2005, Gillespie, 2006) 
Unless insulin is given as a replacement therapy, patients with T1DM will develop 
severe hyperglycemia and ketoacidosis (Williams and Pickup, 2004). In the absence 
of insulin, glucose cannot enter the muscle and fat cells. As a result, the body starts 
to breakdown fat as a source of energy, producing ketone bodies, which accumulate 
in the blood leading to acidosis; ketoacidosis. Untreated ketoacidosis may lead to 
coma and death. Management of T1DM involves daily insulin therapy and/or islet 
transplantation. Table 1.5 shows the different types of insulin formulations with 
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their onset and duration of actions. Short acting insulin analogues are used to lower 
the immediate rise in postprandial glucose concentrations following ingestion of a 
meal while long acting ones are used to control the rise in glucose levels overnight 
(Knip, 2005, Williams and Pickup, 2004).  Islet transplantation represents a novel 
way to cure diabetes. In this procedure, human islets isolated from brain-dead 
donors are infused into the portal vein of patients with T1DM. Unfortunately, 
scarcity of transplantable islets and the requirement for chronic 
immunosuppression make islet transplantation available to only a few people with 
T1DM. Therefore, alternative therapies such as gene therapy and β-cell 
development from stem cells are now being extensively investigated (Falqui, 2005, 
Knip, 2005, Jones et al., 2008, Williams and Pickup, 2004). 
 
1.7.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is the most common form of the disorder affecting 
nearly 90-95% of overall incidence of diabetes. T2DM develops during adulthood 
around the age of 40 but recently the incidence is rapidly increasing in children due 
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mainly to increasing obesity (Deckelbaum and Williams, 2001, Williams and Pickup, 
2004). It is characterized by a defect in β-cell function (decreased insulin secretion) 
and/or a reduction in insulin responsiveness in insulin-sensitive tissues such as 
liver, muscle and adipose tissue (Figure 1.6) (Cerasi, 1992, Weyer et al., 1999). 
 
T2DM is a multifactorial disease where both genetic and environmental factors play 
a very important role in its development. Environmental factors such as obesity, 
sedentary life style and hormone excess markedly influence the development of 
T2DM in genetically susceptible individuals (Cerasi, 1992). Recently, variations 
within several genetic loci were reported and were associated with an increased 
risk of T2DM as summarized in Table 1.6. The involvement of most genes (except of 
FTO and PPAR-γ genes) in β-cell function and insulin secretion further support the 
role of β-cell dysfunction in the development of T2DM (Frayling, 2007, Horikoshi et 
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al., 2007, Leroith and Accili, 2008, Lindgren and McCarthy, 2008, Sladek et al., 2007, 
Staiger et al., 2007, Zeggini et al., 2008, Zeggini et al., 2007).  
 
The symptoms of T2DM present gradually and patients may remain asymptomatic 
for many years. Symptoms such as polyuria, polydipsia and/or fatigue may be the 
only complaints that patients may suffer from. T2DM is often diagnosed due to an 
abnormal blood or urine glucose on routine physical examination or screening 
(Rang et al., 2003, Steil, 1999).  
1.7.2.1 Complications of T2DM 
Untreated or poorly controlled diabetes mellitus type 2 increases the risk of 
developing macrovascular and microvascular complications, involving many 
different organs of the body (Steil, 1999). Macrovascular complications, which 
involve large vessels, can lead to coronary heart disease, stroke and peripheral 
vascular disease. It has been shown that such complications are responsible for 
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about 70-80% of the mortality among patients with T2DM (Steil, 1999). 
Microvascular complications, which affect small arteries and arterioles, are 
developed as a result of hyperglycemia and may lead to neuropathy, retinopathy 
and nephropathy. Lowering blood glucose reduces the risk of retinopathy, 
neuropathy and nephropathy by 73%, 60% and 54%, respectively (Rang et al., 
2003, Steil, 1999). 
1.7.2.2 Management of T2DM 
Management of T2DM consists of non-pharmacological and pharmacological 
therapies (Rang et al., 2003). Non-pharmacological therapy involves life-style 
modifications such as healthy diet, physical activity, weight reduction and smoking 
and alcohol cessation. If these modifications fail to normalize blood glucose, 
pharmacological therapy should be initiated.  
There are many classes of drugs that have been used to treat type 2 diabetes which 
can be classified as insulin secretagogues and non- insulin secretagogues (Table 
1.7) (Blonde, 2009, Chen et al., 2009). The insulin secretagogues increase the 
release of insulin from β–cells (Lebovitz, 2004, Rang et al., 2003). Sulphonylureas 
and meglitinides are classes of insulin secretagougues drug (Rendell and Kirchain, 
2000). Sulphonylureas enhance insulin secretion by binding to the SUR1 subunit of 
KATP-channel in β-cells, causing a closure of the KATP-channels. Closure of the KATP-
channels is followed by opening of VGCC. Increased [Ca2+]i  triggers exocytosis of 
insulin from storage vesicles (Heine, 1996, Rang et al., 2003, Rendell and Kirchain, 
2000). Sulphonylureas are classified according to their potency, duration of action 
and incidence of side effects, into first generation sulphonylureas (tolbutamide, 
chlorpropamide, acetohexamide and tolazamide) and into second generation 
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sulphonylureas (glibenclamide, gliclazide, glipizide and glimepiride) (Lebovitz, 
2004, Rang et al., 2003, Rendell and Kirchain, 2000). 
The other class of insulin secretagogues is meglitinide analogues. They include 
repaglinide and nateglinide and have no sulphonylurea moiety but have similar 
mechanism of action to sulphonylureas (Lebovitz, 2004, Rendell and Kirchain, 
2000). They block SUR1/Kir6.2 channels and trigger insulin exocytosis from the 
storage vesicles (Chachin et al., 2003, Hansen et al., 2002, Hu et al., 2000).  
The non-insulin secretagogue drugs are biguanides (metformin), insulin sensitizers 
(thiazolidinediones), and α–glucosidase inhibitors. The mechanism of action of 
metformin involves activation of  adenosine monophosphate-activated protein 
kinase (AMPK). Metformin reduces hepatic glucose production and thus improving 
fasting hyperglycemia (Bailey and Krentz, 2010, Lebovitz, 2004). The 
thiazolidinediones (rosiglitazone and pioglitazone) act as peroxisome proliferator-
activated receptor gamma (PPARγ) agonists. PPARγ is part of a heterodimer that 
includes a retinoid X receptor (RXR). The drug-receptor complex binds to response 
elements within the promoter regions of specific genes involved in lipid metabolism 
resulting in either activation or inhibition of gene transcription leading to increased 
insulin sensitivity (Lebovitz and Banerji, 2001).  
Other drugs which can be used are the starch blockers. These agents are α–
glucosidase inhibitors, which inhibit the breakdown of carbohydrates to glucose 
resulting in a decrease in glucose absorption and a lower glycemic peak 
concentration. Examples of these agents are acarbose and miglitol (Lebovitz, 2004, 
Rendell and Kirchain, 2000). 
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Patients with progressive or uncontrolled T2DM may benefit from insulin 
treatment. Improvement in glycemic control has been seen in patients with 
uncontrolled T2DM on SUs or metformin when insulin was added as an add-on 
therapy. 
 
1.7.2.3 New treatment for T2DM 
New therapies for the treatment of T2DM have been introduced in the past few 
years. Some have been already available commercially while others are still in the 
developmental phase. One of the recently introduced class of compounds is the 
incretin-based therapy which involves GLP-1 analogues and dipeptidyl peptidase-4 
(DPP-4) inhibitors (Table 1.8). GLP-1 acts though cAMP-coupled G-protein receptor 
located on β- and α-cells, CNS and GI tract to exert its actions. Binding of GLP-1 to 
its receptor on islet cells causes potentiation of glucose-induced insulin secretion 
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and suppression of glucagon release. It also increases and decreases β-cells survival 
and apoptosis, respectively, at least in studies using experimental animals. Through 
its action on GI tract, GLP-1 slows gastric emptying time leading to a reduction in 
post-prandial blood glucose level. GLP-1 reduces appetite and food intake through 
its action on CNS and thus contributes to weight loss. The therapeutic use of GLP-1 
is limited due to its rapid degradation and inactivation by DPP-4 enzyme.  
Therefore, GLP-1 analogues that are resistant to the action of DPP-4 and DPP-4 
inhibitors that inhibit the activity of the enzyme have been developed. GLP-1 
mimetics include exendin-4, which is originally derived from the salivary secretion 
of the lizard Heloderma suspectum (the Gila moster), and its synthetic form 
exenatide. Another GLP-1 analogue which is yet to be approved by FDA is liraglitide. 
It is a long-acting once daily injection analogue to overcome the short half-life of 
exenatide (t1/2= 3 hours). Sitaglibtin and saxagliptin are both DPP-4 inhibitors and 
result in 2-3 fold enhancements in endogenous levels of GLP-1. Clinically, GLP-1 
analogues and DPP-1 inhibitors improve glycemia but only GLP-1 analogues are 
associated with weight loss and GI effects (Chen et al., 2009, Triplitt, 2007). 
Amylin analogues are a class of compounds that have been recently approved for 
the treatment of T2DM. Pramlintide (table 1.8) is the only synthetic amylin 
analogue available in the market. Amylin is a 37 amino acid peptide co-secreted 
with insulin from β-cells. The actions of amylin involve reduction in glucagon 
secretion in a glucose-dependent manner and delaying gastric emptying time. Both 
actions reduce post-prandial blood glucose concetrations without causing 
hypoglycemia (Chen et al., 2009). 
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Two new classes of drugs, although waiting approval, have been identified as 
potential therapies for T2DM. The first class is type 2 sodium-glucose co-
transporter (SGLT2) inhibitors. SGLT2 is located in the proximal tubule of the 
kidney and is responsible for renal glucose reabsorption. Blocking these co-
transporter prevent reabsorption and increases excretion of glucose in the urine 
thus lowering blood glucose levels. A number of selective inhibitors of SGLT2 have 
been developed and are still in clinical trials (Table 1.9) (Boldys and Okopien, 
2009). The other new class is glucokinase (GK) activators (Table 1.9). Activation of 
GK in β-cells and liver stimulates glucose-stimulated insulin secretion and 
augments hepatic glucose metabolism leading to improvement in glucose clearance 
from the blood stream (Al-Hasani et al., 2003). 
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1.8 Apoptosis pathway 
Apoptosis, or programmed cell death, is a sequence of controlled processes that 
occurs in almost all types of cells leading to cell self-destruction. It is crucial in the 
removal of defective and potentially harmful cells. Impairment or excessive 
stimulation of the apoptotic pathway can lead to various types of diseases, including 
diabetes mellitus. Cells undergoing apoptosis manifest characteristic morphological 
changes such as shrinking of cells, condensation of chromatin, budding of plasma 
membrane and fragmentation of cells into membrane-bound structure called 
apoptotic bodies which contain cytosol, condensed chromatin and organelles 
fragments. These bodies are engulfed by macrophages and are removed without 
triggering inflammatory response. The molecular events underlying these changes 
are quite complex and require activation of certain proteolytic enzymes called 
caspases (Gewies, 2003). 
1.8.1 Caspases: structure and function 
Caspases are cysteine proteases derived from cysteine-dependent aspartate-
specific proteases. The catalytic activities of these enzymes depend on cysteine 
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residue and their substrate cleavage site is after the aspartate residue. To date, 
there are 14 members of the caspase family in mammals with caspase-11 and -12 
being only found in mouse. The caspase family is subdivided, according to their 
function, into two major groups 1) caspase-2, -3, -6, -7, -8, -9 and -10 which are 
activated during apoptosis or 2) caspases that are activated during inflammatory 
process (caspase-1, -4, -5, -11 and -12). In general, caspases are similar in their 
amino acid sequence, structure and substrate specificity. They are synthesized from 
their precursor procaspases which are composed of three domains: N-terminal 
prodomain, a large unit and a small unit. Proteolytic activation of procaspases 
releases the large and small subunits and the active caspase is formed as a 
heterodimer of two small and two large subunits (Creagh et al., 2003). 
The caspases involved in apoptosis (group 1) are further subdivided into two 
categories: 1) initiators (caspase-2, -8, -9, -10) which have long prodomains 
containing either death effector domain (DED) or caspase recruitment domain 
(CARD). They are primarily responsible for initiating the apoptotic cascades. The 
second category involves caspase-3, -6 and -7 which are called effector caspases. 
They have short or absent prodomains and are activated by the initiators. Their 
main function is to amplify the death signal and execute cell death (Creagh et al., 
2003, Gewies, 2003). 
Apoptosis is triggered by various stimuli which activate caspases via several 
pathways: 1) the mitochondrial/apoptosome pathway (intrinsic pathway), 2) the 
death receptor pathway (extrinsic pathway), 3) the endoplasmic reticulum (ER) 
stress pathway and 4) granzyme B-mediated cell death. Although these pathways 
may be initially activated differently; cross-talk between them may occur (Araki et 
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al., 2003, Creagh et al., 2003, Gewies, 2003, Hui et al., 2004, Szegezdi et al., 2006). 
Figure 1.7 shows a schematic representation of some major apoptotic signaling 
pathways. 
1.8.2 Mitochondrial/apoptosome activation of caspases 
The mitochondria play an integral part in both initiation and amplification of 
caspase activation. Cellular stimuli such as heat shock, oxidative stress, cytotoxic 
drugs and DNA damage can initiate caspase activation through permeabilization of 
the mitochondrial outer membrane. The disruption of the mitochondrial potential 
causes the release of cytochrome C and other mitochondrial factors into the cytosol. 
The permeability of mitochondrial outer membrane and the release of cytochrome 
C are largely regulated by pro-apoptotic and anti-apoptotic members of Bcl-2 
family. The release of mitochondrial factors is inhibited by anti-apoptotic members 
of Bcl-2 such as Bcl-2 and Bcl-xL, and promoted by pro-apoptotic Bcl-2 members 
such as Bax, Bak, Bad, Bim and Bid. The released cytochrome C binds to a 
monomeric cytosolic protein called Apaf-1 (apoptosin protease activating factor-1) 
which undergoes conformational changes and oligomerizes in the presence of dATP 
(deoxy adenosine triphosphate) with procaspase-9 forming an apoptosome, a 
heptomeric wheel-like structure. The activated apoptosome triggers the activation 
of caspase-9 which leads to subsequent stimulation of effector caspase-3 and -7. 
Caspase-3 further stimulates caspase-2 and -6 which indirectly activates caspase-8 
and -10. Caspases affect several downstream effectors to execute cell death. One of 
the final targets of caspases is ICAD (inhibitor of caspase-activated DNase). 
Activation of caspases inactivates ICAD and cause the release of its DNase subunit 
(CAD). Caspase-activated DNase (CAD) enters the nucleus and fragments DNA 
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leading to the formation of “DNA ladder”, a characteristic commonly seen in 
apoptotic cells (Creagh et al., 2003, Gewies, 2003, Hui et al., 2004).  
1.8.3 Death receptor pathway 
Death receptors are cell surface receptors that are involved in transducing the 
death signal and they belong to TNF receptor (TNFR) superfamily. The TNFR has a 
conserved sequence in the cytoplasmic part of the receptor called the death domain 
(DD). Upon binding of extracellular ligands such as TNF, Fas ligand (FasL/CD95L) 
or TNF-related apoptosis-inducing ligand (TRAIL) to the receptor, oligomerization 
and conformational changes occur in the receptor. Adaptor molecules such as Fas-
associated death domain (FADD) proteins are recruited to the receptor by their 
own DD to form death-inducing signaling complex (DISC). FADD also possesses 
death effector domain (DED) and forms homotypic DED-DED interaction with DED-
containing procaspase-8 leading to proteolytic activation and release of active 
caspase-8. The death signal generated upon the activation of caspase-8 can be 
transmitted by two mechanisms according to cell types. In type I cells, the 
stimulation of death receptor results in sufficient activation of caspase-8, which, in 
turn, activates downstream caspases which result in cell death. On the other hand, 
the signal generated from death receptor in type II cells is not strong enough to 
elicit a direct and full activation of caspase cascades; therefore, the signal is 
amplified by mitochondria-dependent activation of caspases. The active caspase-8 
cleaves Bid of the Bcl-2 family. The truncated form of Bid is then translocated to the 
mitochondria where it activates Bax and Bak. These pro-apoptotic factors induce 
cytochrome C release, apoptosome assembly and activation of effector caspases 
(Creagh et al., 2003, Gewies, 2003, Hui et al., 2004). 
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1.8.4 ER stress mediated caspase activation 
The ER is a vital organelle for post-translation modification, folding and assembly of 
proteins and storage of intracellular Ca2+. Thus, defective folding, accumulation of 
misfolded protein and alteration in Ca2+ homeostasis can precipitate ER stress. ER 
stress triggers apoptosis by four major pathways. The first is through induction of 
transcription of CHOP (C/EBP homologous protein/GADD153), also known as 
growth arrest and DNA damage-inducible gene (GADD). Its major actions involve 
reduction in Bcl-2 protein expression and increased translocation of Bax into the 
mitochondria. The second is through activation of the JNK (c-Jun NH2-terminal 
kinase) pathway which in turn regulates gene expression of proteins associated 
with apoptosis and survival. The third is by activating caspase-12 especially in mice. 
The final pathway is through stimulation of pro-apoptotic Bcl-2 family (Araki et al., 
2003, Szegezdi et al., 2006). 
1.8.5 Granzyme B-mediated cell death 
Activation of cytotoxic T-cells and natural killer cells can trigger the release of 
cytosolic granules which contain proteins responsible for initiating apoptosis. 
Perforin, one content of the granule, is a protein that functions by forming pores 
into the target cells to facilitate the entry of other granule components such as 
granzyme B. Granzyme B is a serine protease which cleaves aspartate-containing 
proteins involved in the apoptosis cascades. The major substrates of granzyme B 
are caspase-3, caspase-8 and Bid. Granzyme B-mediated Bid activation involves 
cleavage of Bid to produce a fragment, gtBid, which is then translocated into the 
mitochondria causing the release of cytochrome C and the assembly of apoptome 
(Creagh et al., 2003, Hui et al., 2004).   
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1.8.6 Regulatory mechanisms in apoptosis 
1.8.6.1 Bcl-2 family and IAPs 
Apoptosis and caspase activation are tightly regulated by a set of various pro and 
anti-apoptotic molecules such as Bcl-2 family and inhibitors of apoptosis proteins 
(IAPs). Members of Bcl-2 family are proteins containing conserved sequence motifs 
known as Bcl-2 homology domains (BH1 to BH4). Bcl-2 family consists of 
approximately 30 members which can be divided into anti and pro-apoptotic 
subgroups. The anti-apoptotic group includes Bcl-2 and Bcl-xL and posses the 
Chapter 1  Introduction 
The role of plant extracts on islet function in vivo & in vitro Page | 68  
 
domain BH1,2,3,4 whereas the pro-apoptotic group includes two subdivisions 1) 
the Bax members such as Bax and Bak which contain the domain BH1,2,3 and 2) the 
BH3-only proteins such as Bid, PUMA, NOXA, Bim and Bad which have BH3 as the 
only domain. The function of the Bcl-2 family is to control mitochondrial outer 
membrane integrity and thus the release of cytochrome C and mitochondrial 
factors. The Bcl-2 family members interact and regulate the activity of each other. 
Under basal condition, the anti-apoptotic Bcl-2 members bind to the pro-apoptotic 
Bax-related members and thereby inhibit Bax or Bak activation. However, upon the 
arrival of an apoptotic stimulus, the BH3 only proteins interact with the anti-
apoptotic members on the outer mitochondrial membrane to remove the inhibition 
of anti-apoptotic proteins imposed on the pro-apoptotic Bax members and thus 
promote their release. The Bax-related proteins integrate into the mitochondrial 
membrane contributing to the permeability of its outer membrane and the release 
of pro-apoptotic proteins (Gewies, 2003, Hui et al., 2004). 
The other group of proteins which are very important in caspase regulation are 
IAPs. IAPs are a family of anti-apoptotic proteins that are transactivated by nuclear 
factor κB (NF-κB). Eight members of IAPs have been identified in human. The 
function of XIAP, c-IAP I and c-IAP TT is to directly inhibit caspase-3,-7 and -9 
(Gewies, 2003, Hui et al., 2004). 
1.8.6.2 PI3K/AKT pathway 
Survival pathways are also activated to regulate apoptosis and one important 
pathway is the PI3K/AKT pathway. Activation of G-protein coupled receptors or 
tyrosine kinase receptors can recruit specific SH2-domain containing proteins 
including phosphotidyl inositol-3 kinase (PI3K). PI3Ks are heterodimeric proteins 
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that initiate signaling cascades through the phosphorylation of phosphotidyl 
inositol at the 3' position of the inositol ring to produce phosphatidylinositol 3-
phosphate (PtdIns-3-P), phosphatidylinositol 3,4 bisphosphate (PtdIns-3,4-P2) and 
phosphatidylinositol 3,4,5 triphosphate (PtdIns-3,4,5-P3). These lipid products act 
as second messengers that activate several cellular target proteins such as AKT 
(Cantrell, 2001). AKT is a serine/threonine protein kinase and three isoforms (AKT 
1, AKT 2, and AKT 3) have been identified in human to date. AKT exhibits its anti-
apoptotic actions by modifying the activities of certain protein and transcription 
factors. AKT phosphorylates Bad and thus inhibits its activation. AKT also activates 
NF-κB-mediated expression of pro-survival genes by regulating IκB kinase (IκK) 
activity. Activation of AKT also affects transcription factors such as Forkhead 
transcription factors (FKHR). AKT phosphorylates three members of forkhead 
transcription factors namely FOX1 (previously known as FKHR), FOX3 (previously 
known as FKHRL1) and FOX4 (previously known as AFX). AKT-mediated 
phosphorylation of these transcription factors promotes transcription inactivation 
and nuclear exclusion. Forkhead transcription factors are involved in the regulation 
of cell apoptosis (Kim and Chung, 2002, Rena et al., 1999). 
1.9 β-cell death in diabetes mellitus 
β-cell mass is tightly controlled by a balance between proliferation and neogenesis  
on one side and apoptosis and necrosis on the other side (Figure 1.8) (Lupi and Del 
Prato, 2008). Dysregulation of this balance can precipitate loss of β-cell mass and 
susequent diabetes. The reduction in β-cell mass is caused by either a decrease in 
proliferation or an increase in apoptosis with the latter being the most predominant 
factor. Increased apoptosis has been reported in both types of diabetes and it is 
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responsible for 80% and 50% loss of β-cells in T1DM and T2DM, respectively 
(Donath and Halban, 2004, Porte and Kahn, 2001). In general, there are three main 
factors that may initiate apoptosis and contribute to the loss of β-cell volume: 1) 
cytokines, 2) hyperglycemia and 3) dyslipidemia (Cnop et al., 2005, Donath and 
Halban, 2004, Eizirik and Mandrup-Poulsen, 2001, Johnson and Luciani, 2010, Lupi 
and Del Prato, 2008, Mandrup-Poulsen, 2001, Robertson et al., 2004). 
 
1.9.1 Cytokine-induced β-cell death 
Several inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis 
factor-α (TNF-α) and interferon-γ (INF-γ) are involved in mediating β-cell death. 
They are secreted by islet-infiltrating leucocytes (T-cells and macrophages) 
especially during the development of T1DM. An individual cytokine alone is not 
enough to elicit cell lysis but rather their combinations promote β-cell dysfunction 
and death. The susceptibility of β-cells to the cytotoxic effect of an individual 
cytokine is dramatically increased when two or more cytokines are combined 
together. The exact nature of the cytokine mixture that is able to produce the 
strongest death signal in T1DM is unclear, although a synergism of IL-1β + INF-γ, 
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TNF-α + INF-γ and IL-1β + TNF-α have been reported (Kim and Lee, 2009). Short 
term exposure of β-cells to cytokines impairs β-cell function due to downregulation 
of important genes involved in insulin secretion such as insulin, GLUT-2, 
glucokinase and PDX-1 (Cnop et al., 2005, Donath et al., 2010, Donath et al., 2003, 
Eizirik and Mandrup-Poulsen, 2001, Johnson and Luciani, 2010). 
The binding of IL-1β, TNF-α and INF-γ to their receptors on β-cells stimulate district 
signaling pathways leading to the activation of multiple transcription factors 
(Figure 1.9). IL-1β and TNF-α exert their action through activation of NF-κB 
pathway. NF-κB is a transcription factor involved in cellular stress response, cell 
growth, survival and apoptosis. It normally dimerizes with inhibitor of NF-κB (IκB) 
in the cytosol preventing its translocation into the nucleus. Upon cytokine 
activation, IκB kinase (IκK) phosphorylates IκB and facilitates its degradation by 
the proteasome. NF-κB is freed and translocated into the nucleus to regulate the 
promoter activity of genes encoding important proteins involved in the β-cell 
apoptosis pathway such as inducible nitric oxide synthase (iNOS), pro-apoptotic 
Bcl-2 family and Fas. Expression of iNOS and subsequent formation of nitric oxide 
(NO) disrupt β-cell mitochondrial glucose oxidation and deplete ER Ca2+ store 
leading to ER stress and destruction of β-cells. In addition to the activation of NF-κB 
pathway, IL-1β also activates members of MAPK family, namely p38, ERK and JNK. 
ERK and p38 pathways contribute to the production of nitric oxide (NO) while JNK 
signaling cascade negatively regulates the activity of pro-survival members of Bcl-2 
family and thus promotes apoptosis (Cnop et al., 2005, Donath et al., 2003, Melloul, 
2008). 
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INF-γ, on the other hand, stimulates mainly the action of JAK/STAT-1 pathway. JAK 
(Janus kinase) is a tyrosine kinase and following activation by INF-γ, it 
phosphorylates STAT (signal transducer and activator of transcription)-1 which 
dimerizes in the cytosol and is translocated into the nucleus to up-regulate the 
expression of major mediators in β-cell death such as INF-γ regulatory factors-1 
(IRF-1), MHC class I and iNOS (Cnop et al., 2005, Gysemans et al., 2008). Although, 
the involvement of cytokines in the pathogenesis of T1DM is well defined, the role 
of cytokines especially IL-1β in β-cell death in T2DM is controversial. A group of 
researchers reported that glucose induced IL-1β production and contributed to β-
cell death in T2DM (Maedler, 2002). However, this was challenged by others who 
reported that the IL-1β pathway was not activated in human islets following 
glucose challange (Welsh et al., 2005). 
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1.9.2 Hyperglycemia-induced β-cell death 
Elevated levels of plasma glucose (hyperglycemia) are the major characteristic of 
T2DM. Glucotoxicity is a phenomenon where chronic elevations of glucose 
concentrations cause impairment of β-cell function and insulin sensitivity. Long 
term exposure of β-cells to high glucose levels has been associated with increased 
apoptotic rate though oxidative stress and mitochondrial activation of caspases. 
Activation and generation of reactive oxygen radicals (ROS) following excessive 
glucose metabolism blocks mitochondrial respiration, diminishes glucose-induced 
insulin secretion and activates apoptosis. Chronic hyperglycemia results in chronic 
stimulation of insulin biosynthesis. This will increase the metabolic demands on β-
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cells as a result of an increased insulin output. Increased synthesis rate of 
proinsulin increase protein flux though ER precipitating ER stress and apoptosis 
(Donath and Halban, 2004, Evans, 2002, Johnson and Luciani, 2010, Maiese et al., 
2007, Poitout and Robertson, 2008, Robertson et al., 2004). 
1.9.3 Dyslipidemia-induced β-cell death 
Obesity is a major risk factor of T2DM and is associated with increased circulating 
free fatty acid (FFA) levels. Chronic elevations in FFAs impair β-cell function and 
promote β-cell death by apoptosis. These deleterious effects of FFA are linked to 
saturated, but not unsaturated, fatty acids. This is due to the ability of unsaturated 
fat to form intracellular triglyceride (TG). The induction of β-cell death by FFA is 
mediated by a number of mechanisms including: 1) accumulation of lipid-derived 
metabolites, most importantly ceramide, 2) generation of ROS and subsequently 
oxidative stress and 3) increased NO production and ER stress. Increased ceramide 
synthesis is a key component of FA-induced β-cell apoptosis. In addition to the 
ability of ceramide to cause oxidative stress, it also inactivates pro-survival signals 
mediated by phosphotidylinositol 3-kinase/protein kinase B (PI3K/PKB). Ceramide 
blocks PKB activation thus removes the imposed inhibition on some of the pro-
apoptotic effectors such as Bad and caspase-9 (Figure 1.10) (Donath and Halban, 
2004, Evans, 2002, Poitout and Robertson, 2008, Robertson et al., 2004).  
FFAs have also been reported to modulate islet function through a number of lipid-
binding GPCR including GPR40, GPR41, GPR43 and GPR119 in which GPR40 is the 
most extensively studied. It is thought that acute exposure of islets to FFAs 
potentiated glucose-induced insulin secretion via GPR40. However, chronic 
activation of GPR40 by FFAs in islets may lead to deterioration in islet function and 
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impairment in glucose-induced insulin secretion as reported in studies using 
genetically modified animals. It has been reported that glucose-induced insulin 
responses were restored in high fat fed GPR40 -/- knockout mice (Winzell and 
Ahren, 2007). 
 
1.10  Phytochemicals as potential novel treatment for T2DM 
Currently, there is a trend towards the development of new drugs for the 
management of T2DM. Currently available drugs reduce hyperglycemia either by 
increasing insulin secretion or reducing insulin resistance as detailed in section 
1.7.2.2. Development in T2DM management techniques involves production of 
agents that target β-cell function. Among the available drugs used to manage T2DM, 
sulphonylureas and incretin-based therapy are the only classes that affect the 
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function of β-cells. The increased rate of failure with the use of sulphonylureas, up 
to 25% failure rate/year (Steil, 1999), and the deleterious effect of these drugs on 
cardiac and vascular functions during ischemia (Smits et al., 1996) have limited 
their usage as a first-line therapy in patients with T2DM. Similarly, issues 
concerning long-term safety and cost of incretin-based therapies have also 
shadowed the use of these drugs in the treatment of T2DM. Incretin-based 
therapies mainly GLP-1 analogues are expensive and available in injection forms 
which may be inconvenient for patients with T2DM. In addition, they have been 
associated with incidence of acute pancreatitis in vivo and increase risk of tumor 
growth in vitro (Persaud and Jones, 2008). Therefore, identifying new or β-cell 
targeted drugs for the treatment of T2DM is an area of active research.  
 Herbal medicines have attracted attention as alternative therapeutic agents 
for treating T2DM because they are relatively inexpensive and many have been 
used for decades or centuries without deleterious side effects (Swanston-Flatt et al., 
1991). One successful example of plant-derived antidiabetic drug is metformin. 
Metformin, which was originally isolated from Galega officinalis, is now one of the 
standard treatment of T2DM.. A recent report has shown that 35-48% of patients 
with diabetes use alternative medicine (Garrow and Egede, 2006, Yeh et al., 2003). 
Ethnopharmacological studies have reported that approximately 800 plants may 
have anti-diabetic activity (Alarcon-Aguilara et al., 1998). Nevertheless, few have 
been shown to be effective in treating the symptoms of T2DM in rodents and 
humans, and their mechanisms of action are uncertain. Two of these promising 
plant extracts are Gymnema sylvestre and Costus pictus. 
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1.11   Gymnema sylvestre 
Gymnema sylvestre (GS) is a large woody climber plant, from the Asclepiadaceae 
family, and is native to central and southern India, tropical Africa and Australia. A 
five year old plant is shown in Figure 1.11. This plant has been used as an ayurvedic 
medicine for the treatment of diabetes in India for centuries. It was also used in 
treating eye diseases, dental decay, rheumatic arthritis and gout (Kanetkar et al., 
2007, Leach, 2007). 
The first scientific and experimental study of GS was started during the early 1930s 
by Mhaskar and Caius who found that the leaves of GS had the ability to reduce 
blood glucose levels in rabbits (Mhaskar and Caius, 1930).  Since then, a lot of effort 
and work have been spent to identify the pharmacological actions and the chemical 
composition of this plant.  
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1.11.1 Chemical composition of Gymnema sylvestre 
Different chemical constituents have been isolated and characterized from the 
leaves of GS during the past years. The GS leaves contain oleanane and dammarene 
classes of triterpene saponins. gymnemic acids and gymnemasaponins are 
Oleanane saponins. At least 17 different gymnemic acids and 7 different types of 
gymnemasaponins have been identified. Gymnemasides, components of GS, belong 
to the dammarene saponins group. There are 6 members of gymnemasides (A-F). In 
addition, a number of other constituents have also been reported in GS leaves (Arai 
et al., 1995, Liu et al., 2004, Manni and Sinsheimer, 1965, Murakami et al., 1996, Rao 
and Sinsheimer, 1971, Sahu et al., 1996, Sinsheimer and McIlhenny, 1967, 
Sinsheimer and Rao, 1970, Sinsheimer et al., 1970, Ye et al., 2000, Yoshikawa et al., 
1997a, Yoshikawa et al., 1997b, Zhu et al., 2008). Table 1.10 lists the components 
that have been isolated from the GS leaves. 
GS leaves have been shown to have anti-diabetic, anti-sweetener, anti-dental caries 
and anti-viral activities. These actions are believed to be mostly mediated by 
gymnemic acids (GA), although contribution of the remaining isolates is also 
possible (Porchezhian and Dobriyal, 2003). 
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1.11.2 Pharmacological actions of Gymnema sylvestre 
1.11.2.1 Effect on glucose homeostasis 
GS dried leaves or aqueous alcoholic extracts have been shown to lower blood 
glucose levels in both animal and human studies. During the 1960s, Gupta and his 
co-workers reported that GS had an inhibitory effect on hyperglycemia induced by 
adrenaline, somatotropin and corticotrophin (Gupta, 1961, Gupta, 1963, Gupta and 
Variyar, 1961, Gupta and Variyar, 1964). In an attempt to identify the possible 
mechanism of actions of GS, several studies were conducted. The antihyperglycemic 
effect of GS was reported to be due, in part, to the ability of plant leaf extract to 
increase insulin secretion from β-cells of the islets of Langerhans. In a study done 
by Shanmugasundaram et al. 1981, the effect of chronic oral GS administration on 
glucose and insulin levels was assessed in alloxan-treated rabbits. The results 
showed that in fasting and post-prandial conditions there were reductions in blood 
glucose levels and elevations in insulin concentrations in GS-treated diabetic 
animals in comparison to control animals (Shanmugasundaram et al., 1981). Other 
research groups reported that single or chronic ingestion of GS attenuated the 
increase in blood glucose levels and raised insulin levels during oral glucose or 
sucrose tolerance test in alloxan- or STZ- treated rats (Okabayashi et al., 1990, 
Shanmugasundaram et al., 1988, Srivastava et al., 1985, Srivastava et al., 1986) 
The insulin-releasing effect of GS was further reported by subsequent studies. In a 
study done by Shanmugasundaram et al 1983, oral administration of a dried leaf 
powder of GS increased enzymes activities involved in glucose utilization by an 
insulin- dependent pathway (Shanmugasundaram et al., 1983). A Japanese team led 
by Sugihara tested the effect of 4 gymnemic acids (GA I-IV). They found that GA-IV, 
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unlike the other fractions, caused a concentration-dependent fall in blood glucose 
levels correlated with a rise in insulin concentration in STZ diabetic mice (Sugihara 
et al., 2000). 
In addition to the insulin-releasing activity of GS, GS alcoholic extract may also 
protect β-cells from damage during the development of diabetes. Histological and 
morphological studies of pancreata from GS-treated STZ diabetic animals showed 
an increased number of β-cells compared to untreated diabetic rats. Regeneration 
or repair of islets of Langerhans may therefore be a possible effect of GS (Ahmed et 
al., 2010, Shanmugasundaram et al., 1990a). 
Suppression of glucose absorption from the small intestine may also contribute to 
the antihyperglycemic effect of GS aqueous alcoholic extract. A study performed by 
Shimizu et al. (1997) showed that gymnemic acids from GS leaves inhibited glucose 
uptake through interfering with Na+-glucose co-transport system (Shimizu et al., 
1997a). Similar results were obtained from other studies (Fushiki et al., 1992, 
Shimizu et al., 1997b, Shimizu et al., 2001). 
The effectiveness of GS in controlling hyperglycemia was also tested in patients 
with diabetes (Balasubramaniam et al., 1988, Khare et al., 1983, 
Shanmugasundaram et al., 1981). Twenty two patients with T2DM and 27 patients 
with T1DM on conventional oral anti-hyperglycemic drugs and insulin therapy, 
respectively, were given 400mg/day GS alcoholic extract. In both groups, the 
patients showed a significant decrease in blood glucose level. In patients with 
T2DM, there was a reduction in their drug requirements. Similarly, in patients with 
T1DM, the insulin requirement came down after GS supplementation although the 
mechanism by which GS improved T1DM was not clear and may not be directly 
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mediated by insulin release (Baskaran et al., 1990, Shanmugasundaram et al., 
1990b). 
1.11.2.2 Effect on lipid metabolism 
Alteration in lipid metabolism contributes to the development of T2DM and 
increased levels of fatty acids, triglyceride, and cholesterol are seen in patients with 
diabetes. The influence of GS on lipid metabolism has been investigated by a 
number of researchers. Shigematsu et al. (2001) studied the effect of ethanol/water 
extract of GS on liver lipids. Oral administration of GS to high fat fed rats markedly 
reduced liver cholesterol and triglyceride levels and prevented fat accumulation in 
peritoneal cavity (Shigematsu et al., 2001). Furthermore, GS promoted fecal 
excretion of steroids in high fat fed animals as reported in a number of studies 
(Nakamura et al., 1999, Terasawa et al., 1994). Wang et al (1998) also reported that 
GS can alter lipid absorption by reversibly inhibiting oleic acid absorption in rat 
intestine, in a dose-dependent manner (Wang et al., 1998). 
1.11.2.3 Effect on sweet receptors 
The leaves of GS were formally called "Gurmar", an Indian word that means sugar-
destroying. GS extract reversibly suppressed the sweetness of sucrose, sodium 
saccharin, glycine and alanine (Meiselman and Halperin, 1970, Meiselman and 
Halpern, 1970, Warren et al., 1969). The mechanism by which GS modulates sweet 
taste is not completely understood but may involve blockage of sweet taste 
receptors by either gurmarin, a peptide found in the GS leaves, or by GA, a 
triterpene saponin (Imoto et al., 1991, Ninomiya and Imoto, 1995, Suttisri et al., 
1995, Yackzan, 1969, Ye et al., 2001). It is postulated that this effect may reduce 
sugar craving contributing to the antidiabetic effect of GS. 
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1.12   Costus pictus 
Costus pictus (CP), commonly known as spiral ginger, belongs to the Costaceae 
family and grows in gardens as an ornamental climbing plant. It was originated in 
Mexico and introduced recently into the southern states of India. CP has shown to 
have antidiabetic and antioxidant activities (Benny, 2004, Jayasri et al., 2009b). 
The first report examined the activities of CP showed that the leaves of this plant 
were responsible for the antidiabetic properties of CP (Benny, 2004) . The primary 
analysis of the CP leaves identified several chemical compounds including saponins, 
alkaloids, tannins, glycosides and flavonoids that may mediate the beneficial actions 
of CP on diabetes (George et al., 2007). 
 
1.12.1 Antidiabetic actions of CP 
The glucose-lowering activity of CP leaves methanolic extract has been tested 
chronically in animals in vivo, where it was reported to reduce blood glucose levels 
in rats in which hyperglycemia had been induced by administering the β-cell toxins 
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alloxan or streptozotocin (STZ). Thus, 28 days oral administration of methanolic CP 
extract to hyperglycemic rats at 2 gm/kg body weight induced a significant 
(p<0.001) reduction in fasting blood glucose levels (Jayasri et al., 2008). Similarly, 
Jothivel et al. also reported a reduction in blood glucose concentrations following a 
21 day regime with methanolic extract of CP leaves in alloxan-treated rats (Jothivel 
et al., 2007). The precise mechanism of the glucose-lowering effect of CP is not 
completely clear but it may be due, in part, to a direct stimulation of insulin 
secretion from pancreatic β-cells. Several studies have shown that the reduction of 
blood glucose in CP-treated animals was associated with increased in plasma 
insulin levels (Benny, 2004, Jayasri et al., 2008, Jothivel et al., 2007).  
The antihyperglycemic activity of CP may also be due to a reduction in 
carbohydrate absorption. Jayasri et al. reported that aqueous CP extract inhibited 
the activities of α-amylase and α-glucosidase enzymes. Thus CP may prevent the 
breakdown of carbohydrates and suppress glucose absorption (Jayasri et al., 
2009a). 
Improving insulin responsiveness in insulin-sensitive tissues may also contribute to 
the antidiabetic effect of CP. In a study done by Shilpa et al., an extract of CP induced 
GLUT4 translocation and increased glucose uptake in insulin-responsive tissues 
(Shilpa et al., 2009). 
1.13  Aims and Objectives 
Most biologically active compounds isolated from GS leaves have relatively low 
molecular weights (Murakami et al., 1996, Sinsheimer and Rao, 1970, Sinsheimer et 
al., 1970, Sugihara et al., 2000), and the previously documented glucose-lowering 
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activities of GS  have been attributed to these low molecular weight components.  In 
this thesis I used a high molecular weight aqueous alcoholic GS extract (Chatterji, 
2005a, Chatterji, 2005b) which was subsequently designated as the OmSantal 
Adivasi extract (OSA®) after the Santal tribe who first used GS leaves in Ayurvedic 
medicine. Therefore the main aim of this thesis was to examine the role of OSA® 
and on islet function and to compare OSA® profile to a methanolic extract of CP, 
another promising plant extract. The detailed objectives are listed below: 
Thesis objectives were: 
 To test the hypothesis that OSA® and methanolic extact of CP have a 
direct insulinotropic action on β-cells using MIN6 cells, a β-cell line, 
and primary islets in perfusion experiments. 
 To test the dependence of OSA® and CP on intracellular Ca2+ 
concentrations in fura-2-loaded MIN6 cells and dispersed mouse 
islets using single cell Ca2+ microfluorimetry technique. 
 To examine the chronic effect of OSA® on insulin gene expression 
and biosynthesis. 
 To measure the effect of OSA® on intracellular cAMP levels in MIN6 
cells and mouse islets. 
 To explore the possible signaling pathways activated following OSA® 
exposure using pharmacological inhibitors of VGCC and protein 
kinases. 
 To determine the effect of OSA® on glucagon secretion from mouse 
islets. 
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 To determine the effect of OSA® on β-cell mass and apoptosis by 
measuring caspase levels in MIN6 cells and mouse islets and 
identifying the possible underlying pathways of the cytoprotective 
effect of OSA® using microarray gene expression. 
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2.1  Plant material and preparation 
2.1.1 Gymnema sylvestre extract 
The GS extract used in this study (OSA®) was prepared by extracting fresh GS 
leaves by aqueous alcohol according to the protocols described in the US Patents 
6949261 and 6946151 (Chatterji, 2005a, Chatterji, 2005b). Briefly, GS leaves were 
soaked first in water for 18 hours (1 Kg/4 L) and then aqueous alcohol (40% 
ethanol) for 4 hours at room temperature. The solution was filtered and then 
treated with sulphoric acid to recrease the pH to 2. Any acid-insoluble salt that was 
precipitated was removed by filtration. The filtrate was neutralized with sodium 
hydroxide and seperated according to size using a membrane having a molecular 
weight cut-off of 3 KDa. The material retained by the membrane was collected and 
concetrated using a rotary flask in water bath (55-70C°). The final product was light 
brown powder. 
GS leaves were identified by a botanist, and a voucher specimen (reference GS1-
OSA1-G123/C) was deposited with Ayurvedic-Life International LLC (Neenah, WI 
54946-0010, USA). The OSA® extract used in this study was a gift from Ayurvedic 
Life International LLC, Wisconsin, USA. OSA® solutions were freshly prepared for 
glucose tolerance test (GTT) as a 100 mg/ml stock in water for use in the in vivo 
animal study and 200 mg/ml stock in water and diluted in Gey & Gey buffer (Table 
2.1) (Gey and Gey, 1936) for use in the in vitro experiments. 
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2.1.2 Costus pictus extract 
Costus pictus (CP) leaves were collected from Kerala Agricultural University 
Mannuthy and a voucher specimen is deposited in the VIT University herbal garden, 
Vellore, Tamil Nadu (VIT/CP/G1). The leaves were processed as follows. Shade 
dried plant material was ground into powder and an extract was prepared by 
successive maceration of the powder (10 g) at room temperature with methanol for 
48h in a shaker. The final extract was filtered and the filtrate was lyophilized to 
obtain a powdered extract. The powder was provided by M. A. Jayasri from VIT 
University. The extract was stored as a 100 mg/ml stock and diluted as appropriate 
in a physiological salt solution (Gey & Gey buffer) for use in experiments. The yield 
of the dry extract as a percentage weight of the starting fresh leaves of CP was 
1.42%. 
In vivo study 
2.2 Studies using animals 
2.2.1 Ob/ob mice 
In 1949, an outbred colony at Roscoe B. Jackson Memorial lab was discovered and 
named ob/ob mice (OM). The OM has been used as a model of obesity and T2DM. 
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The major characteristic of the OM is that they are deficient in leptin. Leptin is a 
polypeptide hormone secreted from adipocytes and plays a key role in regulating 
food intake and energy expenditure. The lack of leptin in OM produces certain 
phenotypic features in these animals. They are infertile, hyperphagic, obese and 
insulin resistant. The hyperinsulinemia in OM develops after 2-weeks of birth while 
hyperglycemia is evident at the fourth week and peaks after 3-5 months. The 
pancreatic islets of OM are hyperplasic and have high number of β-cells (˃ 90% of 
cells are β-cells) (Ingalls et al., 1950, Lindstrom, 2007, Lindstrom, 2010, Wolf, 
2001). 
2.2.2 Experimental Animals 
Obese hyperglycemic male ob/ob mice (Harlan, UK) were used. They were 
produced by selective mutation of the Ob gene which encodes the hormone leptin. 
Insulin resistance and glucose intolerance was seen as soon as 2-4 weeks after 
birth. Lean male C57BL/6J mice (Charles River, Margate) served as controls to 
establish the obesity and hyperglycemia status of the ob/ob mice. The weight and 
fasting blood glucose of each mouse were measured before the start of experiment. 
2.2.3 Glucose tolerance test 
Glucose tolerance tests (GTT) were performed to evaluate the glucose intolerance 
status of the ob/ob mice. Before GTT, ob/ob or C57BL/6J mice were starved for at 
least 16 hours. 2 g/Kg body weight of 30% glucose was injected intraperitoneally 
(IP) and the glucose concentration was measured in blood samples taken from the 
tail vein at baseline and 15, 30, 60 and 120 minutes of glucose injection. Blood 
glucose measurements were performed using an Abbott glucometer (mediSence 
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opium 99765-15). To investigate the effect of a single oral dose of OSA® on blood 
glucose in ob/ob mice, 500mg/Kg of OSA® or vehicle was administered by gavage 
30 minutes before performing the GTT. All experiments using animals were 
performed under UK Home Office License (PPL no. 70/5848). 
Stduies using human subject examining the effect of OSA® in patients with T2DM 
was also carried out by our collegues in Burdwan Medical College clinic, West 
Bengal, India and is detailed in Appendix 1.  
In Vitro studies 
2.3 MIN cells 
MIN cell lines are one of the insulinoma cell lines that have been developed by 
targeted expression of SV40 (Simian Virus) T antigen into pancreatic β-cells of 
transgenic mice. MIN6 cells have been used in our lab and considered to be a good 
and useful tool to study β-cell function. They rapidly transport and metabolize 
glucose by GLUT-2 and glucokinase, respectively. In addition, MIN6 cells have 
insulin secretory granules and secrete insulin in response to glucose. The glucose 
dependent increase in insulin secretion resembled that of isolated islets from rats 
and mice. The major disadvantage of MIN6 cells is that they have an unstable 
phenotype. Low passage cells respond to glucose in a concentration dependent 
manner but this ability is lost with high passage cells when they are kept in culture 
for prolonged period of time (Ishihara et al., 1993, Persaud, 1999). Configuring the 
MIN6 cells as islet-like aggregates known as pseudoislet is one way of maintaining 
some glucose-dependent insulin secretion (Hauge-Evans et al., 1999).  
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2.3.1 Cryopreservation and reconstitution of cells from frozen storage 
The process by which cells or tissues are preserved by cooling to sub-zero 
temperature is called cryopreservation. Liquid nitrogen is used to achieve a 
temperature of -196C°, at which temperature any biological activity inside the cells 
is stopped. However, cells may die from sudden freezing. Therefore, slow 
programmable freezing is now widely used to avoid the freezing-induced rupture of 
intracellular compartment of cells. To cryopreserve MIN6 cells, 70-80% confluent 
MIN6 cells were trypsinized and resuspended in 10% DMSO containing DMEM. 
DMSO acts as cryoprotectant. Cells were homogenized by pipetting up and down 
and then transferred into 1ml cryovials. These vials were placed into a Nalgene® 
container and kept at -80C° overnight. Nalgene® contains a solution of 100% 
isopropyl alcohol and has the advantage of a controlled cooling rate of -1C°/minute. 
The vials were then transferred to liquid nitrogen for long-term storage. 
MIN6 cells were reconstituted from frozen storage when needed for experiments. 
One cryovial ampoule containing MIN6 cells was defrosted quickly in water bath at 
37C°. The cells were transferred into 15ml centrifuge tube, mixed with 10ml of 
DMEM and pelleted by centrifugation. The pellet was resuspended in DMEM and 
cultured in T-25 flask. 
2.3.2 Maintenance of MIN6 cells 
MIN6 cells (passage 28-44) were maintained as monolayers at 37C° (95% O2/ 5% 
CO2) in DMEM supplemented with 10% foetal calf serum (FCS), 2mM L-glutamine 
and 100 U/ml penicillin with 0.1 mg/ml streptomycin in tissue culture flask with 
75cm2 growing surface area (T-75). The medium contains vitamins and amino acids 
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and has a high glucose (25mM) content to meet the metabolic requirements for 
MIN6 cells growth. MIN6 cells form monolayers if cultured in negatively-charged 
tissue culture plastic which allows the adherence of MIN6 cells to their surface 
forming monolayers. Figure 2.1 shows the MIN6 cells growing as monolayers.  
The medium was changed every 3-4 days and the MIN6 cells were detached and 
trypsinized when the flask confluency reached ≈ 70-80%. 0.1% trypsin/0.02% 
EDTA was used for trypsinization. Briefly, the medium was aspirated and the cells 
were washed with phosphate buffered saline (PBS). A T-75 flask containing MIN6 
monolayers was incubated with 3 ml of trypsin/EDTA mixture at 37C° for 3-5 
minutes to allow the detachment of MIN6 cells from the plastic surface. Seven ml of 
DMEM was added to inactivate trypsin since DMEM contains FCS which inhibits 
trypsin. The flask content was transferred to a sterile 15 ml falcon tube and 
centrifuged at 1000g for 3 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 1ml DMEM. Ten μl of the resuspension was used for cell 
counting as described in section 2.7. 
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2.3.3 Formation of MIN6 Pseudoislets (PIs) 
To form PIs, MIN6 monolayers were trypsinized and cultured in 10 ml DMEM 
supplemented with 10% FCS, 2mM L-glutamine and 100 U/ml penicillin with 0.1 
mg/ml streptomycin in 90mm bacterial Petri dishes at 37C° (95% O2/ 5% CO2). 
Incubation of MIN6 cells in bacterial Petri dishes prevents the adhesion of MIN6 
cells to plastic surfaces and as a result MIN6 cells adhere to each other and form 
three-dimensional aggregates called pseudoislets (PIs). The medium was changed 
every 3-4 days and PIs were used in the experiments 7-10 days after subculturing 
of the MIN6 cells. Figure 2.2 shows the MIN6 cells growing as PIs. 
 
2.4 Isolation of mouse islets 
The pancreata of outbred white albino ICR (Harlan, UK) mice were digested by 
collagenase as described previously (Papadimitriou et al., 2007). Briefly, the mouse 
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was killed by neck dislocation and the abdominal area was opened. The common 
bile duct was exposed and clamped. Once collagenase (1 mg/ml) was injected, the 
pancreas was removed and digested at 37C°. The digested pancreas was washed 
with EMEM supplemented with 10% NCS (neonatal calf serum) and 100 U/ml 
penicillin with 0.1 mg/ml streptomycin and sieved into a sterile tube.  The islets 
were purified on Histopaque® density gradients and cultured in 35mm bacterial 
dishes in RPMI medium supplemented with 10% FBS and 100 U/ml penicillin/0.1 
mg/ml streptomycin. 
2.5 Isolation of human islets 
Human islets were provided by Dr. Guo Cai Huang, King’s Human Islet Isolation Unit 
at King’s College Hospital, UK. Briefly, pancreas was removed from non-diabetic 
heart-beating organ donor with permission from donor relatives and approval from 
Ethical Committee of King’s College Hospital. Islets were isolated under aseptic 
conditions and cultured in Connaught Medical Research Laboratories (CMRL) 
medium at 37C° (95% O2/ 5% CO2). The islets were ≈ 90% viable and 70-80% pure 
(Brandhorst et al., 1998, Huang et al., 2004, Lakey et al., 1997). 
2.6 Counting of MIN6 cells 
Cell counting was performed using a haemocytometer, consisting of 4 corner 
squares, each of which is composed of 16 smaller squares. It also contains centrally 
located square which has 25 smaller squares. All corner and centre squares have a 
total area of 1 mm2. Placing a cover slip on the haemocytometer creates a chamber 
with a volume of 0.1 mm. Therefore, the total volume is 1 mm2 x 0.1 mm or 0.1 
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mm3. Since 1 cm3 is equivalent to 1 ml, the cell number/ml is calculated as the 
average count of the 4 peripheral squares x dilution factor x 104. 
2.7 Insulin secretion 
2.7.1 Static incubation of MIN6 cells 
MIN6 monolayer cells were seeded into a 96-well plate at a density of 20,000- 
30,000 cells/well and cultured in DMEM supplemented with 10% FCS, 2mM L-
glutamine and 100 U/ml penicillin with 0.1 mg/ml streptomycin at 37C° for 2 days. 
Before the experiment, MIN6 cells were pre-incubated in 2mM glucose Gey & Gey 
buffer supplemented with 2mM CaCl2 and 0.5 mg/ml BSA at 37C° for 120 minutes. 
The cells then were incubated with buffer containing either 2mM or 20mM glucose 
in the presence or absence of agents of interest for 30 minutes. At the end of the 
incubation period, 100μl of incubation medium was removed, added to 400μl 
borate buffer (Table 2.2) and stored at -20C° until insulin was measured by RIA.  
 
2.7.2 Static incubation with mouse islets 
Three or 5 mouse islets were transferred into 1.5 ml eppendorf tubes and 
preincubated for 2hrs, at 37C°, in RPMI supplemented with 2mM glucose. Following 
2hrs incubation, the medium was replaced with the agent of interest for 30-60 
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minutes. The supernatant was removed and stored at -20C° until assayed for insulin 
content by RIA. 
2.7.3 Perifusion with MIN6 PIs, mouse or human islets 
The perifusion apparatus consists of 16 Swinnex chambers, each of which is lined 
with 1 μm pore-size nylon filter and connected by tubes to perifusion buffers and a 
peristaltic pump. The pumping of perifusion buffers occurs at a flow rate of 0.5 
ml/min and perifusates are collected every 2 minutes. Since glucose metabolism is 
temperature-dependent, all perifusion experiments were done in a temperature-
controlled room at 37C°. MIN6 PIs, mouse islets or human islets were aliquoted into 
perifusion chambers containing the nylon filter, and pre-perifused with 2mM 
glucose Gey & Gey buffer supplemented with 2mM CaCl2 and 0.5 mg/ml BSA for 60 
minutes at flow rate of 0.5 ml/min, during which the perifusate was discarded. At 
t=60 minutes, the tissues were perifused with Gey & Gey buffer supplemented with 
either 2mM or 20mM glucose in the presence or absence of agents of interest. The 
perifusion samples were collected every 2 minutes and stored at -20C° until insulin 
content was determined by RIA. 
2.8 Total insulin content of mouse islets 
Five mouse islets were transferred into 1.5 ml eppendorf tubes and incubated for 
24hrs, under normal tissue culture conditions, with RPMI supplemented with 2mM 
glucose in the presence or absences of agent of interest. Following the 24hrs and 48 
hrs incubation, the islets were washed with PBS, sonicated in acidified alcohol and 
stored at -20C° until assayed for insulin content by RIA. 
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2.9   Radioimmunoassay (RIA) 
2.9.1 Background 
Radioimmunoassay was developed by Yalow and Berson in 1960 and since then 
immunoassays represents the most popular method to measure insulin content in 
biological and non-biological fluids. The assay is based on competition between 
unlabelled insulin or antigen (standards or unknown samples) and a fixed amount 
of 125I-labelled insulin (Tracer) for a limited number of insulin antibody binding 
sites (Ab). This reaction follows the law of mass action: 
[AG] + [AG*] + [Ab] ⇄ [AG Ab] + [AG* Ab] + [AG] + [AG*] 
From the above equation, the amount of labelled insulin bound to antibody [AG* Ab] 
is inversely proportion to concentration of unlabelled insulin [AG] (standards or 
samples). Calculating the concentration of unlabelled insulin (unknown samples) 
can be done by measuring the radioactivity of labelled insulin [AG*] (Tracer) and 
extrapolating from a standard curve (Yalow and Berson, 1960). 
2.9.2 Iodination and purification of insulin 
A radioactive isotope of iodine 125I (commercially available as Na125I) was used in 
the labelling of insulin and the synthesis of the tracer. The high specific 
radioactivity, the absence of β radiation and the relatively long half-life (t1/2=60 
days) of 125I make it preferable over other radio-isotopes. The iodination of insulin 
reaction involves two steps 1) oxidation of 125I to iodous ion (I+) by a mild oxidizing 
agent, Iodogen and 2) binding of the oxidized iodine ion into a tyrosine residue, an 
iodine receptor group, of insulin molecules. Iodogen, 1,3,4,6-tetrachloro-3a,ba-
diphenylglycoluril, acts as oxidizing agent for 125I. It is highly soluble in chloroform 
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but insoluble in water so when dispersed in chloroform Iodogen forms a coating 
layer surrounding the walls of a reaction tube after vaporization of the chloroform. 
The deposit formed is inaccessible to insulin but accessible to 125I thus reducing the 
oxidation of insulin by Iodogen. Purification and separation of the iodinated-insulin 
is necessary to remove molecules other than iodinated-insulin and radio- active 
iodine not conjugated to insulin from the reaction mixture. Separation is done using 
gel filtration technique. This technique enables the use of a gel, Sephadex G-50, to 
separate the labelled insulin from the reaction by-products. Sephadex, or dextran 
gel, forms hydrophobic bonds with tyrosine moieties of insulin. Thus albumin-
containing elution solutions are used in order to avoid adsorption and retention of 
insulin on the gel and column wells (Patrona and Peskar, 1987). 
Pre-prepared 50μl of 200μg/ml of Iodogen in chloroform was dispensed in a 
reaction tube and the solvent left to evaporate to form Iodogen deposits. 1mg/ml of 
insulin in 10mM HCl was freshly prepared and diluted 8 times in 0.5M phosphate 
buffer. 40μl of insulin was mixed with 20μl of 125I (activity 74 MBq) and incubated 
at room temperature for 30 minutes with occasional mixing every 5 minutes. The 
iodination reaction was stopped by adding 400μl of 50mM phosphate buffer. The 
sephadex beads were precoated with 50mM phosphate buffer supplemented with 
bovine serum albumin (BSA) to prevent insulin adherence to them. 50mM 
phosphate buffer was used as an elution solution and samples were collected every 
2 minutes for 60 minutes. The radioactivity of each sample was measured using the 
γ-counter (Wizard) and samples with the highest counts/minute (cpm) were 
pooled and diluted to final concentration of 10x106 cpm/ml. Figure 2.3 shows the 
iodination curve of insulin. 
Chapter 2  Materials and Methods 
The role of plant extracts on islet function in vivo & in vitro Page | 99  
 
   
2.9.3 RIA protocol 
Standard tubes were prepared in triplicates from 10ng/ml insulin by serial dilution 
to give final concentration of 10, 5, 2.5, 1.25, 0.64, 0.32, 0.16, 0.08, 0.04 ng/ml. 
Reference tubes were made as the following: Total (T) contained only 100 μl of 
labelled insulin to measure the amount of radioactivity added to each tube. Non-
specific binding (NSB) contained only 100 μl tracer and 200 μl borate buffer. It was 
used to correct for all the measurement in the assay. Maximum binding (MB) 
contained 100 μl of each of the following: tracer, antibody and borate buffer. The 
antibody aganist rat insulin was raised in guinea pigs. The samples were prepared 
in duplicates and contained 100μl of sample and 100 μl of both tracer and antibody. 
The insulin RIA protocol is given in Table 2.3 and the standard curve is shown in 
Figure 2.4. 
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The assay tubes were kept at 4C° for 48 hours to allow the binding and equilibrium 
between antibody and labelled and unlabelled insulin. The antibody bound antigen 
complexes were precipitated by adding 1 ml of polyethelenglycol (PEG) mixture 
containing 1 mg/ml γ-globulin, 15% PEG in PBS and 0.05% Tween to each tube 
except to the total (T) and centrifuged at 3000 rpm for 15 minutes. Supernatant was 
discarded and the radioactivity of the pellets containing the complexes was 
measured using the γ-Counter (Wizard). 
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2.10  Glucagon secretion 
Measurement of glucagon secretion was carried out using perifusion experiments 
similar to section 2.7.3. 100 mouse islets were transferred into perifusion chambers 
containing the nylon filter. Islets were pre-perifused with 2mM glucose Gey & Gey 
buffer supplemented with 2mM CaCl2 and 0.5 mg/ml BSA for 60 minutes to 
establish basal rate of glucagon secretion. Any perifusate collected during this time 
were discarded. Following 60 minutes, islets were perifused with 2mM glucose Gey 
& Gey buffer at a flow rate of 0.5 ml/min in the presence or absence of agent of 
interest. Perifusate samples were collected every 2 minutes and stored in -20C° 
until assayed for glucagon by RIA. 
2.11  Cell viability 
To estimate the proportion of viable and non-viable cells, the Trypan Blue exclusion 
test was used. This test depends on the fact that viable cells can be differentiated 
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from non-viable cells through the integrity of their membranes. Viable cells have 
intact cell membranes that prevent the entry of macromolecules such as Trypan 
Blue dye (MW ≈ 1000 Da) while non-viable cells have compromised plasma 
membranes therefore they become permeable to the dye, which has the ability to 
stain nuclear proteins. Hence non-viable cells appear blue under the light 
microscope (Johnson, 1995).  
In our experiment, MIN6 cells or mouse islets, treated with the agent of interest, 
were stained and incubated with 0.1% (wt/vol) Trypan Blue dye in PBS for 15 
minutes at 37C°. The cells were then washed with PBS and visualized under the 
light microscope. Images were captured using a Nikon Coolpix 4500 digital camera 
(Surrey, UK). 
2.12  Calcium microfluorimetry 
2.12.1 Background 
Calcium microfluorimetry is an important technique in estimating intracellular Ca2+ 
concentration [Ca2+]i in a single β-cells. It uses fluorescent Ca2+ indicators which 
emit light as a result of changes in [Ca2+]i. The fluorescent Ca2+ indicators are 
divided into two groups: single-wavelength dyes (single-wave length indicators) 
and dual wavelength ratiometric dyes (ratiometric indicators). The ratiometric 
indicators include Fura-2, Indo-1 and Rhod-2. The advantages of Fura-2 and 
ratiometric indicators in general over those of single wavelength include 1) the 
marked sensitivity of Fura-2 since the peaks of Ca2+-free and Ca2+-bound spectra 
arose at different wavelength and 2) Fura-2 is excited at two wavelengths allowing 
the estimation of a ratio which correlates well with changes in [Ca2+]i thus 
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minimizing Ca2+-unrelated artefacts. The major drawback of Fura-2 is its poor 
membrane permeability. Therefore, Fura-2 is provided as Fura-2/AM. The 
introduction of acetoxymethyl (AM) group masks the –ve charge on the carboxy 
group on Fura-2 molecule and facilitates the entry of Fura-2 into the cells. However, 
Fura-2/AM is inactive and enzymatic hydrolysis by esterases inside the cells is 
needed to liberate the active Fura-2, which then trapped inside the β-cells (Kao, 
1994, Murchison and Griffith, 2007).  
2.12.2 Preparation of coverslips 
MIN6 cells were seeded on ethanol-washed glass coverslips which were first soaked 
in 2N acetic acid for 1hr at room temperature and then washed with deionised 
water. To disinfect the coverslips, they were soaked with 70% ethanol for 1hr. They 
were then washed with deionised water and left to dry in a sterile tissue culture 
hood for at least 1hr. The coverslips were sterilized by UV light for few seconds and 
stored at 4C° for further use in experiments. 
To measure [Ca2+]i in mouse islet cells, they were seeded on poly-D-lysine coated 
coverslips. One side of the acid-washed ethanol coverslips were covered with 0.1 
mg/ml poly-D-lysine in PBS and left for 10 minutes. The coverslips were then 
washed with sterile water, left to dry in a tissue culture hood and stored at 4C° for 
further use in experiments 
2.12.3 Seeding cells 
MIN6 cells were trypsinized and resuspended in serum-free DMEM. The cells were 
placed on the coverslips and left to adhere for 2hrs at 37C°. Following 2hrs, DMEM 
supplemented with serum was added and cells were incubated for overnight. 300 
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islets were dissociated using EDTA, resuspended in serum-free RPMI and placed on 
poly-D-lysine coated coverslips and left to adhere for 1hr. The cells were 
maintained in culture for overnight RPMI supplemented with serum.  
MIN6 cells were seeded on ethanol-washed glass coverslips at a density of 50,000 
cell/coverslip while dispersed mouse islets were seeded on poly-D-lysine glass 
coverslips at a density of 160,000 cells/coverslip and allowed to adhere overnight 
under standard tissue culture conditions. 
2.12.4 Procedure 
The cells were loaded with 5μM of the Ca2+-fluorophore Fura-2/AM for 30 minutes 
at 37C°. The coverslips were placed in a steel chamber which was mounted into a 
heating platform (37C°) on the stage of an Axiovert 135 Research Inverted 
Microscope. The cells were perifused with buffers containing the agents of interest 
at a flow rate of 1 ml/min. Cells were illuminated alternately at 340 and 380nm 
using an Axon Imaging Work-bench (Axon Instruments). Emitted light was filtered 
using a 510nm long pass barrier filter and detected using a Photonics Science ISIS 
camera. Data were collected every 3 seconds for multiple regions of interest in any 
one field of view and changes in the emission intensity of Fura-2 expressed as a 
ratio of dual excitation were used as an indicator of changes in [Ca2+]i.  
2.13  Measurement of intracellular cAMP  
Intracellular cAMP [cAMP]i in MIN6 cells or mouse islets was measured by enzyme 
immunoassay as stated by manufacturer’s protocol. Briefly, MIN6 cells (30,000 
cells/well) or mouse islets (5 islets/well) were incubated with Gey & Gey buffer in 
the presence or absence of agents of interest for 30 minutes at 37C°. The 
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supernatant was removed and stored at -20C° for estimation of insulin content. The 
cells were lysed and incubated with Rabbit anti-cAMP serum for 2 hrs at 3-5C°. 
cAMP-horseradish peroxidase conjugate was added to each well and incubated for 
an extra 1 hr. The wells were thoroughly washed with 0.01M phosphate buffer 
containing 0.05% tween 20 for at least 3 times. Enzyme substrate containing TBM 
(tetramethylbenzidine/1% hydrogen peroxide) was dispensed into each well and 
left for 30 min at room temperature. Once the blue color had developed, the 
reaction was stopped by addition of 1.0 M sulphuric acid. The concentration of 
[cAMP]i was determined relative to a standard curve by measuring the optical 
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2.14  Measurement of apoptosis 
2.14.1 Background 
Caspases are the major proteolytic enzymes that are activated during apoptosis. In 
our experiments we measured caspases 3 and 7. The caspase 3/7 was measured 
using Caspase-Glo® 3/7 apoptosis assay kit (Promega, UK). The assay uses the 
luminogenic substrate (Z-DEVD-amino-luciferin) and a stable luciferase enzyme 
(Figure 2.6). Caspases cleaves the substrate liberating free amino-luciferin which 
can then be acted upon by luciferase to generate a luminescent signal which is 
directly proportional to caspase 3/7 activity (Promega, 2009) .  
 
2.14.2 Assay protocol 
MIN6 cells (10,000 cells/well) or mouse islets (5 islets/well) were seeded in white 
96-well plates and left overnight under standard tissue culture conditions. On the 
day of the experiment, cells were preincubated with the agent of interest for 8 hrs 
before incubation with the agent of interest in the presence or absence of cytokines 
Chapter 2  Materials and Methods 
The role of plant extracts on islet function in vivo & in vitro Page | 107  
 
for 16-18 hours. Caspase 3 and 7 activities were measured using Promega caspase-
Glo® 3/7 assay kit (Promega Cat G8093) according to manufacturer procedure. 
Briefly, Caspase-Glo® 3/7 buffer was mixed with Caspase-Glo® substrate to form 
Caspase-Glo® reagent. Both Caspase-Glo® reagent and the cells were left to 
equilibrate at RT for 1 hr, after which, 50μl of Caspase-Glo® reagent was added to 
each well of the 96-well plate, mixed for 30 sec and incubated for 1 hr. The 
luminescent signal generated was measured using Veritas luminometer (Turner 
Biosystems) and the data were processed using Promega software 
2.15  mRNA estimation 
2.15.1 RNA extraction 
Mouse RNA was extracted using Qiagen RNeasy mini kit according to the 
manufacturer’s protocol. 150 islets treated with agents of interest were washed 
with PBS and lysed with RLT (a highly denaturing guanidine thiocyanate-containing 
buffer) supplemented with 14.3M β-mercaptoethanol, which immediately 
inactivates RNases to ensure purification of intact RNA. The lysed cells were 
transferred into RNase-free 1.5 eppendorf tube and homogenized by vortexing & 
passing the lysate 5 times through a 20-G needle fitted to an RNase-free syringe. 
One volume of 70% ethanol was added to the lysate and mixed by pipetting up and 
down to provide appropriate binding condition. The sample was applied to a 
RNeasy mini spin column, where the total RNA binds to the membrane. Each tube 
was centrifuged for 1 minute at 12,000 rpm and the flow-through was discarded. 
The column was washed with RW1 and the flow-through was discarded. Any 
residual DNA was removed by on-column DNase digestion using the RNase-Free 
DNase Set. The DNase-I stock was prepared by dissolving DNase-I stock with 550μl 
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RNase-free water. The DNase-I mix was prepared by mixing DNase-I with buffer 
RDD. 80μl of DNase-I mix was added to each column.  The contaminants were 
washed with 350μl RW1 (ethanol-containing buffer) and then 500μl RPE (80% 
alcohol-containing buffer) and the flow-through was discarded. The column was 
centrifuged for an additional minute to dry it. The column was transferred into 
clean 1.5 RNase-free eppendorf tube and the RNA was eluted in 30μl RNase-free 
water.  
2.15.2 RNA quantification 
RNA concentrations were quantified spectrophotometrically, using 1 μl of RNA of 
each sample in the nanodrop-1000, by reading the absorbance at 260/280nm wave 
length. An efficacy ratio of ∼ 2 indicated the purity of the RNA sample. The 
Concentration of each sample was calculated according to the following equation:  
Concentration of RNA(ng/μl)= A260 x dilution factor x 40 
2.15.3 cDNA synthesis 
0.5 μg of RNA was converted to cDNA using Moloney Murine Leukemia Virus 
Reverse Transcriptase (mmLV-RT; Invitrogen 18080-044). The conversion was 
carried out according to the mmLV-RT manufacturer’s procedures. Briefly, 0.5 μg of 
RNA of each sample was first mixed with 0.5μg/μl Oligo dT primer and 0.5μg/μl 
random primer. Each sample was incubated at 72C° for 5 minutes and then chilled 
on ice for 5 minutes. 18μl of Master Mix (Table 2.4) was added to each sample. The 
reaction was initiated by incubating the samples at 42C° for 50 minutes and 
inactivated by incubating the samples at 70 C° for 15 minutes. The samples were 
stored at -20 C° for quantitative PCR. 
Chapter 2  Materials and Methods 
The role of plant extracts on islet function in vivo & in vitro Page | 109  
 
 
2.16  Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was discovered by Karry Mullis in 1983 and 
since then it has been widely used in molecular biology. PCR is an in vitro method 
for amplifying a defined sequence of DNA using a thermo-stable DNA polymerase 
enzyme. Real time PCR (RT-PCR) is a highly sensitive method for detection and 
quantification of mRNA as compared to conventional PCR methods. RT-PCR collects 
data by monitoring fluorescence emitted during the reaction in an exponential 
growth phase as the fluorescence signal generated corresponds to the amount of 
PCR products amplified in each cycle during the reaction, unlike traditional PCR 
where the PCR amplification products are measured at the end point (plateau). RT-
PCR quantifies mRNA transcripts using fluorescent indicators. There are three 
major fluorescence systems for DNA amplification so far: 1) DNA-binding dyes 
(SYBR green), 2) hydrolysis probes (Taqman and scorpion) and 3) hybridizing 
probes (molecular beacons). SYBR green is a fluorescent intercalating agent that 
exhibits little fluorescence in solution but upon binding to double stranded DNA (ds 
DNA) it emits strong light (522nm) after excitation at 498nm. SYBR green is widely 
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used in RT-PCR due to the fact that it is cheap, simple to use, temperature stable 
and does not interfere with DNA polymerase. In addition, SYBR green can be used 
to monitor any gene since it does not discriminate between double-stranded DNA 
sequence. The non-specificity of SYBR green binding can result in binding of SYBR 
green to primer and non-specific amplification products. This can be overcome by 
performing melting curve analysis. The melting point of ds DNA is the temperature 
when 50% of DNA is singley stranded. Another potential drawback of SYBR green is 
the amplicon length which can be overcome by synthesizing primers that amplify 
short amplicons. Short amplicons (200-300 bp) can be amplified efficiently than the 
long ones because long amplicons generate strong fluorescence signals that can 
saturate the camera inside the thermocycler (Bustin, 2000, Nolan et al., 2006). 
The RT-PCR reaction and incorporation of SYBR green dye involve three major 
steps (Figure 2.7). In denaturation, DNA is unwound by heating the reaction tube to 
94-95C°. At this step SYBR green is unbound therefore emitting little if any 
fluorescence. The temperature is reduced to 55-72C° (dependent on primer 
sequence) allowing annealing of the primer to the single stranded (ss) DNA to take 
place. Few molecules of SYBR green bind to the ds-primer/DNA and emit light upon 
excitation. During extension, DNA polymerase (at 72C°) adds new nucleotides to the 
free 3’-OH of the primers forming new templates of DNA. As the new synthesis of 
DNA continues, more molecules of the dye bind to the new strand and fluorescence 
is increased. The fluorescence is detected when it exceeds the threshold cycle (CT 
point). CT is the cycle number at which fluorescence emission crosses the threshold 
(above baseline) and it reflects the amount of templates available at the start of the 
reaction. Thus the more templates present at the beginning of the reaction, the 
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lower the CT value and the fewer number of cycle needed for the fluorescence to 
exceed the baseline (Bustin, 2000). 
 
Quantification of mRNA transcription can be either relative or absolute with the 
latter being more accurate then the former. Absolute quantification or standard 
curve method calculates the exact copy number/sample and is based on 
construction of an absolute standard curve for each amplicon. Extrapolation from 
the standard curve can be used to calculate the copy number of unknown sample.   
2.16.1 Primer design and synthesis 
The whole sequence of each gene was found on pubmed nucleotide network 
(http://www.ncbi.nlm.nih.gov/nuccore). The primers were designed using Primer 
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3 software (http://frodo.wi.mit.edu/primer3/). Primer 3 software was set to 
synthesize primers that have similar annealing temperature, amplify short 
amplicons (100-300 bp), and have GC contents of 40-60%. The specificity of 
primers was checked by nucleotide BLAST (Basic Local Alignment Search Tool; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). Mouse preproinsulin I and II cDNA 
sequences were used to design forward and reverse PCR primers that detected both 
preproinsulin mRNAs. The preproinsulin and actin were designed to amplify a 125 
and 285 bp target PCR product, respectively, and their sequences are given in 
Appendix 2.   
2.16.2 Gel electrophoresis 
1.8% agarose gel was prepared for electrophoretic separation of the PCR products. 
900mg of agarose was dissolved by microwaving for approximately 1 minute in 
50ml 1x Tris-Base-EDTA (TBE, sigma, UK). Five μl of ethidium bromide (10mg/ml) 
was added to the dissolved agarose to give a final concentration of 1 μg/ml. The gel 
was poured in a comb-containing tank and left to solidify for 30-60 minutes. The gel 
was submerged with 1x TBE. The PCR products which were mixed with 5x loading 
dye (Qiagen) were loaded into the wells. The gel was developed at 75 volts for 30 
minutes. 
2.16.3 Preparation of standards 
A standard curve of each gene of interest was prepared to allow for absolute 
quantification of the unknown samples. A PCR reaction for each gene was carried in 
duplicates. A gel electrophoresis was performed as described in section 2.17.2 and 
the product was visualized under UV light. A single band of the expected product 
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size was generated in all samples. The bands were excised, pooled and DNA was 
extracted using QIAquick® gel extraction kit (Qiagen). Briefly, the excised gels were 
weighed, mixed with 3 volumes of QG buffer (e.g 100mg ~ 300μl QG) and incubated 
at 50C˚ for 10 minutes until the slices were completely dissolved. The tubes were 
vortexed every 2-3 minutes during the incubation time to aid in solubilization. 
Isopropanol (v/v) was added to the dissolved gel slice which then were applied to 
the QIAquick® spin columns and centrifuged (13,000 rpm) for 1 minute. The flow-
through was discarded and 0.5 ml of QG buffer was added to the column and 
centrifuged for 1 minute. The columns were washed with 0.75 ml of ethanol-
containing PE buffer and centrifuged for 1 minute to remove any salts. The flow-
through was discarded and any residual ethanol from the PE buffer was removed by 
centrifugation for an additional 1 minute.  The columns were placed into clean 1.5 
ml RNase-DNase tube and DNA was eluted in 30μl of RNase-DNase water. The DNA 
was quantified using NanoDrop-1000. The number of copies/μl was calculated as 
follows: 
Number of molecules in 1 ng = (Avogadro no./ molecular weight of product) x 10-9 
The molecular weight of product is the average molecular weight of a base pair 
(660) multiplied by the length of the product. 
Total number of copies/μl= concentration of the product (ng) x number of 
copies/ng 
Serial dilutions were made to prepare standards ranging from 109-101 in RNase-
DNase water. 
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2.16.4 Quantitative PCR 
Quantitative-PCR was carried using Roch® thermocycler (LightCycler 480) and 
LightCycler® FastStart DNA masterPLUS SYBR green I (Roch®, UK). At the start of 
the experiment, SYBR green mix was prepared by mixing 14μl of the enzyme with 
the dye. A master mix was prepared as detailed in Table 2.5. 16μl of master mix was 
added to either 4μl of cDNA or standard or water (Negative Control; NC) or RNA 
(not reverse transcribed, -RT). 
 
Primer specificity was assessed by melt curve analysis followed by gel 
electrophoresis. mRNA accession number, cycling conditions, gel electrophoresis, 
melt curve analyses, assay efficiencies of standard curves series for each gene are 
described in Appendix 2. 
2.17  Microarray 
Applications of cDNA microarray in biological sciences are numerous and include 
measurement of mRNA expression levels, detection of single nucleotide 
polymorphisms (SNPs) and genotyping or resequencing part or whole genome. 
cDNA microarray consists of collection of short sequence of DNA (probes) that are 
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attached to a solid surface (silicone). Each probe is complimentary to a target 
sequence. The probe-target hybridization is detected optically by either 
fluorophore or chemiluminescence-labelled target. The labelled target generates a 
signal once they bind to the probes. The signal generated is directly proportional to 
the amount of target sample alreadu bound to the corresponding probes. In our 
experiment, Affymetrix chips (GeneChip® mouse genome 430 2.0 array) were used 
to measure the expression levels of mRNA. Each chip has 45,000 set of probes 
which detect the expression levels of more than 39,000 transcripts. The 
measurement of transcription level is based on the fact that each probe has 11 pairs 
which include a perfect match and a mismatch probe .  
2.17.1 Measurement of RNA integrity 
The quality of RNA samples was assessed using Agilent RNA 6000 Nano kit. Each kit 
contains four solutions: the ladder, dye concentrate, marker and gel matrix. The gel 
was prepared by pipetting 550μl of the gel matrix into a spin filter and centrifuging 
the mixture at 1500g for 10 minutes at room temperature. 65μl of the filtered gel 
was aliquoted into 0.5ml RNase-free tubes and used within 4 weeks of preparation. 
To prepare the gel-dye mix, the dye concentrate was left to equilibrate to room 
temperature for 30 minutes before mixing 0.5μl of the dye with 35μl of the filtered 
gel. This mix was vortexed well and centrifuged at 13000g for 10 minutes at room 
temperature. Before loading the gel-dye mix, the Nanochip was placed in the chip 
priming station. 9μl of the dye-gel mix was pipetted into the well marked (G). The 
chip priming station was closed and a plunger was pressed down until it was held 
by the clip. The clip was released after 30 seconds, the plunger was pulled back and 
the chip priming station was opened. 9μl of the gel-dye was pipetted into the 
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remaining wells marked (G). 5μl of the marker was loaded in all samples wells and 
in well marked #. 1μl of the ladder was pipetted into its corresponding well. The 
ladder was denatured by heating for 2 minutes at 70C°. 1μl of each sample was 
loaded into the 12 remaining wells. The chip was vortexed at 2400 rpm for 1 
minutes and run in the Agilent 2100 bioanalyzer. 
2.17.2 RNA amplification 
 Amplification and labelling of RNA samples for microarray analysis was carried out 
using the MassageAmp™ Premier RNA amplification kit. The protocol involves 
cDNA synthesis, in vitro transcription and aRNA (amplified RNA) purification. 
Figure 2.8 summarizes the RNA amplification process. 
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2.17.2.1 cDNA synthesis 
The First Strand cDNA was synthesized by mixing 500 ng of RNA with 5μl of First 
Strand Master Mix (Table 2.6). The mixture was incubated for 2 hours at 42C° in 
thermal cycler. The Second Strand cDNA was synthesized by incubating 10μl cDNA 
sample and 20μl of Second Strand Master Mix (Table 2.7) for 1 hour at 16C° and 
then 10 minutes at 65C°. The double stranded (ds) cDNA is ready for the in vitro 
transcription. 
  
2.17.2.2 In vitro transcription (IVT) 
The RNA was amplified and labelled with biotin using oligo T7. 30μl of ds cDNA 
sample was mixed with 30μl T7 IVT Master Mix (Table 2.8). The reaction was 
incubated for at least 14 hours at 40C°. 
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2.17.2.3 aRNA purification and elution 
To ensure the removal of salts and enzymes from the previous reactions, the aRNA 
was purified as follows. Each sample was mixed with 60μl of aRNA Binding Mix 
(Table 2.9) and then transferred to a U-bottom plate. 120μl of 100% ethanol was 
added to the wells and the plate was shaken for 2 minutes at 900 rpm. The RNA 
binding beads were captured by placing the plate on a magnetic stand for 5 
minutes. The RNA binding beads will form a pellet in the bottom of the plate with a 
transparent supernatant. The supernatant was discarded. The plate was removed 
from the magnetic stand and the samples were washed twice with 100μl of aRNA 
wash solution. The plate was shaken for 1 minute at 1200 rpm and the beads were 
captured as previously described. The plate was shaken vigorously for 3 minutes at 
4000 rpm to evaporate any residual ethanol. The purified aRNA was eluted from the 
RNA binding beads by adding 50μl of pre-heated (50-60C°) aRNA elution solution 
to each sample. The plate was shaken vigorously for 3 minutes at 4000 rpm and the 
RNA binding beads were captured as previously described. The aRNA- containing 
supernatant was transferred to RNase-free tubes.  
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2.17.3 Fragmentation of labelled aRNA 
To hybridize the array chip, 15.5μg of biotinylated aRNA was fragmented by 
incubating the reaction with 5x array fragmentation buffer (Table 2.10) at 94C° for 
35 minutes. 1μl of fragmented aRNA was removed to test the quality of the 
fragmentation reaction. The reaction should yield a profile of 25-500 nucleotides of 
aRNA fragments with a peak at approximately 200 nucleotides. The fragmented 
aRNA was used in the hybridization step. 
 
2.17.4 Hybridization of fragmented aRNA 
30μl of each fragmented aRNA was transferred to 1.5 ml RNase-free screw tube. 
270μl of hybridization cocktail Master Mix (Table 2.11) was added to each sample. 
The full cocktail mix was first denatured for 5 minutes at 99C° then for 5 minutes at 
95C°. After denaturation, the mixture was centrifuged for 5 minutes at 14000 rpm. 
200μl of the supernatant was used to hybridize the chip. 
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2.17.5 Chip hybridization 
Mouse 430 2.0 Array Affymetrix Genechips® were used. The chips were pre-
hybridized with pre-hybridization buffer for 10 minutes at 40C° in the oven. The 
pre-hybirdization buffer was removed from the chip and replaced with 200μl of the 
full hybridization cocktail. The chips were incubated in the oven at 45C° for at least 
16 hours. After 16 hours, the full hybridization cocktail was removed and replaced 
with the array holding buffer. Now the chip is ready for the washing and staining 
steps. 
2.17.6 Washing, staining and scanning of Affymetrix chips 
The Fluidics station 450 was primed with Wash A for 15 minutes before placing the 
chips in their corresponding chambers. Each chip was stained with 600μl of two 
stain solutions: stain cocktail 1 (Table 2.12) and stain cocktail 2 (Table 2.13).  
Chapter 2  Materials and Methods 
The role of plant extracts on islet function in vivo & in vitro Page | 121  
 
 
The wash/stain protocol is summarized in Table 2.14. The compositions of Wash A, 
Wash B and Array holding buffers are summarized in Table 2.15, 2.16 and 2.17, 
respectively. Acquisition of images was done using Affymetrix GeneChip® 
Command Console (AGCC). The Chips were scanned at 570nm using GeneChip® 
Scanner 3000 7G. The signal intensity was normalized and analyzed using 
Affymetrix Expression Console software and Affymetrix Microarray Suite (MAS 5.0). 
MAS 5.0 uses algorithm of the average of the differences in perfect match and 
mismatch probes. Mismatch probe is used to measure the background noise levels 
for each probe pair. 
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2.17.7 Quality control of gene chip array 
To assess the validity of the results of a microarray experiment, certain quality 
control measures were considered. These measures allow for direct comparison 
between chips and assure sample quality (illumina, 2010). The criteria for quality 
control included: 
 Number of gene detected: all similar samples should have similar amount of 
transcript detected. A gene expression chip normally has 40-60% gene 
present. Low number of detected genes usually reflect high background or 
poor signal. 
 Housekeeping genes and background: the expression of housekeeping genes 
should be fairly consistent among samples. The signals from housekeeping 
genes should be higher than that produced from the background. In 
Affymetrix chip, GAPDH, β-actin, transferring receptor and pyruvate 
carboxylase are the housekeeping genes used as control genes. 
 Hybridization controls: Affymetrix chips have probes for eukaryotic RNA 
(bioB, bioC, bioD and cre). These probes are used as controls and their 
expression profile should produce a signal of low ˃ intermediate ˃ high. 
 Measures of normality and correlation: histogram and box plot were used to 
determine the variation between arrays. Abnormal and dissimilar 
distribution of signal intensities between samples hinder direct comparison 
between samples. Pearson correlation was used to test the association 
between samples. Similar samples show strong correlation.  
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2.18  Data Analysis 
 Data are represented as mean ± SEM. In perifusion experiments with more 
than one treatment, the mean represents the area under the curve. Differences 
between treatments groups were assessed using analysis of variance (ANOVA), 
Student’s t-test, and Bonferroni’s multiple comparison test as appropriate and 
considered significant at p < 0.05. 
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3.1 Introduction 
The prevalence of diabetes mellitus is growing worldwide and it has been estimated 
that by the year 2030, 440 million people will be suffering from this disease, with 
the vast majority having Type 2 diabetes mellitus (T2DM) (Internaional Diabetes 
Federation, 2009). The most common pharmacological treatments for T2DM, 
sulphonylureas and biguanides, tend to lose their effectiveness with prolonged 
treatment duration, so new pharmacological agents have been employed, including 
Peroxisome Proliferator-Activated Receptor- (PPAR) agonists and agents that 
stimulate insulin secretion such as Glucagon-Like Peptide-1 (GLP-1) analogues and 
Dipeptidyl Peptidase IV (DPPIV) inhibitors (Persaud and Jones, 2008). However, the 
widespread application of these novel agents is limited by their cost and by 
concerns about their long-term safety (VanDeKoppel et al., 2008, Persaud and 
Jones, 2008).  
Some herbal medicines have been shown to have anti-diabetic activities (Alarcon-
Aguilara et al., 1998, Swanston-Flatt et al., 1991, Yeh et al., 2003). Nevertheless, few 
have been shown to be effective in treating the symptoms of T2DM in rodents and 
humans, and their mechanisms of action are uncertain. 
Crude or low molecular weight GS extracts have been reported to have anti-diabetic 
effects in alloxan- or streptozotocin-treated animals by raising plasma insulin levels 
and attenuating blood glucose responses during oral glucose/sucrose tolerance 
tests (Gupta, 1961, Gupta, 1963, Gupta and Variyar, 1961, Mhaskar and Caius, 1930, 
Okabayashi et al., 1990, Shanmugasundaram et al., 1983, Srivastava et al., 1985, 
Srivastava et al., 1986). Similarly, crude or low molecular weight GS extracts have 
been reported to have hypoglycemic effects in patients with hyperglycemic diabetes 
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(Baskaran et al., 1990, Khare et al., 1983, Shanmugasundaram et al., 1981, 
Shanmugasundaram et al., 1990b). The antihyperglycemic effect of GS extracts in 
these studies was postulated to be due, at least in part, to the ability of the plant 
leaves to increase insulin secretion from β-cells of the islets of Langerhans, although 
this was not directly demonstrated. 
The studies described in this chapter investigated the effects of oral OSA® on 
glucose tolerance in an animal model of T2DM, as prelude to identifying the site and 
mechanism of action of OSA®. 
3.2 Materials and Methods 
3.2.1 Experimental Animals 
Obese hyperglycemic male ob/ob mice (10 animals) were used, in which insulin 
resistance and glucose intolerance is seen as soon as 2-4 weeks after birth. Lean 
male C57BL/6J mice (10 animals) served as control to establish the obesity and 
hyperglycemia status of ob/ob mice. The weight and fasting blood glucose of each 
mouse were measured before the start of the experiment (Section 2.2.2). 
3.2.2 Plant extract preparation 
The GS extract used in this study (OSA®) was prepared by extracting fresh GS 
leaves by aqueous alcohol and fractionating it using molecular weight cut-off 
filtration (Chatterji, 2005a; 2005b). GS leaves were identified by a botanist, and a 
voucher specimen (reference GS1-OSA1-G123/C) was deposited with Ayurvedic-
Life International LLC (Neenah, WI 54946-0010, USA). The OSA® extract used in 
this study was a gift from Ayurvedic Life International LLC, Wisconsin, USA. OSA® 
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solutions were freshly prepared for glucose tolerance test (GTT) as a 100 mg/ml 
stock in water (section 2.1.1).  
3.2.3 Glucose tolerance test (GTT) 
Glucose tolerance tests (GTT) were performed to test the glucose tolerance status of 
ob/ob mice as compared to their control (C57BL/6J) mice (section 2.2.3). Before 
GTT, the ob/ob mice or C57BL/6J mice were starved for at least 16 hours.  2 g/Kg 
body weight of 30% glucose was injected intraperitoneally (IP) and blood glucose 
level was measured in samples taken from the tail vein at baseline and 15, 30, 60 
and 120 minutes of glucose injection. Blood glucose measurements were performed 
using an Abbot glucometer (mediSence opium 99765-15). To investigate the effect 
of a single oral dose of OSA® on blood glucose in ob/ob mice, 500mg/Kg of OSA® 
or vehicle was administered by gavage 30 minutes before performing the GTT. All 
experiments using animals were performed under UK Home Office License (PPL no. 
70/5848). 
3.2.4 Statistical analysis 
Data are represented as mean ± SEM unless otherwise stated. Differences between 
treatment groups were assessed using analysis of variance (ANOVA) and 
Bonferroni’s T test for multiple comparisons or Student’s paired T test (two tailed), 
as appropriate. Differences between treatment groups were considered significant 
when p< 0.05. 
 
 
Chapter 3                            GS stimulates insulin secretion from mouse and human β-cells in vivo 
The role of plant extracts on islet function in vivo & in vitro Page | 129  
 
3.3 Results 
3.3.1 Effect of single OSA® administration in mouse model of diabetes 
Table 3.1 summarizes the major characteristics of the experimental animals. In 
ob/ob mice, fasting blood glucose levels were markedly elevated as compared to 
their corresponding control values. In addition, the weights of ob/ob mice were 
significantly higher than those of the controls. During the glucose tolerance tests, 
ob/ob mice showed deterioration in glycemic control as presented by the elevation 
in circulating blood glucose at all time points when compared to their controls 
(Figure 3.1). A single oral administration of OSA® (500mg/Kg) to ob/ob mice 30 
minutes prior to glucose challenge significantly ameliorated the glucose intolerance 
status of these mice (Figure 3.2) with OSA®-treated ob/ob mice showing a 
significant reduction in blood glucose levels and this effect was apparent at t=90 
and 120 min. Vehicle-treated ob/ob mice remained glucose intolerant throughout 
the experiment. 
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Crude extracts of GS leaves or low molecular weight isolates from GS extracts have 
been reported to reduce hyperglycemia in alloxan or streptozotocin-animal models 
of diabetes (Gupta, 1961, Gupta, 1963, Gupta and Variyar, 1961, Mhaskar and Caius, 
1930, Okabayashi et al., 1990, Shanmugasundaram et al., 1983, Srivastava et al., 
1985, Srivastava et al., 1986, Sugihara et al., 2000). The GS extract used throughout 
the experiments was of a high molecular weight extract of >3000 Da, as determined 
by molecular weight cut-off filtration (Chatterji, 2005a, Chatterji, 2005b). To date, 
there have been relatively few reported studies of any GS extracts in humans 
(Baskaran et al., 1990, Khare et al., 1983, Shanmugasundaram et al., 1981, 
Shanmugasundaram et al., 1990b), and no reported studies in either animals or 
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humans using OSA® or other high molecular weight isolates. An essential pre-
requisite for developing drugs as potential therapies for T2DM is to ensure that 
they are efficacious in animals and human subjects, therefore this chapter 
investigated whether this novel isolate from GS leaves had an effect on clinically 
relevant parameters such as glucose concentrations in a mouse model of T2DM and 
on insulin, C-peptide and glucose levels in a small cohort of patients with T2DM. 
Ob/ob mice have been used as a model of obesity and T2DM in numerous 
experimental studies. They have a single mutation in leptin gene (ob) which code 
for the protein hormone, leptin, which plays a key role in energy expenditure and 
food intake. In comparison to control mice, ob/ob mice were hyperglycemic and 
obese, consistent with the reported phenotypic characteristics of these animals 
(Lindstrom, 2007, Lindstrom, 2010). As expected ob/ob mice had an impaired 
glucose tolerance but this was significantly improved upon administration of a 
single oral dose of OSA® prior to the glucose tolerance test. The dose of OSA® was 
chosen to mimic that used in the human study. The improvement of glucose 
tolerance started soon after glucose administration but did not achieve significance 
until 60 min after glucose injection. This may represent the time required for OSA® 
to reach its site of action and produce an effect after oral administration. The 
improvement of glucose tolerance could be due to either reduction in intestinal 
glucose absorption (especially if glucose load was given orally), alleviation of 
insulin resistance or increasing circulating plasma insulin levels. OSA® has shown 
previously to block glucose absorption in the intestine (Shimizu et al., 1997a, 
Shimizu et al., 1997b); however, this could not attribute to the improvement of 
glucose tolerance in our experiment because glucose was injected intraperitoneally 
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and thus intestinal glucose absorption was bypassed. OSA® is not likely to act by 
altering insulin resistance as reports have shown that crude GS extract attenuated 
hyperglycemia without altering insulin sensitivity in targets tissues (Tominaga et 
al., 1995). Therefore, OSA® most likely improved glucose tolerance in ob/ob mice 
as a result of stimulation of insulin secretion. Although plasma insulin levels from 
ob/ob mice were not measured because of limitations in blood sample volumes, 
data from the human study support this notion.   
The effect  of OSA® was also investigated on plasma insulin, C-peptide and glucose 
in a small cohort of patients with T2DM (Appendix 1). This study was carried out by 
our collaborators from Burdwan Medical College clinic. The patients recruited to 
this study presented with both fasting and post-prandial hyperglycemia (Appendix 
1: Figure 1 and 2) but with circulating insulin and C-peptide levels within the 
normal range. Oral treatment with OSA® for 60 days resulted in significant 
reductions in fasting and post-prandial plasma glucose levels to nearly normal 
values in 10 out of 11 patients (Appendix 1: Figure 1 and 2), although it is unclear 
why one member of the cohort did not respond to OSA® treatment. The effect of 
OSA® to decrease plasma glucose was not associated with changes in post-prandial 
glucose excursions nor in body weight, indicating that the effect of OSA® on 
glycemia was not secondary to a decrease in either glucose absorption or food 
intake, consistent with an effect via enhanced insulin secretion. Similarly, the lack of 
effect of OSA® on the extent of post-prandial glucose excursion suggests a lack of 
effect on the insulin sensitivity of target tissues, again consistent with a primary 
effect on insulin secretion. In accordance with this, measurements of plasma insulin 
and C-peptide levels demonstrated that OSA®-induced improvements in glycemic 
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control were accompanied by elevations in plasma insulin and C-peptide 
concentrations (Appendix 1: Figure 3 and 4) suggesting that OSA® has a direct 
stimulatory effect on β-cells in the islets of Langerhans. 
In summary, OSA®, which is a high molecular weight fraction isolated from GS leaf 
extract, may provide a potential alternative therapy for the hyperglycemia 
associated with T2DM. I have shown in this chapter that OSA® is effective in 
alleviating glucose intolerance in ob/ob mice and in reducing blood glucose and 
increasing plasma insulin and C-peptide levels in humans. Our findings were 
therefore in consistent with the previously reported antidiabetic effect of GS in vivo. 
The reported antihyperglycemic action of GS was largely associated with elevations 
in plasma insulin levels suggesting a direct effect of GS on β-cells. Therefore I 
hypothesized that at least some of OSA® effects can be attributed to a direct 
stimulatory effect on insulin secretion from β-cells in the islets of Langerhans and 
this hypothesis was tested in the in vitro studies described in chapter 4. 
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4.1 Introduction 
Glucose homeostasis is controlled by the coordinated secretion of two opposing 
hormones: insulin and glucagon released from β- and α-cells, respectively, of the 
islets of Langerhans. Insulin is controlled by a range of stimulatory and inhibitory 
factors (Goodman, 2003). Glucose is the major stimulatory factor and the most 
important nutrient that plays the leading role in insulin release and synthesis in 
mammals (Van Schaftingen and Schuit, 1999). Under fasting conditions, blood 
glucose is normally maintained at around 5mM but this value could reach 10-12mM 
following ingestion of a meal rich in carbohydrates. β-Cells respond to the rise of 
plasma glucose concentrations by secreting insulin in a biphasic fashion. The first 
phase, which lasts a couple of minutes, involves a rapid increase in insulin secretion 
reaching a peak after 2-4 minutes before returning to a lower sustained phase of 
insulin output (phase 2) that lasts throughout glucose stimulation (Del Prato et al., 
2002, Henquin et al., 2002). In rodent islets, glucose stimulation causes the release 
of 11-20 granules/cell/min from a readily available pool of 13,000 granules/cell 
(Ashcroft and Ashcroft, 1992, Eliasson et al., 2008).  
Regulation of insulin gene expression is complex and not completely understood. 
The total preproinsulin (PPI) cellular content is a balance between mRNA stability, 
mRNA gene expression and rate of translation of mRNA (Clark and docherty, 1992). 
Expression of insulin at both levels of mRNA and protein is regulated by glucose. 
During short-term exposure, glucose induces PPI mRNA translation but prolonged 
exposure to glucose causes an increase in PPI mRNA transcription and stability 
(Andrali et al., 2008, Clark and docherty, 1992, Nielsen et al., 1985, Welsh et al., 
1985). Generally, insulin gene expression is controlled by two major elements 
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upstream the transcription site 1) promoters, which initiate transcription and 2) 
enhancers, which do not initiate transcription by their own but rather enhance 
promoters’ activities. Both promoters and enhancers are regulated by transcription 
factors. It has been shown that upon stimulation with glucose, several transcription 
factors are activated by either components or products of glucose metabolism or by 
elements of glucose signaling cascades such as kinases/phosphatases (Andrali et al., 
2008, Melloul et al., 2002, Poitout et al., 2006).  
While insulin secretion is elevated during glucose stimulation, glucagon release is 
inhibited. Glucagon secretion is controlled by either direct nutrient metabolism in 
α-cell or by paracrine regulation from neighboring cells. Amino acids such as 
arginine and alanine are potent stimulators of glucagon secretion whereas insulin is 
a potent inhibitor. Unlike insulin, glucagon functions to counteract hypoglycemia by 
increasing hepatic output of glucose to maintain glucose supply to various part of 
the body, especially the CNS (Goodman, 2003, Gromada et al., 2007, Quesada et al., 
2008).  
Several plant extracts have been reported to stimulate insulin secretion in vivo. 
Leaves of GS plant extract have been shown to elevate plasma insulin levels and 
reduce blood glucose concentrations in vivo in animal models of type 2 and in 
human (Baskaran et al., 1990, Gupta, 1961, Gupta, 1963, Gupta and Variyar, 1961, 
Khare et al., 1983, Okabayashi et al., 1990, Shanmugasundaram et al., 1990b, 
Shanmugasundaram et al., 1981, Shanmugasundaram et al., 1983, Srivastava et al., 
1985, Srivastava et al., 1986, Terasawa et al., 1994). I have shown in chapter 3 that 
OSA® extract alleviated glucose intolerance in mice and raised insulin levels in 
patients with T2DM. It is difficult to explore the possible mechanism of action of any 
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plant extract in vivo, therefore in this chapter, I tested the effect of OSA® in vitro to 
determine whether OSA® has a direct insulinotropic activity in MIN6 cells and 
primary islets. I also examined the chronic effect of OSA® on insulin gene 
expression and total insulin content of mouse islets.   
4.2 Materials and Methods 
4.2.1 Maintenance of MIN6 cells 
MIN6 cells (passage 28-44) were maintained as monolayers under standard tissue 
culture conditions as described in section 2.3.2. They were trypsinized and used in 
experiments when confluency reached 70-80%. 
4.2.2 Formation of MIN6 Pseudoislets (PIs) 
To form PIs, MIN6 cells were subcultered in bacterial dishes under standard tissue 
culture conditions as described in section 2.3.3. PIs were used in experiments 
following 7-10 days of culture. 
4.2.3 Isolation of mouse and human islets 
ICR mice were killed by cervical dislocation. The pancreata of these mice were 
digested by collagenase as described in section 2.4. The islets were purified using 
Histopaque gradient and incubated in RPMI at 37C° (95% O2/ 5% CO2). Human 
islets were isolated from non-diabetic donors as described in section 2.5 following 
obtaining appropriate ethical approval. Islets were cultured in CMRL under 
standard tissue culture conditions. 
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4.2.4 Plant material and preparation 
OSA® leaves were extracted as described in section 2.1.1. High molecular weight GS 
extract, commercially available as OSA®, were isolated and provided as powder. 
Aqueous OSA® extract was prepared as 200mg/ml stock solution and further 
diluted in Gey & Gey buffer for use in experiments. 
4.2.5 Insulin secretion 
4.2.5.1 Static incubation with MIN6 cells 
MIN6 monolayers cells were counted as described in section 2.6, seeded into 96-
well plate at a density of 30,000 cells/well and cultured in DMEM supplemented 
with 10% FCS, 2mM L-glutamine and 100 U/ml penicillin with 0.1 mg/ml 
streptomycin at 37C° for 2 days (Section 2.7.1). MIN6 cells were pre-incubated with 
2mM glucose Gey & Gey buffer supplemented with 2mM CaCl2 and 0.5mg/ml BSA at 
37C° for 2 hrs. The cells then were incubated with buffer containing 2mM glucose in 
the presence or absence of different concentrations of OSA® extract for 30 minutes 
at 37C°. Aqueous OSA® extract (200mg/ml stock solution) was used to prepare 
0.06, 0.125, 0.25, 0.5, 1.0 mg/ml by serial dilution. Tolbutamide (100μM) and/or 
the protein kinase activator, phorbol 12-myristate 13-acetate (PMA: 500nM) were 
used as positive controls to stimulate insulin secretion. At the end of the incubation 
period, 100μl of incubation medium was removed and added to 400μl borate buffer 
and stored at -20C° until insulin was measured by RIA. 
4.2.5.2 Perifusion with MIN6 PIs, mouse and human islets 
To measure the reversibility of OSA® effects and the rate and pattern on insulin 
secretion, perifusions using MIN6 PIs, primary mouse and human islets were 
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performed, as described in section 2.7.3. MIN6 PIs or human islets were harvested 
and resuspended in DMEM medium and 100 μl was aliquoted into each perifusion 
chamber. For mouse islets perifusions, 60 ICR islets were dispensed into each 
chamber. PIs or islets were pre-perifused for 1 hr with buffer containing 2mM 
glucose and then with Gey & Gey buffer supplemented with either 2mM or 20mM 
glucose in the presence or absence of 0.125 or 0.25 mg/ml OSA®. To test the effect 
of OSA® at physiological glucose concentrations, human islets were perifused with 
either 5mM or 10mM in the presence or absence of 0.125 mg/ml OSA®. Perifusates 
were stored at -20C° until assayed for insulin by RIA as described in section 2.9. 
4.2.6 Glucagon secretion 
To investigate the effect of OSA® on glucagon secretion, perifusions with mouse 
islets were performed. As described in section 2.10, 100 ICR mouse islets were pre-
perifused with Gey and Gey buffer supplemented with 2mM glucose for 1 hr. 
Collection of samples was started at t=60 minutes and islets were perifused with 
Gey & Gey buffer containing 2mM glucose or 20mM arginine in the presence or 
absence of 0.25 mg/ml OSA®. Samples were stored at -20C° until assayed for 
glucagon content by RIA (section 2.9). 
4.2.7 Cell viability 
The effect of OSA® on membrane permeability and cell viability was examined 
using the Trypan Blue exclusion test (section 2.11). MIN6 cells or mouse islets 
treated with different concentration of OSA® were stained with Trypan Blue due 
(0.1 mg/ml) for 15 minutes before being visualized under a light microscope. 
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4.2.8 Mouse Preproinsulin mRNA expression 
Measurement of preproinsulin expression was performed to examine the chronic 
effect of OSA® on insulin gene expression. Mouse islets were isolated and incubated 
in RPMI (11.1mM glucose) overnight. 150 islets were preincubated with 2mM 
glucose and then treated with one of the following treatment: 2mM glucose, 20mM 
glucose (as positive control), 2mM glucose + 0.125 mg/ml OSA® for either 24 or 48 
hrs. Islets were then washed with PBS and lysed using cell lysis solution (section 
2.15.1). RNA from each treatment was extracted using Qiagen RNeasy mini kit 
(section 2.15.1). 0.5μg of RNA was reverse transcribed to cDNA using mmLV-RT 
(section 2.15.2). Negative (water only) and –RT controls were included to ensure 
the specificity of the reverse transcription process and the absence of any genomic 
contaminations. cDNA was further diluted 50 times to remove the influence of any 
remaining reagents from cDNA synthesis. Preproinsulin mRNA was quantified in 
real time using specific primers designed to amplify 125bp amplicon in the 
presence of SYBR green as the fluorescence indicator (section 2.16). Preproinsulin 
expression was normalized to actin, a house keeping gene. mRNA accession 
number, cycling conditions, gel electrophoresis, melt curve analyses, assay 
efficiencies and standard curves series for each gene are described in Appendix 2. 
4.2.9 Total insulin content of mouse islets 
Total insulin content of mouse islets (section 2.8) was determined by incubating 5 
islets in 2mM glucose supplemented with either vehicle or 0.125 mg/ml OSA® for 
24 and 48 hrs. 100μl of the medium was removed for insulin secretion 
measurement and islets were sonicated in acidified alcohol (200μl). Samples were 
stored at -20C° until assayed for insulin content by RIA.  
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4.2.10 Statistical analysis 
Data are represented as mean ± SEM. For perifusion experiments with more than 
one treatment, mean was calculated as area under the curve. Differences between 
treatments groups were assessed using analysis of variance (ANOVA), Student’s t-
test, and Bonferroni’s multiple comparison test as appropriate and considered 
significant at p< 0.05. 
4.3 Results 
4.3.1 Effect of OSA® on insulin secretion from MIN6 monolayers 
The effect of OSA® on insulin secretion from MIN6 cell monolayers at basal glucose 
concentrations was assessed as described in Materials and Methods. Thirty minutes 
exposure of MIN6 cells to OSA® caused a concentration-dependent increase in 
insulin secretion at a substimulatory (2mM) glucose levels (Figure 4.1). OSA® 
significantly stimulated insulin release at a concentration of ≥ 0.125mg/ml and 
increasing OSA® concentration to 1.0 mg/ml resulted in a marked increase in 
insulin release from MIN6 cells (2mM glucose: 0.19 ± 0.02 pg/cell/hr; 2mM glucose 
+ 1.0 mg/ml OSA®: 0.50 ± 0.02 pg/cell/hr). Both tolbutamide and/or PMA, insulin-
releasing substances used as positive controls, augmented insulin secretion at 2 and 
20mM glucose, respectively (Figure 4.1). Tolbutamide is a sulphonylurea and acts 
by blocking KATP-channels to increase insulin secretion; Whereas PMA augments 
insulin secretion by non-selectively activating typical PKC isoforms.  
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4.3.2 Effect of OSA® on membrane integrity and cell viability 
The effect of OSA® on membrane integrity was assessed using the Trypan Blue 
exclusion test. Incubating MIN6 cells with 0.1% Trypan Blue dye for 15 minutes in 
the presence of different OSA® concentrations resulted in a dose-dependent 
increase in the uptake of the dye. The blue staining was evident at OSA® ≥ 0.5 
mg/ml and 10-20% and 90-100% of MIN6 cells incubated in the presence of 0.5 and 
1.0 mg/ml OSA®, respectively, showed an uptake of Trypan Blue dye indicating a 
loss of membrane integrity (Figure 4.2). In contrast, exposing MIN6 cells to 500nM 
PMA caused an increase in insulin secretion without compromising membrane 
integrity (Table 4.1). Similarly, Trypan Blue stained cells were apparent in mouse 
islets incubated with 1.0 mg/ml OSA® (Figure 4.2). Note however, OSA® at 
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concentrations of ≤ 0.25 mg/ml had no detectable effect on trypan blue uptake 
suggesting that OSA® was not toxic to β-cells at these concentrations. 
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4.3.3 Effect of OSA® on the rate and pattern of insulin secretion from MIN6 
PIs, mouse and human islets 
The effects of OSA® on the pattern and rate of insulin secretion, and the 
reversibility of its effects, were tested using MIN6 PIs, mouse and human islets in 
vitro, as shown in Figure 4.3, 4.4 and 4.5, respectively. Perifusion of MIN6 PIs with 
buffer supplemented with 0.25 mg/ml OSA® at a substimulatory concentration 
(2mM) of glucose evoked an increase in insulin secretion as shown in Figure 4.3. 
The response to OSA® was rapid in onset, sustained for the duration of exposure to 
OSA®, and rapidly reversible upon its withdrawal. Subsequent exposure to 20mM 
glucose following OSA® treatment induced a further increase in insulin secretion 
(Figure 4.3). OSA® also mounted prompt, long-lived and reversible responses from 
mouse and human islets (Figure 4.4 and 4.5), with subsequent responses to 20mM 
glucose consistent with unimpaired secretory responses after exposure to OSA®.   
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In addition to initiating an insulin secretory response, OSA® (0.25 mg/ml) 
potentiated glucose-induced insulin secretion from MIN6 PIs, as shown in Figure 
4.6. Thus, increasing the glucose concentration from 2 to 20mM (10-30 min) 
resulted in the expected biphasic pattern of glucose-induced insulin secretion. The 
first phase was rapid and transient, reaching a peak within 4 minutes followed by a 
sustained second phase of insulin secretion of a lower magnitude. Exposure to 
OSA® (0.25 mg/ml) in the continued presence of 20mM glucose (30-50 min) 
further potentiated the glucose-induced secretory response, with enhanced rates of 
insulin secretion being maintained for the duration of exposure to OSA®. Similarly, 
20mM glucose caused a biphasic increase in insulin secretion from mouse and 
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human islets. Again, glucose-induced insulin secretion was significantly augmented 
upon exposure to OSA® (Figure 4.7 and 4.8). 
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4.3.4 Effect of OSA® on insulin secretion from human islets at physiological 
glucose concentrations 
The effect of OSA® at more intermediate glucose concentrations was also examined 
using perifusion experiments with human islets. Human islets were perifused with 
either 5mM (Figure 4.9) or 10mM glucose (Figure 5.10) in the presence of 
0.125mg/ml OSA®. Both glucose concentrations caused stimulation in insulin 
secretion which was further potentiated upon exposure to OSA®. The increase in 
OSA®-induced insulin secretion at 5mM and 10mM glucose was similar in profile to 
that seen at 2mM and 20mM glucose. The insulin secretion induced by OSA® was 
rapid and remained elevated throughout the presence of OSA®. 
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4.3.5 Effect of OSA® on glucagon secretion from mouse islets 
The possible contribution of α-cells to the overall effect of OSA® was assessed by 
measuring glucagon release in perifusion experiment using mouse islets. Exposure 
of mouse islets to 0.25 mg/ml OSA® at 2mM glucose initiated a small increase in 
glucagon secretion (Figure 4.11). The glucagon secretory response to OSA® was 
rapid reaching its peak within approximately 2 minutes of the onset of stimulation. 
However, the elevations in glucagon output returned almost to basal despite the 
continuous presence of OSA®. Glucagon secretion was further increased upon 
subsequent exposure to 20mM arginine (Figure 4.11). Under maximum stimulation 
of glucagon secretion (induced by 20mM arginine), OSA® further potentiated 
arginine-induced glucagon secretion (Figure 4.12). 
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4.3.6 Effect of OSA® on preproinsulin mRNA expression 
The possible effect of OSA® on insulin gene transcription was determined by 
measuring preproinsulin (PPI) mRNA expression using quantitative PCR (Figure 
4.13 and 4.14). Stimulatory concentrations of glucose (20mM) caused a 2.5 fold 
increase in PPI mRNA levels following 24 hrs exposure. The PPI mRNA levels 
induced by 20mM glucose remained elevated after 48 hrs. Similarly, 0.125mg/ml 
OSA® at 2mM glucose resulted in a significant increase in PPI expression 
(approximately 1.5 fold increase) at 24 hrs (Figure 4.13) which was also sustained 
after 48 hrs (Figure 4.14). However, the extent of OSA®-induced increase in PPI 
mRNA levels was lower than that of 20mM glucose. 
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4.3.7 Effect of OSA® on mouse total insulin content 
Chronic exposure of mouse islets to either 0.125 mg/ml OSA® or 20mM glucose for 
24 (Figure 4.15) or 48 (Figure 4.16) hrs was not accompanied with any increases in 
total insulin content in response to the increase in PPI mRNA levels (Figure 4.13 
and 4.14). However, simultaneous measurement of insulin in the supernatants from 
OSA® or 20mM glucose-treated islets showed a dramatic stimulation in insulin 
secretion (2mM glucose: 1.7 ± 0.12, 2mM glucose + OSA®: 2.9 ±0.08 and 20mM 
glucose: 4.03 ± 0.7 ng/islet) as expected. The increases in insulin secretion induced 
by 20mM glucose or OSA® with no changes in insulin content were consistent with 
maintaining insulin stores by elevating PPI mRNA levels. 
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It has been established in chapter 3 that OSA® markedly increased plasma insulin 
levels in human with T2DM and improved glycemic control in an animal model of 
diabetes (ob/ob mice) in vivo. This effect may be due in part to the ability of OSA® 
to directly modulate hormone secretion and synthesis in islets of Langerhans. To 
test this hypothesis, I examined the acute effects of OSA® on insulin and glucagon 
secretion and the chronic effects of OSA® on insulin synthesis in vitro. The 
insulinotropic activity of OSA® was first investigated using MIN6 cells and primary 
β-cells (mouse and human islets). 
The MIN6 cell-line is a β-cell line derived from a mouse insulinoma. It was 
established by targeted expression of SV40 (Simian virus 40) T antigen in 
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transgenic mice. SV40 T antigen is a protein which functions to inhibit growth-
suppressing proteins allowing the cells to proliferate indefinitely. The advantages of 
MIN6 cell-line over other β-cell-lines include high insulin content and glucose 
responsiveness (especially at low passage) (Ishihara et al., 1993, Persaud, 1999). I 
used MIN6 cells as a rapid screening tool for establishing the effective OSA® 
concentrations range and static experiments with MIN6 monolayers showed a 
concentration-dependent increase in insulin secretion at basal glucose levels. In all 
our experiments, the basal glucose concentration was maintained at 2mM, a sub-
stimulatory concentration of glucose, to eliminate the possible contribution of 
glucose to the secretory response. The elevation in insulin levels was significant at 
OSA® concentration of ≥ 0.125 mg/ml.  
MIN6 cells used in static experiments were grown as monolayers thus they had a 
minimal cell-cell contact and were less responsive to secretagogues. Nevertheless, 
this was restored when MIN6 cells were configured as three-dimensional islets like 
structure (Pseudoislets: PIs). MIN6 PIs have an improved secretory responsiveness 
due to enhanced β-cell to β-cell contact and communication (Hauge-Evans et al., 
1999) so in our subsequent perifusion experiments MIN6 cells were configured as 
PIs. Perifusion experiments allow the rate and pattern of insulin secretion to be 
determined. In our experiments, OSA® initiated insulin secretion at a 
substimulatory concentration (2mM) of glucose suggesting a nutrient- and 
metabolism-independent mechanism of action on MIN6 cells.  This was further 
confirmed by our observations that OSA® also potentiated the maximum glucose-
induced (20mM) secretory responses, indicating that OSA® does not act as a 
nutrient itself, nor as an enhancer of glucose metabolism, but has an effect 
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independent of nutrient metabolism. A 20mM concentration of glucose was chosen 
to eliminate the contribution of metabolism-induced ATP in OSA®-induced insulin 
secretion. OSA® also initiated and potentiated insulin secretion from mouse and 
human islets supporting a direct effect of OSA® on primary β-cells. Perifusion with 
more physiological concentrations of glucose demonstrated that OSA® stimulated 
insulin secretory responses from human islets at both 5mM (fasting blood 
concentration) and 10mM glucose (post-prandial glucose level). 
Extracts of GS leaves contain a mixture of saponin compounds (Liu et al., 2004, 
Manni and Sinsheimer, 1965, Murakami et al., 1996, Sinsheimer and McIlhenny, 
1967, Sinsheimer and Rao, 1970, Sinsheimer et al., 1970, Sugihara et al., 2000, Ye et 
al., 2000, Yoshikawa et al., 1997b, Zhu et al., 2008). The presence of these 
compounds may be detrimental to membrane integrity and cell viability (Schulz, 
1990), causing pathological and unregulated release of insulin from damaged β-
cells (Persaud et al., 1999) because these saponins are normally used 
experimentally as permeation agents in a number of studies (Ahnert-Hilger and 
Gratzl, 1988, Schulz, 1990). There are a number of reasons why this is unlikely to 
account for the insulin-releasing properties of OSA®. Firstly, OSA® does not 
damage β-cell membranes at a concentration of ≤ 0.25 mg/ml OSA® from MIN6 
cells and islets as assessed by Trypan Blue exclusion test. OSA® concentration of ≥ 
0.5 m/ml caused a marked uptake of the Trypan Blue dye into MIN6 cells and 
mouse islets in a concentration-dependent manner. The Trypan Blue uptake to 
virtually all cells was seen when a concentration of 1.0 mg/ml OSA® was used, 
consistent with a previously reported study (Persaud et al., 1999). Secondly, insulin 
secretory responses induced by ≤ 0.25 mg/ml OSA® were sustained and readily 
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reversible following its removal, consistent with the activation of a regulated 
secretory response. Finally, MIN6 cell or primary islets which had been exposed to 
OSA® alone were capable of mounting a normal secretory response to glucose 
following OSA® treatment, confirming that OSA® treatment was not associated 
with β-cell damage because the cells were subsequently able to metabolize glucose 
and trigger membrane depolarization in response to glucose. 
Nutrients such as glucose have been documented to have a stimulatory effect on 
insulin biosynthesis, which involves transcription and translation of PPI mRNA 
(Andrali et al., 2008, Poitout et al., 2006) which is processed to proinsulin and then 
insulin. Our measurements of mouse PPI mRNA levels indicated that exposure to 
OSA® alone also caused a significant increase in PPI gene expression which was 
apparent at both incubations time (24 and 48 hrs) similar to the effect of 20mM 
glucose on insulin gene expression. 20mM glucose resulted in an approximately 2.5 
fold increase in PPI expression throughout the two time points of the experiment. 
The increase in PPI mRNA levels induced by 20mM glucose have been reported 
previously to be likely due to an autocrine effect of insulin on insulin gene 
transcription in addition to a direct effect of glucose on insulin promoter and 
stabilization of PPI insulin mRNA (Leibiger et al., 2000, Nielsen et al., 1985, Welsh et 
al., 1985). Our results were consistent with other groups who reported a 
stimulation of PPI gene expression by glucose in β-cell lines (da Silva Xavier et al., 
2000, Nielsen et al., 1985), rat (Giddings et al., 1985, Philippe et al., 1994) and 
human islets (Evans-Molina et al., 2007). The reported effect was noticeable during 
prolonged exposure to glucose (most likely after 24-48 hrs), similar to our results. 
OSA® may also increase mRNA levels of PPI in a mechanism partially similar to 
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glucose. Our data using mouse islets demonstrated that OSA® had a sustained 
effect on insulin output during both acute and chronic incubation periods. The 
insulin secretion induced by OSA® may reach sufficient concentrations in the 
vicinity of β-cells to act locally on insulin receptor to promote insulin gene 
expression. 
The elevated levels of PPI mRNA were not associated with increases in insulin 
content from mouse islets exposed to OSA®. Our results showed that following 24 
and 48 hrs mouse islets treated with OSA® secreted only less than 5% of their total 
insulin content, in agreement with published reports that showed islets released 
about 10% of total insulin content even after prolonged stimulation with 20mM 
glucose (Bailey et al., 1992). These observations are consistent with a physiological 
effect of OSA® to compensate for the released insulin by increasing production 
without overloading the β-cell. This is crucial to maintain stores of insulin and to 
prevent β-cell insulin depletion. 
The stimulatory effect of OSA® was not only confined to β-cells only but also 
applied to α-cells. OSA® stimulated glucagon secretion at both basal glucose and 
stimulatory arginine concentrations supporting our observations that OSA® did not 
act as a nutrient nor via enhanced nutrient metabolism. The ability of insulin 
secretagogues to modulate glucagon secretion is not uncommon. Sulphonylureas 
have been shown to increase glucagon secretion in mouse α-cells (MacDonald et al., 
2007) and in patients with T1DM (Bohannon et al., 1982). This may possibly reflect 
some similarities in the mechanism of action between sulphonylurea and OSA®. 
In conclusion, OSA® has a direct insulinotropic activity on a β-cell line and on 
primary islets. It modulates islet function by initiating and potentiating insulin and 
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glucagon secretion. The secretory responses of OSA® were further supported by 
the elevations of preproinsulin mRNA and thus maintenance of insulin stores. The 
ability of OSA® to preserve insulin stores is consistent with therapeutic usefulness 
in patients with T2DM. Unfortunately, the therapeutic use of OSA® may be 
hindered by the obscurity of the signalling pathways underlying OSA® actions. 
Therefore, in chapter 5 the possible molecular mechanisms of actions of OSA® 
were investigated. 
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5.1 Introduction 
Increasing cytosolic Ca2+ and protein kinase activation play important roles in 
insulin-stimulus secretion coupling. Glucose and other nutrients stimulate insulin 
secretion primarily through a KATP channels-sensitive pathway. When glucose 
enters β-cells, it gets metabolized rapidly generating ATP. Increases in ATP 
concentration and ATP/ADP ratio cause closure of KATP channels, depolarization of 
β-cells and opening of voltage gated Ca2+ channels (VGCC). Opening of VGCC results 
in Ca2+ influx, elevation of intracellular Ca2+ concentration ([Ca2+]i) and insulin 
exocytosis (Ashcroft and Ashcroft, 1992, Howell, 1984). Non-nutrients potentiate 
insulin secretion through receptor-mediated activation of second messengers and 
protein kinases. Activation of G-protein coupled receptors linked to either αq and 
αs leads to activation of PLC and AC, respectively. PLC generates IP3 and DAG which 
increases Ca2+ release from intracellular stores and activates DAG-sensitive PKC, 
respectively. On the other hand, AC generates cAMP from ATP which in turn 
amplifies the stimulus signal through PKA-dependent and PKA-independent 
pathways (Howell et al., 1994). PLA2 also has been reported to influence insulin 
secretion by librating arachidonic acid (AA) from phosphatidylcholine. PLA2 has 
been categorized into three major groups: cytosolic PLA2 (cPLA2), Ca2+-independent 
PLA2  (iPLA2)and secretory PLA2 (sPLA2) (Persaud et al., 2007). While cPLA2 and 
iPLA2 can be activated by glucose (Jones et al., 2004), sPLA2 is mainly activated 
under inflammatory conditions (Sun et al., 2004). Although the mechanism of action 
of AA-induced insulin secretion is not completely understood, it may involve 1) 
facilitating Ca2+ entry through VGCC, 2) increasing Ca2+ release from intracellular 
Chapter 5                      GS-induced insulin secretion: role of extracellular Ca2+ and protein kinases 
The role of plant extracts on islet function in vivo & in vitro Page | 167  
 
stores, 3) activating protein kinases and 4) stimulating fusion of insulin vesicles and 
exocytosis (Jones and Persaud, 1993). 
I have established in chapter 4 that OSA® directly initiated and potentiated insulin 
secretion from the MIN6 cell line and from mouse and human islets. It is important 
to understand the molecular mechanism of action(s) of OSA® if OSA® is to be used 
therapeutically but the intracellular signaling pathway by which OSA® increases 
insulin secretion is currently unknown. Therefore, in this chapter I investigated 
whether the stimulatory action of OSA® on insulin secretion from MIN6 cells and 
mouse islets is dependent on extracellular Ca2+ and indentified the possible 
intracellular signaling components(s) of OSA®-induced insulin secretion from 
mouse and human islets. 
5.2 Materials and Methods 
5.2.1 Plant material and preparation 
OSA® was prepared by extracting the fresh GS leaves as mentioned in section 2.1.1. 
The OSA® powder was a gift from Dr. Arun Chatterji (Ayurvedic Life International, 
Wisconsin, USA). Aqueous stock (200 mg/ml) of OSA® was freshly prepared and 
diluted in physiological solution for experiments. 
5.2.2 Maintenance of MIN6 cells 
MIN6 cells (passage 30-37) were maintained as monolayers in DMEM 
supplemented with 10% fetal bovine serum (FBS), 2mM glutamine and 100U/ml 
penicillin/0.1mg/ml streptomycin under standard tissue culture conditions 
(section 2.3.2). The cells were harvested and used in experiments when the cell 
confluency reached 70-80%. 
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5.2.3 Isolation of mouse and human islets 
Islets from male ICR mice and non-diabetic humans were isolated as described in 
section 2.4 and 2.5. The isolated mouse islets were cultured in RPMI supplemented 
with 10% newborn calf serum (NCS) and 100U/ml penicillin/0.1mg/ml 
streptomycin while the human islets were kept in CMRL supplemented with 10% 
NCS and 100U/ml penicillin/0.1mg/ml streptomycin in humidified (5% CO2, 95% 
O2) incubator. 
5.2.4 Insulin secretion 
5.2.4.1 Static and perifusion secretion with MIN6 cells, mouse and human 
islets 
The effect of various inhibitors on OSA®-induced insulin secretion from MIN6 cells, 
mouse and human islets were assessed using either static secretion experiments or 
temperature-controlled perifusion apparatus, essentially as described previously in 
section 2.7. In static incubations, MIN6 cells (20,000 cells/well), section 2.7.1, or 
mouse islets (3 islets/300μl), section 2.7.2, were pre-treated with 2mM glucose 
medium for 2 hrs. MIN6 cells and mouse islets were treated for 30 minutes and 1 
hr, respectively, with OSA® in the presence or absence of agents mentioned in the 
corresponding figure legends. 100μl of supernatant was removed and stored at -
20C° until assayed for insulin content by RIA.  
In perifusion experiments (section 2.7.3), groups of 60 mouse islets or 100μl of the 
suspended human islets were perifused with buffer containing 2mM glucose, 2mM 
CaCl2 and 0.5 mg/ml BSA and supplemented with 0.25 mg/ml OSA® in the 
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presence or absence of various pharmacological inhibitors. The perifusate was 
collected every 2 min and stored at -20C° until assayed for insulin content by RIA. 
5.2.5 Measurement of intracellular Ca2+ levels ([Ca2+]i) 
MIN6 cells (50,000 cells/coverslip) or dispersed mouse islets (160,000 
cells/coverslip) were seeded on ethanol-washed and poly-D-lysine coated glass 
cover slips, respectively. Cells were allowed to adhere overnight under standard 
tissue culture conditions. The effect of OSA® on [Ca2+]i were measured by Ca2+ 
microfluorimetry as described in section 2.12. Cells were loaded by Fura-2/AM for 
30 min at 37C° and then perifused with 2mM glucose supplemented with OSA® 
(flow rate 1ml/min) in the presence or absence of either 0.1mM EGTA or 10μM 
nifedipine. Cells were excited at 340 and 380nm and the emitted light was captured 
by a CCD camera. Changes in [Ca2+]i were expressed as a 340:380 ratio. 
5.2.6 Measurement of intracellular cAMP levels 
MIN6 cells (30,000 cells/well) or mouse islets (5 islets/well) were treated for 30 
minutes at 37C° with treatments shown in the corresponding Figure legends. 100μl 
of supernatant was removed and assayed for insulin content by RIA while the cells 
were lysed and intracellular cAMP levels [cAMP]i was quantified by enzyme 
immunoassay as described in section 2.13. 
5.2.7 Statistical analysis 
Data were expressed as mean ± SEM. The mean for some perifusion expreriments 
represents the area under the curve was. Differences between treatment groups 
were assessed using one way analysis of variance (ANOVA), Student’s t-test, or 
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Bonferroni’s multiple comparison test as appropriate, and differences between 
treatments were considered significant at p< 0.05. 
5.3 Results 
5.3.1 Effect of OSA® on mouse β-cell [Ca2+]i 
Addition of OSA® caused a marked elevation in [Ca2+]i in MIN6 cells even at a 
concentration as low as 0.03 mg/ml (Figure 5.1). This increase in [Ca2+]i was 
completely abolished by the removal of extracellular Ca2+ using 0.1mM EGTA or by 
blocking VGCC by 10μM nifedipine. The response to OSA® had a lag time of 
approximately 3 min and persisted even after washing the cells with 2mM glucose 
buffer solution creating a new higher basal [Ca2+]i. Further elevation of [Ca2+]i, 
above the new baseline, was observed after addition of 0.06 mg/ml OSA®. In 
addition, The cells were able to further elevate [Ca2+]i after exposure to 500μM 
Carbachol. Similar to MIN6 cells, dispersed mouse islets responded to 0.06 mg/ml 
OSA® in a similar fashion to that seen with MIN6 cells (Figure 5.2). Exposing mouse 
islets to OSA® resulted in a delayed (onset of approximately 3 minutes) and a 
sustained (even after the removal of OSA®) increase in [Ca2+]i. This response was 
also completely inhibited by the presence of EGTA and nifedipine. 
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5.3.2 Effect of KATP channel opening on OSA®-induced insulin secretion from 
mouse islets 
One hour incubation of mouse islets with 0.25 mg/ml OSA® caused a significant 
increase in insulin secretion as shown in Figure 5.4. Addition of 250µM diazoxide, a 
KATP channel opener, completely blocked glucose-induced insulin secretion (Figure 
5.3) but did not alter the OSA® effect on insulin secretion (Figure 5.4).  
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5.3.3 Effect of extracellular Ca2+ removal and VGCC blockade on OSA®-
induced insulin secretion from MIN6 cell monolayers 
Thirty minutes exposure of MIN6 cell monolayers to OSA® (0.25 and 1.0 mg/ml) 
caused an increase in insulin secretion. Removal of extracellular Ca2+ (+ 0.1mM 
EGTA) or addition of nifedipine reduced the increases in insulin output in the 
presence of 0.25 mg/ml but not 1.0 mg/ml OSA®-treated cells (Figure 5.5 and 5.6, 
respectively).  
Chapter 5                      GS-induced insulin secretion: role of extracellular Ca2+ and protein kinases 
The role of plant extracts on islet function in vivo & in vitro Page | 175  
 
 
Chapter 5                      GS-induced insulin secretion: role of extracellular Ca2+ and protein kinases 
The role of plant extracts on islet function in vivo & in vitro Page | 176  
 
 
5.3.4 Effect of VGCC blockade on OSA®-induced insulin secretion from 
mouse and human islets 
Perifusing either mouse (Figure 5.8) or human islets (Figure 5.9) with buffer 
containing 0.25 mg/ml OSA® for 20 minutes induced a rapid and sustained insulin 
secretion at 2mM glucose. The sustained increase in insulin secretion caused by 
OSA® was significantly decreased but not completely abolished when VGCC were 
blocked with 10µM nifedipine, a concentration that showed to be effective in 
blocking glucose-induced insulin secretion (Figure 5.7). These results were 
consistent with the partial inhibitory effect seen in static incubations of MIN6 cell 
monolayers. 
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5.3.5 Effect of protein kinase inhibition on OSA®-induced insulin secretion 
from mouse and human islets 
The involvement of protein kinases in the signaling of OSA®-induced insulin 
secretion was assessed using pharmacological inhibitors of protein kinases known 
to be involved in insulin-secretion coupling. Staurosporine, a non-selective ATP site 
general protein kinase inhibitor, inhibited carbachol-induced insulin secretion 
(Figure 5.10). However, it partially but not completely inhibited the stimulatory 
effect of OSA® on insulin secretion from mouse (Figure 5.11) and human (Figure 
5.12) islets, consistent with the involvement of protein kinase activation in OSA-
induced insulin secretory responses.  
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The possible contributions of diacylglycerol (DAG)-sensitive protein kinase C and 
Ca2+/calmodulin kinase II (CaMK II) were further investigated by perifusing OSA®-
treated islets with buffers containing selective inhibitors of DAG-dependent 
isoforms (α and β) of protein kinase C (Gö 6976) and CaMK II (KN62). Interestingly, 
neither 1M Gö 6976 (Figure 5.14 and 5.15) nor 10μM KN62 (Figure 5.17 and 5.18) 
inhibited the insulin secretory profile from either mouse or human islets exposed to 
OSA®, although both compounds have shown to be effective at the concentrations 
used in these experiments (Harris et al., 1997, Li et al., 1992) (Figure 5.13 and 5.16). 
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5.3.6 Effect of OSA® on mouse β-cells [cAMP]i 
The possible role of cAMP in mediating the effect of OSA® on insulin secretion was 
also investigated. MIN6 cells or mouse islets were treated with buffer containing 
2mM or 20mM glucose in the presence of 0.25 mg/ml OSA® or 10μM 
noradrenaline. The treated cells were incubated throughout the experiments with 
the non-selective phosphodiesterases inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX) or IBMX plus forskolin (FSK), an activator of adenylate cyclase, to allow for 
[cAMP]i measurements. Thirty minutes exposure of MIN6 cells to 20mM glucose in 
the presence of 0.25 mg/ml OSA® significantly reduced glucose-induced [cAMP]i in 
cells treated with IBMX (Figure 5.19). This effect was further manifested when the 
cells were incubated with FSK. OSA® completely attenuated FSK-induced elevation 
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in [cAMP]i stimulated by glucose (Figure 5.20). Noradrenaline, which is α2 agonist, 
reduced [cAMP]i and thus decreased glucose-stimulated insulin secretion and is 
used as a positive control. Similarly, OSA® blocked the increase in [cAMP]i-induced 
by glucose in IBMX or FSK-treated mouse islets (Figure 5.23 and 5.24). Despite the 
reductions of [cAMP]i in MIN6 cells and mouse islets, concurrent measurement of 
insulin showed a stimulation of insulin secretion by OSA® (Figure 5.21, 5.22, 5.25 
and 5.26).  
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In the previous chapter, I have established that OSA® initiated insulin secretion at 
2mM glucose by direct effects on β-cells. The concentration of OSA® used was not 
associated with any damage to the β-cell plasma membrane, as evident by the 
Trypan Blue exclusion test, suggesting that OSA® stimulates insulin secretion by 
interacting with a regulated secretory pathway. 
The classic insulin secretion pathway is mainly initiated by glucose and other 
nutrients which when they are metabolized within pancreatic β-cells trigger closure 
of KATP-channels, depolarization of β-cells and opening of VGCC leading to 
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elevations of [Ca2+]i and insulin exocytosis. Several reports have shown that [Ca2+]i 
alone can induce insulin release. This pathway is largely modulated by hormones 
and neurotransmitters through activation of second messengers such as DAG, IP3 
and cAMP and subsequent stimulation of various mediators such as PKC, CaMKs, 
PKA, and AA.     
Insulin secretagogues such as sulphonylurea induce insulin secretion by blocking 
KATP-channels leading to β-cells depolarization, opening of L-type VGCC and 
subsequent increases in [Ca2+]i thus bypassing glucose metabolism. Since OSA® 
also induced insulin secretion at a substimulatory glucose concentration the effect 
of OSA® on KATP-channels and [Ca2+]i was tested. Maintaining KATP-channels in the 
open state by diazoxide was not associated with a reduction in OSA®-induced 
insulin secretion from mouse islets implying that OSA® acts beyond KATP-channels 
closure and subsequent depolarization of β-cells.  In our study, exposing MIN6 cells 
or mouse β-cells to OSA® significantly elevated [Ca2+]i which was completely 
abolished when extracellular Ca2+ was removed or VGCCs were blocked by 
nifedipine, indicating that OSA®-induced elevation of [Ca2+]i occurs solely because 
of Ca2+ entry though L-type VGCC and may contribute to the stimulatory action of 
OSA® on insulin secretion. Furthermore, depletion of extracellular Ca2+ or blockade 
of VGCC by nifedipine also resulted in reductions in insulin secretion from MIN6 
cells treated with 0.25 mg/ml but not 1.0 mg/ml OSA®. This was in agreement with 
our data using Trypan Blue exclusion tests (chapter 2) which demonstrated that 
OSA® at a concentration of ≥ 0.5 mg/ml caused a massive release of insulin in a 
Ca2+-unregulated manner due to extensive damage to plasma membrane and 
effective permeabilization of the cells. Blocking VGCC with nifedipine also affected 
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OSA®-induced insulin secretion from primary islets. Our results from perifusion 
experiments of mouse and human islets with OSA® in the presence and absence of 
nifedipine showed a partial inhibition in the increase in insulin secretion caused by 
OSA®. These data suggest that the secretory responses to OSA® were dependent, 
at least in part, on the ability of OSA® to increase cytosolic Ca2+ by facilitating Ca2+ 
entry through VGCC. 
The involvement of protein kinases in stimulating insulin secretion is well 
documented. Glucose and other receptor-operated agonists stimulate insulin 
secretion through activation of second messengers and protein kinase signaling 
cascades (Howell et al., 1994). Thus I tested the possible contribution of protein 
kinases in the stimulatory effect of OSA® on insulin secretion. Our experiments 
showed that staurosporine did not completely block OSA®-induced insulin 
secretion in either mouse or human islets even when it was used at a concentration 
that has been shown previously to inhibit islet PKC, PKA and Ca2+-sensitive protein 
kinases (Persaud et al., 1993). These observations are consistent with a partial 
involvement of kinase activation in the stimulatory effect of OSA® on insulin 
secretion. To identify the possible kinases involved in β-cell secretory responses to 
OSA®, I assessed the contribution of islets DAG-sensitive PKC, CaMKII and PKA, in 
OSA®-induced insulin secretion. 
DAG-sensitive PKC isoforms and CaMKII are Ca2+-sensitive protein kinases and their 
role in mediating the effect of some receptor-operated agonists such as 
acetylcholine and carbachol is well established. PLC activation leads to the 
generation of DAG which subsequently activates DAG-sensitive PKC. PLC also 
liberates Inositol trisphosphate (IP3) which causes Ca2+ release from intracellular 
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stores. The released Ca2+ is associated with calmodulin to activate CaMKII which 
plays an important role in mobilizing insulin vesicles and insulin exocytosis (Howell 
et al., 1994). Both kinases (DAG-sensitive PKC and CaMKII) are also stimulated 
following Ca2+ influx into β-cells. However, our data do not support a role for these 
two kinases in the β-cell secretory responses to OSA®. The inhibitors of DAG-
sensitive PKC (Gö6976) and CaMKII (KN62) had no effect on OSA® stimulation of 
insulin secretion. The involvement of other Ca2+-dependent kinases or lipases is still 
possible and identification of these mediators merits further investigation. 
Protein kinase A has been reported to have an important role in β-cell responses to 
cAMP-elevating agents such as glucagon and glucagon-like peptide (GLP-1). 
Activation of AC through G-protein coupled receptors generates the second 
messenger cAMP which activates PKA and thus potentiates insulin secretion as well 
as having PKA-independent effects (Furman et al., 2010). Activators (such as FSK) 
or inhibitors (such as noradrenaline) of AC can largely modulate the levels of cAMP 
so I assessed whether cAMP was involved in OSA®-induced insulin secretion by 
directly measuring the effect of OSA® on [cAMP]i. cAMP is rapidly inactivated by 
phosphodiesterases (PDEs) (Shafiee-Nick et al., 1995) so I used a PDE inhibitor, 
IBMX to allow for accurate measurement of intracellular cAMP ([cAMP]i). Our 
results showed that OSA®, unexpectedly, inhibited [cAMP]i accumulation in IBMX-
treated MIN6 cells and mouse islets. Stimulation of AC by FSK led to enhanced 
production of [cAMP]i which was again reduced by the presence of OSA®. The 
reduction in [cAMP]i by OSA® presumably reflects a G-protein-mediated effect 
linked to Gαi/o. Although OSA® decreased [cAMP]i levels from MIN6 cells and 
mouse islets, concomitant measurement of insulin output from these cells showed 
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that insulin secretion was significantly stimulated by OSA®, as expected, suggesting 
a dissociation of the insulin secretory response to OSA® from its cAMP-reducing 
effect. In accordance with our results, carbachol, a muscarinic receptor agonist 
known to stimulate secretion, has been previously reported to lower cAMP levels 
while increasing [Ca2+]i in a number of cell types including β-cells (Dai et al., 1991, 
Madison and Yamaguchi, 1996, Nakagawa et al., 2009, Watson et al., 1993). 
Our results also demonstrated that OSA® stimulated insulin secretion 
independently of Ca2+ influx and protein kinase activation as shown by the 
persistent activity of OSA® on insulin secretion even when the cells were incubated 
with nifedipine, a VGCC blocker, or staurosporine, a general protein kinase 
inhibitor. This may suggest that OSA® acts at least in part at a late stage of the 
secretory cascade distal to VGCC and protein kinase activation. In this context, 
OSA® may share some similarities with arachidonic acid (AA). Similar to OSA®, AA 
induced insulin secretion at substimulatory concentrations of glucose (Persaud et 
al., 2007). In addition, neither OSA®- nor AA-induced insulin secretion was fully 
blocked by closing VGCC or inhibiting protein kinase activation (Band et al., 1992, 
Basudev et al., 1993), suggesting an effect on the exocytotic process to directly 
release insulin (Band et al., 1993). These similarities between OSA® and AA may 
indicate that OSA® mediates some of its effects either through the generation of AA, 
or through a similar mechanism to AA. 
In summary, a proposed mechanism of action of OSA® on insulin secretion is 
shown in Figure 5.27 in which OSA® may increase [Ca2+]i through VGCC either 
directly or through activation of a Gαi/o protein coupled receptor. Association of 
OSA® with the receptor librates Gαi which acts on AC to inhibit cAMP formation. 
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The beta gamma (βγ) subunit of the G protein may act as stimulatory subunits to 
activate PLA2 to liberate AA. It has been reported in the literature that PLA2 can be 
activated by the βγ subunit in a number of cell types including platelets and retinal 
rod cell (Jelsema and Axelrod, 1987, Murayama et al., 1990). AA can then initiates 
insulin secretion as described in the Figure. 
 
Chapter 6                                                            GS protects β-cells from cytokine-induced apoptosis 










Chapter 6                                                            GS protects β-cells from cytokine-induced apoptosis 
The role of plant extracts on islet function in vivo & in vitro Page | 199  
 
6.1 Introduction 
DM has been associated with reductions in β-cell volume and mass, mainly due to 
excessive induction of apoptosis (Donath and Halban, 2004, Johnson and Luciani, 
2010, Lupi and Del Prato, 2008). In T1DM, for example, β-cell death can be 
precipitated by the release of pro-inflammatory cytokines from activated 
macrophages and T-cells. Cytokines (IL-1β, TNF-α and INF-γ) acting through their 
receptors activate several signaling pathways which are involved in apoptosis and 
β-cell survival (Cnop et al., 2005). The NF-κB pathway is one of the major pathways 
induced by cytokines. In unstimulated cells, NF-κB is bound to its inhibitory protein 
IκB in the cytosol. Upon activation, NF-κB is released from its regulatory protein 
and translocated into the nucleus where it acts as transcription factor to directly 
regulate the expression of numerous pro and anti-apoptotic genes (Melloul, 2008). 
It has been previously reported that NF-κB-responsive genes encode proteins that 
can promote either β-cell apoptosis - such as iNOS, pro-apoptotic Bcl2-family and 
Fas - or β-cell survival - such as MnSOD and IAPs (Cnop et al., 2005, Melloul, 2008). 
NF-κB-independent signaling pathways are also involved in triggering apoptosis, 
including signaling through MAPKs, JAK/STAT and granzyme B (Cnop et al., 2005, 
Eizirik and Mandrup-Poulsen, 2001, Gysemans et al., 2008, Hui et al., 2004, 
Mandrup-Poulsen, 2001). In addition, cross talk with other crucial pathways 
involved in cell survival has been observed and down regulation of these pathways 
may augment cell death and apoptosis. PKA-CREB signaling is one of these 
pathways. Activation of AC causes enzymatic cleavage of ATP to cAMP which 
activates PKA. Activation of PKA stimulates the induction of certain transcription 
factors involved in cell survival through CREB-CREM interaction (Costes et al., 
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2006). AKT signaling has also been involved in cell survival. AKT exerts its anti-
apoptotic actions by 1) phosphorylating and thus inactivating BAD, a pro-apoptotic 
member of Bcl2 family, 2) preventing the cleavage of pro-caspase-9 to caspase-9 
leading to the inhibition of caspase signaling, 3) stimulating IκK activity to 
positively regulate NF-κB-induced anti-apoptotic genes, 4) inactivating FOXO-
stimulated pro-apoptotic genes and 5) blocking DNA fragmentation by increasing 
the activity of ICAD and thus preventing the nuclease action of CAD (Kim and 
Chung, 2002). 
Prevention of β-cell death has been the ultimate therapeutic target for DM 
treatment. Unfortunately, none of the commonly-used existing therapies have 
shown to affect the deterioration of β-cells in humans. Recently, exendin-4, a GLP-1 
agonist, has been shown to protect β-cell from apoptosis in insulin-secreting cells 
and in primary islets (Ferdaoussi et al., 2008). However, the cost, route of 
administration and possible side-effect of acute pancreatitis have limited the use of 
exendin-4 as one of the ideal/first-line therapies (Persaud and Jones, 2008). 
Therefore, the search for an affordable, orally administered and safe drug which 
protects the β-cell mass continues. I have shown in previous chapters that OSA®, a 
GS extract, is effective in improving β-cell secretory function without any 
deleterious effect. Other GS extracts have been reported to preserve β-cell mass in 
STZ- or alloxan-treated rodents (Ahmed et al., 2010, Shanmugasundaram et al., 
1990a). However, the molecular signaling underlying this effect is unknown. 
Therefore, the aim of this chapter was to investigate whether OSA® has a 
protective effect in β-cells which have been challenged with cytokines and to 
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determine the possible components/pathways which contribute to the 
mechanism(s) by which OSA® exerts its action. 
6.2 Materials and Methods 
6.2.1 Plant material and preparation 
OSA® which contains GS leave was extracted as described in section 2.1.1 and 
provided as powder. Aqueous stock (200 mg/ml) was prepared in physiological 
solution for use in experiments. 
6.2.2 Maintenance of MIN6 cells 
MIN6 cells (passage 40-44) were maintained as monolayers in DMEM 
supplemented with 10% fetal bovine serum (FBS), 2mM glutamine and 100U/ml 
penicillin/0.1mg/ml streptomycin under standard tissue culture conditions 
(section 2.3.2). The cells were harvested and used in experiments when the cell 
confluency reached 70-80%. 
6.2.3 Isolation of mouse islets 
Islets from male ICR mice were isolated as described in section 2.4. The isolated 
mouse islets were cultured in RPMI supplemented with 10% newborn calf serum 
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6.2.4 Apoptosis assay 
6.2.4.1 Measurement of caspase 3/7 activity in MIN6 cells and mouse islets 
following chronic cytokines exposure 
The effect of mixed cytokines on apoptosis in MIN6 cells and mouse islets was 
assessed using Promega Caspase Glo® 3/7 apoptosis assay, following the 
manufacturer’s protocol (section 2.14.2). Briefly, MIN6 cells (10,000 cells/well) or 
mouse islets (5 islets/well) were seeded in white 96-well plate overnight under 
standard tissue culture condition. MIN6 cells were treated with either IL-1β (50 
U/ml) or TNF-α (1000 U/ml) or INF-γ (1000 U/ml) in combination of two or more 
cytokines, as indicated in the figure legends, for 16-18 hours. Mouse islets were 
treated with a mixture of cytokines (IL-1β, TNF-α and INF-γ) for 16-18 hours. 
Caspase Glo® reagent was prepared as described in section 2.14.2 and added to 
each well. Following 1 hr, luminescence was measured using Veritas luminometer. 
6.2.4.2 Measurement of caspase 3/7 activity in MIN6 cells and mouse islets 
following OSA® exposure 
The protective effect of OSA® on apoptosis was assessed as described in section 
2.14.2. MIN6 cells (10,000 cells/well) or mouse islets (5 islets/well) were seeded in 
white 96-well plate and incubated overnight under standard tissue culture 
conditions. MIN6 cells or mouse islets were pretreated with OSA® for 8 hrs before 
incubating them with cytokines mixture as indicated in the figure legends. 
Luminescence from each well was measured using Veritas luminometer after 1 hr 
incubation with caspase Glo® reagent. 
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6.2.5 Microarray 
6.2.5.1 Experimental design 
Mouse islets were grouped into the following groups: control, control + 0.125 
mg/ml OSA®, cytokines (50U/ml IL-1β, 1000U/ml TNF-α and 1000U/ml INF-γ) 
and cytokines + 0.125 mg/ml OSA®. 290 islets were picked in triplicates into these 
groups. In OSA® treated groups, the islets were preincubated with OSA® for 8 
hours before treating them with their corresponding treatment for 16-18 hours. 
The islets were washed with ice-cold PBS and RNA was extracted as described in 
section 2.15. The RNA integrity of each sample was assessed as described in section 
2.17.1. The RNA integrity number and the gel electrophoresis of each sample are 
shown in Appendix 3 (Figure 1). 
6.2.5.2 Gene expression profiling 
RNA of each sample was amplified, labeled and purified according to section 2.17.2. 
Fragmentation of each aRNA was carried as section 2.17.3. The expected profile of 
the aRNA fragments is shown in Appendix 3 (Figure 2). Each fragmented sample 
was mixed with hybridization cocktail (section 2.17.4) and the mixture was 
hybridized to a mouse genome 430 2.0 array chip (section 2.17.5). The chips were 
washed, stained and scanned as described in section 2.17.6. The normalized signal 
intensities were generated using MAS 5.0. Signal distribution (in normal and log 
scale) and Pearson’s correlation of all samples are listed in Appendix 3 (Figure 3). 
6.2.6 Statistical analysis 
Data were expressed as mean ± SEM. Differences between treatment groups were 
assessed using one way analysis of variance (ANOVA), Student’s t-test, or 
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Bonferroni’s multiple comparison test as appropriate, and differences between 
treatments were considered significant at p<0.05. The signal intensities, in 
microarray experiment, were calculated using MAS 5.0. The Qlucore software was 
used to determine and to calculate the ratio and fold changes of genes between two 
different treatment groups in which one group acted as basal. A false discovery rate 
of at least 40% and a p<0.05 were used to filter genes that are differently expressed. 
The possible signaling pathways and networks were generated using GeneGo® 
software, a pathway analysis tool. 
6.3 Results 
6.3.1 Effect of cytokines on apoptosis in MIN6 cells and mouse islets 
Chronic exposure of MIN6 cells to a combination of two or more cytokines induced 
apoptosis as assessed by elevations in caspase-3 and -7 activities. A mixture of IL-
1β + TNF-α with or without INF-γ caused the highest elevations in caspase-3 and -7 
levels (Figure 6.1). Similarly, chronic exposure of mouse islets to a mixture of 
cytokines resulted in increases in caspase-3 and -7 concentrations (Figure 6.2). 
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6.3.2 Effect of OSA® on cytokine-induced apoptosis in MIN6 cells and mouse 
islets 
In MIN6 cells, OSA® (0.03-0.125mg/ml) or exendin (1µM) alone did not increase 
basal levels of cell apoptosis. Addition of two or more cytokines significantly 
increased caspases activities, indicative of increased apoptosis. Pre-incubation with 
OSA® reduced apoptosis induced by IL-1β+ TNFα (Figure 6.4) and IL-1β+ TNFα + 
INFγ(Figure 6.3)combinations but not by TNFα + INFγ mix (Figure 6.4). Exendin 
was used as a positive control and shown to decrease caspase-3 and -7 levels in the 
same fashion as OSA®. Pre-treatment of MIN6 cells with exendin for 8 hrs also 
protected them from apoptosis induced by cytokines mix. 
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Similar to MIN6 cells, mouse islets incubated with OSA® or exendin alone did not 
show any detectable changes in apoptosis, as assessed by changes in caspase-3 and 
-7 levels. However, pre-treating mouse islets with either OSA® or exendin for 8 hrs 
caused a reduction in cytokine-induced caspase-3 and -7 levels (Figure 6.5). 
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6.3.3 Microarray analysis of effect of OSA® on apoptosis-induced gene 
expression in mouse islets 
Microarray analysis was used to investigate the genes responsible for the protective 
effect of OSA® against cytokine-induced apoptosis. Chronic (16-18 hrs) incubation 
of islets in the presence of cytokines modified the mRNA expression of 
approximately 200 genes related to apoptosis and cell survival. Selected genes that 
were modified by cytokines are listed in Table 6.1. A number of pro-apoptotic genes 
were upregulated including casp3, Fasl, FADD, JAK2 and XAF1. In addition, 
expression of anti-apoptotic genes including Bcl-2, XIAP, TNFAIPs and TRAFs was 
concomitantly increased. The pathways modulated by cytokines were analyzed 
Chapter 6                                                            GS protects β-cells from cytokine-induced apoptosis 
The role of plant extracts on islet function in vivo & in vitro Page | 210  
 
using GeneGo® software. Enrichment analysis showed upregulation in pathways 
and networks involved in DNA damage and apoptosis. Several gene pathways 
including the p-53-dependent pathway (p-53, Bard1, E2F1), ER stress-dependent 
pathway (GRP78, ire1, Mek3, MAPK-14/p-38, JNK/jun), mitochondrial stress 
pathway (NOXA, mcl-1, granzymes), NF-κB-dependent pathway (Rela, IκB, IκK, NF-
κB, Bcl-xL, Bcl-2, Bim, cIAP) and metabolic pathways (PI3K, AKT, FOXO, AC, PKA, 
creb1) were altered. GeneGo process networks of cytokine-induced genes are listed 
in Appendix 3. 
Pre-incubation in the presence of OSA® before exposure of the islets to cytokines 
was associated with down regulation in casp3 gene expression, consistent with our 
Promega Caspase Glo® 3/7 data (Fig 6.5). Furthermore, OSA® caused the 
upregulation in mRNA transcripts of protective, anti-apoptotic genes including   
AKT-2 (2.1 fold increase), ICAD (3.9 fold increase) and MnSOD (1.4 fold increase). 
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It is well known that reduction in β-cell mass is a major contributor of DM 
pathogenesis. In principle a decrease in the β-cell mass could be caused by either a 
decrease in the rate of proliferation or an increase in cell loss through apoptosis. 
Inappropriate activation of apoptosis is thought to be  the main mode of β-cell loss 
in DM (Donath and Halban, 2004, Johnson and Luciani, 2010, Lupi and Del Prato, 
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2008). Pro-inflammatory cytokines (IL-1β, TNF-α and INF-γ) have been reported to 
play important roles in β-cell death in DM (Cnop et al., 2005), especially in T1DM 
although there is now accumulating evidence that T2DM is an inflammatory 
condition associated with inappropriate levels of circulating cytokines (Donath et 
al., 2003). Cytokine-induced NF-κB-dependent and -independent pathways lead to 
apoptosis by acting on various steps in both intrinsic and extrinsic pathways of 
apoptosis. In the intrinsic pathway, the permeabilization of mitochondrial 
membrane, cytochrome C release and caspase activation are upregulated by pro-
apoptotic members of the Bcl2 family such as Bax, Bak, Bad and Bim, and 
downregulated by anti-apoptotic members of Bcl2 family such as Bcl2 and Bcl-xL. In 
the extrinsic pathway, ligand-activated death receptors, including the TNFR 
superfamily, recruit FADD which subsequently activates caspase-8. Both pathways 
are inhibited by IAPs, a family of caspase inhibitors (Creagh et al., 2003, Gewies, 
2003, Hui et al., 2004, Mandrup-Poulsen, 2001). NF-κB plays a pivotal role in the 
regulation of apoptosis, because it induces the expression of both pro- and anti-
apoptotic genes (Melloul, 2008). Cytokine-induced NF-κB- independent pathways 
are mainly activated by MAPKs and JAK/STAT pathways (Gysemans et al., 2008, 
Mandrup-Poulsen, 2001). JAK/STAT activation via the INF-γ receptor causes 
upregulation of gene expression of major mediators involved in β-cell death such as 
IRF-1 and iNOS (Gysemans et al., 2008). 
In our experiments, chronic exposure of MIN6 cells to cytokines induced apoptosis 
as assessed by our measurements of caspase 3/7 levels. As expected, elevated levels 
of caspase 3/7 were evident in MIN6 cells treated with a mixture of two or more 
cytokines. These observations were consistent with published data that showed 
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activation of caspase-3 was noticeable by 18 to 24 hrs in MIN6 cells (Sarkar et al., 
2009). In the present study the increases in caspase 3/7 levels were markedly 
reduced in cells pretreated with OSA®. This effect of OSA® was comparable to that 
seen with exendin, which was reported to protect β-cells from apoptosis in vitro 
(Ferdaoussi et al., 2008). Similarly, prolonged incubation of mouse islets with 
cytokines also prompted caspase 3/7 production which again was significantly 
inhibited by pretreatment with OSA®. The increase in caspase-3 levels in mouse 
islets was also confirmed using microarray analysis of mRNA expression. Consistent 
with previously published data (Sarkar et al., 2009), cytokines induced a 2.4 fold 
increase in caspase-3 levels, which was significantly reduced by approximately 50% 
by OSA® treatment. Therefore, OSA® may have a protective effect on β-cells from 
cytokine-induced apoptosis. To explore the possible molecular pathways by which 
OSA® inhibited caspase 3/7, microarray analysis of cytokine-treated mouse islets 
in the presence or absence of OSA® was performed. 
Our microarray data, as well as other published microarray data (Cardozo et al., 
2001a, Cardozo et al., 2001b, Sarkar et al., 2009), showed that exposing mouse 
islets to cytokines caused general modifications in the expression of genes involved 
in cell metabolism, cell adhesion, antigen presentation, cell cycle, ion channel 
formation, cytokine processing, DNA repair, apoptosis and cell defense. Changes in 
mRNA levels of some of these genes may precipitate β-cell death. Our microarray 
results showed complex changes in the expression of genes involved in apoptosis. 
Cytokines caused the upregulation of both pro- and anti-apoptotic genes. The 
complex nature of cytokine-mediated signaling makes it difficult to ascertain which 
key factor is responsible for the changes in mRNA expression seen in microarray 
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analysis. Activation of NF-κB could contribute to these changes but interestingly our 
data showed a cytokine-induced reduction in the expression of mRNA levels of both 
NF-κB and most of the up- and down-stream effectors of NF-κB with the exception 
of IκB, suggesting a down-regulation of this pathway. NF-κB target genes may exert 
a negative feedback mechanism on NF-κB. The NF-κB expression in our study was 
associated with an increase in IκB expression, which may be explained by the fact 
that the IκB expression was elevated to provide negative feedback mechanism to 
regulate and reduce NF-κB activity. It seems that the newly synthesized IκB acts by 
binding to the nuclear-localized NF-κB and then exporting it to the cytoplasm 
causing a temporary switch off in NF-κB gene expression. The reduction in NF-κB 
expression seen in our microarray data may be explained by this oscillatory nature 
of NF-κB expression following cytokine exposure. 
Our observations were in contrast to previously published data which showed 
activation of NF-κB expression following cytokines exposure (Cardozo et al., 2001a, 
Cardozo et al., 2001b, Sarkar et al., 2009). These discrepancies in the results may 
reflect differences in cell preparation and in the time-course of cytokine treatment. 
In our study, I used whole islets preparation while the other report used FACS-
purified β-cells. In addition, the total exposure time to cytokines in our study was 
shorter that the one used in the published report.  
Other possible key regulators of the changes in the gene expression seen in our 
experiments may include augmentation of the death signal through activation of 
MAPKs, via the NF-κB-independent pathway, or through reducing expression of the 
survival pathways such as the AKT and PKA pathways. It was previously 
demonstrated that IL-1β induced apoptosis through activation of ERK and p-38 
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MAPK in whole islets and purified β-cells (Larsen et al., 1998, Pavlovic et al., 2000). 
In agreement with this, our results also showed that cytokines treatment 
upregulated ERK and p-38 MAPK expression. It has been reported that AC-cAMP-
PKA-CREB pathway is involved in the transcription of anti-apoptotic genes and thus 
in cell survival (Furman et al., 2010). Our measurement of the genes encoding these 
elements showed a reduction in the expression of all of them, suggesting 
impairment in cell defenses and repair. Similarly, it is well known that AKT exerts 
anti-apoptotic effects by a number of different mechanisms involving activation of 
IκK and ICAD and inactivation of BAD, caspases and some transcription factor 
including FOXO (Kim and Chung, 2002). Our results demonstrated that the 
expression of AKT and subsequently ICAD genes was reduced and FOXO expression 
was increased in response to cytokines. This may suggest that stimulation of MAPKs 
pathways or inhibition of PKA and AKT signaling may account for the cytokine-
induced modification of gene expression seen in our study. 
In addition to the activation of these pathways, signs of mitochondrial stress, ER 
stress and DNA damage were evident in the cytokine-treated islets. The mRNA 
levels of granzyme B which stimulates mitochondrial ROS production and caspase 
signaling was significantly upregulated. Similarly, genes involved in the regulation 
of protein folding such as GPR78 and Dnajc3 were compromised, which can lead to 
ER stress. Our data also showed elevations in genes involved in DNA fragmentation 
and cleavage such as p-53, Trp73 and ICAD, consistent with increased levels of 
apoptosis.   
It has been demonstrated that islets are equipped with free radical scavenging 
systems. During normal oxidative phosphorylation, a small percentage of ROS are 
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produced but are quickly detoxified by MnSOD to H2O2 which is converted to H2O 
and O2 by catalase in the cytosol (Evans, 2002). Our microarray analysis of OSA-
treated mouse islets in the presence of cytokines indicated an upregulation in the 
expression of a key member of the free radical scavengers. Thus, OSA® increased 
the expression levels of MnSOD which may contribute to the reduction in caspase-3 
levels, consistent with a possible role for OSA® as an anti-oxidant. These results 
were in agreement with previously published reports showing that aqueous extract 
of GS leaves elevated SOD activity in rat islets (Diwan et al., 1995, Ohmori et al., 
2005). 
Enrichment analysis of pathways using GeneGo® software indicated that the anti-
oxidant and anti-apoptotic activity of OSA® may be mediated through activation of 
pathways involved in call survival, most notably the PI3K/AKT signaling pathway. 
Our observations showed that islets treated with OSA® in the presence of cytokines 
showed increased AKT mRNA levels, especially the AKT-2 isoform, when compared 
to cytokine-treated islets. The mRNA expression of down-steam effectors of AKT 
were also increased by OSA®. Therefore, it is possible that OSA® activates PI3K 
which generates numerous second messengers including phosphotidyl inositol 
(3,4,5) tri phosphate (PIP3). This lipid product activates AKT-2 which mediates the 
activation and transcription of survival genes such as MnSOD and ICAD. However, 
further confirmation of these results with quantitative RT-PCR is required.   
In conclusion, a heightened state of oxidative and ER stresses, apoptotic-based cell 
death and impairment of PI3K/AKT signaling contributes to β-cell deterioration 
and death seen in T2DM. Chronic OSA® treatment partially protected a β-cell line 
and primary islets from cytokine-induced apoptotic cell death suggesting that 
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OSA® may have important therapeutic actions as a potential therapy in the 
treatment of T2DM in addition to the insulin-releasing effects described in previous 
chapters. The anti-apoptotic effect of OSA® may be mediated through the 
PI3K/AKT pathway and further experiments using pharmacological inhibitors 
and/or genetic knock down of PI3K or AKT are required to validate the involvement 
of PI3K/AKT elements in the cytoprotective activity of OSA®. 
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7.1 Introduction 
In the past few years the pharmacotherapy of T2DM has changed dramatically with 
the addition of new classes of drugs to achieve tighter glycemic control to reduce 
the risk of developing microvascular and macrovascular complications and to 
improve the quality of patients’ lives. Despite the introduction of new chemical 
classes of drugs and the effort spent on drug development, the appropriate glycemic 
control in most patients with T2DM is still under target and may require intensive 
multiple drug therapy, increasing the risk of developing adverse drug effects and 
drug-drug interactions (Stolar et al., 2008).  
The use of herbal medicine for the treatment of diabetes mellitus has been known 
for centuries (Yeh et al., 2003). I have established in previous chapters (chapter 3-
6) the efficiency and mechanism of action of one particular GS extract named OSA®. 
However, in this chapter, I screened for more phytochemicals to identify potential 
therapeutic agents to treat T2DM. Many plants have been reported efficacy in the 
treatment of T2DM (Grover et al., 2002), and recently extracts of Costus pictus (CP) 
have been reported to show antidiabetic properties (Gireesh et al., 2009, Jayasri et 
al., 2008, Jayasri et al., 2009a, Jothivel et al., 2007, Shilpa et al., 2009). The plant, 
commonly known as spiral ginger, belongs to the Costaceae family and grows in 
gardens as an ornamental climbing plant (Benny, 2004, George et al., 2007). The 
antidiabetic activity of CP extracts has been tested chronically in animals in vivo, 
where it was reported to reduce blood glucose levels in rats in which 
hyperglycemia had been induced by administering the β-cell toxins alloxan or 
streptozotocin (STZ) (Gireesh et al., 2009, Jayasri et al., 2008, Jothivel et al., 2007). 
The precise mechanism of the glucose-lowering effect of CP is not completely clear 
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but it may be due to 1) an inhibition of α-amylase and α-glucosidase enzymes 
resulting in reduced carbohydrate absorption (Jayasri et al., 2009a); 2) an increase 
in GLUT4 translocation and glucose uptake in insulin-responsive target tissues 
(Shilpa et al., 2009); or 3) a direct stimulation of insulin secretion from pancreatic 
β-cells (Gireesh et al., 2009).  
The aim of this chapter was, therefore, to determine whether an aqueous extract of 
CP acutely and directly stimulates insulin secretion from the mouse MIN6 β-cell line 
and from primary mouse and human islets and to investigate the effect of chronic 
CP treament on insulin gene expression from mouse islets. Many insulin 
secretagogues initiate insulin secretion by increasing cytosolic Ca2+ ([Ca2+]i) 
through facilitating extracellular Ca2+ entry into β-cells via voltage-gated Ca2+ 
channels (VGCC) in the plasma membrane, so I have also examined the dependence 
of CP-induced insulin secretion on Ca2+ . 
7.2 Materials and Methods 
7.2.1 Plant material and preparation 
CP leaves were extracted as described in section 2.1.2. The lyophilized powder was 
prepared as 100 mg/ml stock in water and diluted as appropriate in Gey & Gey 
buffer. 
7.2.2 MIN6 cells maintenance 
MIN6 cells (passage 32-39) were maintained as described in section 2.3.2. MIN6 
cells grow as adherent monolayers on negatively-charged tissue culture plastic. The 
medium was changed every 3-4 days and when the cell confluency reached ≈ 70-
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80% the MIN6 cells were detached for use in experiments by incubation with 0.1% 
trypsin/0.02% EDTA. 
7.2.3 Formation of MIN6 pseudoislets (PIs) 
MIN6 cells were cultured in bacterial Petri dishes to prevent the adhesion of the 
cells to the substrate, resulting in the formation of three dimensional islet-like cell 
clusters known as pseudoislets.  PIs were maintained as described in section 2.3.3. 
The medium was changed every 3-4 days and PIs were used in the experiments 
after 7-10 days. 
7.2.4 Mouse and human islets isolation 
Mouse and human islets were isolated and cultured as described in section 2.4 and 
2.5 for 24 hrs before use in experiments. 
7.2.5 Insulin secretion 
7.2.5.1 Insulin secretion from MIN6 monolayer cells 
Static secretion experiments were carried as described in section 2.7.1. The cells 
were incubated with buffer containing 2mM glucose in the presence or absence of 
CP extract (0.06-1.0 mg/ml) for 30 min at 37°C. At the end of the incubation period, 
100μl of incubation medium was removed and stored at -20°C until insulin was 
measured by RIA. 
7.2.5.2 Insulin secretion from MIN6 PIs, mouse and human islets 
To measure the time-course of the effects of CP extract on insulin secretion, 
perifusion experiments using MIN6 PIs, isolated mouse and human islets were 
performed (section 2.7.2). PIs or islets were transferred into chambers lined with 1 
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μm pore-size nylon filter and perifused with physiological buffer supplemented 
with 2mM glucose, 2mM CaCl2 and 0.5 mg/ml BSA, in a temperature-controlled 
(37°C) environment. At the start of each experiment the PIs or islets were perifused 
for 60 min at a flow rate of 0.5 ml/min, during which time the perifusate was 
discarded. At t=60 min, the tissues were perifused with buffer supplemented with 
either 2mM or 20mM glucose in the presence or absence of 0.1 mg/ml of CP extract. 
Perifusate samples were collected every 2 min and stored at -20°C until insulin 
content was determined by RIA. 
7.2.6 Total insulin content of mouse islets 
The chronic effect of CP on total insulin content of mouse islets was measured as 
described in section 2.8. Mouse islets (5 islets/well) were incubated for 24hrs with 
DMEM supplemented with 2mM glucose in the presence or absence of 0.1 mg/ml 
CP. Following 24hrs, the islets were washed with PBS, sonicated in acidified alcohol 
and stored at -20°C until assayed for insulin content by RIA. 
7.2.7 Cell viability 
The effects of CP on membrane integrity were assessed using a Trypan Blue 
exclusion test (section 2.11). MIN6 monolayers or mouse islets that had been 
exposed to CP extract (1.0 mg/ml) for 30 min were incubated with 0.1% (w/v) 
Trypan Blue dye for 15 min at 37°C. The cells were then washed with PBS and 
visualized under a light microscope. Images were captured using a Nikon Coolpix 
4500 digital camera (Surrey, UK). 
7.2.8 Ca2+ microfluorimetry 
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The effects of CP extract on [Ca2+]i were assessed using single cell calcium 
microfluorimetry as described in section 2.12. Briefly, MIN6 cells were seeded on 
ethanol-washed glass coverslips at a density of 50,000 cells/coverslip and allowed 
to adhere overnight in DMEM under standard tissue culture conditions. The cells 
were loaded with 5μM of the Ca2+-fluorophore Fura-2/AM for 30 min at 37°C. The 
coverslips were placed in a steel chamber which was mounted into a heated 
platform (37°C) on the stage of an Axiovert 135 Research Inverted Microscope. The 
cells were perifused with 0.1 mg/ml CP in the presence or absence of the Ca2+ 
chelator, EGTA (0.1mM), or nifedipine (10μM), a voltage-gated Ca2+ channel (VGCC) 
blocker, at a flow rate of 1 ml/min. Cells were illuminated alternately at 340 and 
380nm, and emitted light at 510nm was detected using a CCD camera. 
7.2.9 Insulin gene expression 
The effect of CP on PPI mRNA expression was assessed by quantitative RT-PCR. 150 
mouse islets were pre-incubated with 2mM glucose and then incubated with 2mM 
glucose in the presence or absence of 0.1 mg/ml CP or 20mM glucose. Total RNA 
was extracted by Qiagen RNeasy mini kit (section 2.15.1) and reverse transcribed to 
cDNA by mmLV-RT (section 2.15.2). PPI and actin, as a house keeping gene, mRNA 
levels were determined using SYBR green as fluorescence indicator (section 2.16). 
Specific primers were used to amplify 125 and 285 bp amplicons of PPI and actin, 
respectively. PPI expression was normalized by actin and expressed as fold increase 
over basal (2mM glucose). 
7.2.10  Data analysis 
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Data are represented as mean ± SEM. In perifusion experiment with more than one 
treatment, the mean represents the area under the curve. Differences between 
treatment groups were assessed using one way analysis of variance (ANOVA), 
Student’s t-test, or Bonferroni’s multiple comparison test as appropriate, and 
differences between treatments were considered significant at P< 0.05. 
7.3 Results 
7.3.1 Effect of CP extract on insulin secretion from MIN6 monolayers and 
MIN6 membrane integrity 
The effect of CP on insulin secretion from MIN6 cell monolayers at a basal 
concentration of glucose (2mM) is shown in Figure 7.1. Thirty min exposure of 
MIN6 cells to the CP extract (0.06-1.0 mg/ml) caused a concentration-dependent 
increase in insulin secretion (P<0.01) which could not be attributed to the extract 
causing non-specific leakage of insulin from the cells by damaging their plasma 
membranes. Thus, the effect of CP extract on membrane integrity was assessed 
using the Trypan Blue exclusion test. Incubating MIN6 cells or mouse islets with 
0.1% (w/v) Trypan Blue dye for 15 min in the presence of CP extract (1.0 mg/ml) 
was not accompanied by increased Trypan Blue uptake (Figure 7.2). 
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7.3.2 Effect of CP extract on insulin secretion from MIN6 PIs, isolated mouse 
and human islets 
A multichannel, temperature-controlled perifusion system was used to examine the 
effects of CP extract on the pattern and rate of insulin secretion. MIN6 PIs, mouse 
and human islets were perifused with buffers supplemented with 0.1 mg/ml CP 
extract at glucose concentrations selected to mimic conditions of fasting blood 
glucose (2mM) and uncontrolled hyperglycemia (20mM). In the presence of 2mM 
glucose, the CP extract induced a rapid but transient increase in insulin secretion 
from MIN6 PIs, reaching a peak of 323 ± 60% basal (p<0.01) after 4-6 min (Figure 
7.3). The rate of insulin secretion subsequently subsided to almost basal levels 
despite the continued presence of the CP extract. Similarly, CP-induced insulin 
secretion from perifused mouse (Figure 7.4) and human (Figure 7.5) islets was also 
rapid in onset but transient during the 20 min exposure to CP.  
Chapter 7                                CP stimulates insulin secretion from mouse and human islets in vitro 
The role of plant extracts on islet function in vivo & in vitro Page | 231  
 
 
Chapter 7                                CP stimulates insulin secretion from mouse and human islets in vitro 
The role of plant extracts on islet function in vivo & in vitro Page | 232  
 
 
Chapter 7                                CP stimulates insulin secretion from mouse and human islets in vitro 
The role of plant extracts on islet function in vivo & in vitro Page | 233  
 
 
The CP extract (0.1 mg/ml) did not potentiate glucose-induced (20mM) insulin 
release from MIN6 PIs (Figure 7.6) nor from mouse (Figure 7.7) or human islets 
(Figure 7.8). In these experiments, exposing MIN6 PIs, mouse or human islets to 
20mM glucose evoked a bi-phasic and maintained increase in insulin secretion as 
expected. Addition of CP extract slightly elevated insulin release from MIN6 PIs and 
mouse islets over the first phase of glucose-induced insulin secretion but this effect 
was not statistically significant, neither when assessing the rate of insulin secretion 
at individual time points, nor when comparing area under the curve estimates of 
the total mass of insulin secreted during the experiment. 
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7.3.3 Effect of CP extract on MIN6 cell [Ca2+]i 
Exposure to CP extract (0.1 mg/ml) at 2mM glucose was associated with an 
increase in [Ca2+]i in Fura-2-loaded MIN6 cells (Figure 7.9). The elevations in [Ca2+]i 
levels were delayed in onset,  with a lag time of approximately 3 min, consistent 
with the time-course of the effects of the extract on insulin secretion (Figure 7.3) 
and similar to the time course seen in similar experiments using OSA® (chapter 5). 
The CP-induced increase in [Ca2+]i was completely abolished in the absence of 
extracellular Ca2+ or in the presence of nifedipine. MIN6 cells that had been exposed 
to CP showed further elevation of [Ca2+]i levels upon exposure to 100μM ATP (basal 
to peak amplitude: 0.3±0.01, p<0.01, 30/30 cells). 
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7.3.4 Effect of CP extract on preproinsulin mRNA expression 
Quantitative measurement of PPI mRNA levels from mouse islets exposed to 0.1 
mg/ml CP for 24 hrs showed no increase in insulin gene transcription as compared 
to 2mM glucose (Figure 7.10). However, 20mM glucose, as expected, raised the 
levels of mRNA encoding PPI (p˂0.05).  
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7.3.5 Effect of CP extract on mouse total insulin content 
Prolonged exposure of mouse islets to CP was not associated with any changes in 
islet total insulin content. The total insulin content of islets incubated in the 
presence of 2mM glucose alone was 29.5 ± 5.5 ng/islet. Addition of CP did not cause 
any changes in islet total insulin content (28.7 ± 2.1 ng/islet, p>0.2)  
7.4 Discussion 
The previous chapters have discussed the role of OSA® as a potential antidiabetic 
agent. In this chapter I investigated the role of another promising plant extract, 
Costus pictus (CP), which has reported to have glucose-lowering activity in diabetic 
rats. The beneficial antidiabetic effect of CP seen in hyperglycemic rats was 
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reported following chronic and prolonged treatment with the plant extract. Thus, 
28 days oral administration of the same aqueous CP extract as used in the current 
study to hyperglycemic rats at 2 gm/kg body weight induced a significant (p<0.001) 
reduction in fasting blood glucose levels, associated with increased serum insulin 
levels (Jayasri et al., 2008). Other studies have also reported similar results (Gireesh 
et al., 2009, Jothivel et al., 2007). It is difficult to investigate cellular mechanisms of 
action using in vivo models, so in our current study I investigated the acute effect of 
a CP extract in vitro using MIN6 cells and primary mouse and human islets. MIN6 
cells, which are a transformed insulin-secreting β-cell line derived from a mouse 
insulinoma, are a useful experimental model for studies of insulin secretion 
because, unlike other β-cell lines, they contain a relatively high insulin content 
(Ishihara et al., 1993, Persaud, 1999).  
Our preliminary data using MIN6 cells grown as adherent monolayers 
demonstrated that CP extract caused a concentration-dependent increase in insulin 
secretion, and that the extract was capable of initiating an insulin secretory 
response in the absence of a stimulatory concentration of glucose. In all our 
experiments, the basal glucose concentration was maintained at 2mM, a sub-
stimulatory concentration of glucose, to eliminate any possible contribution of 
glucose to the secretory response.  
Different chemical constituents including saponins, flavonoids, glycosides and other 
compounds have been isolated and characterized from a wide range of medicinal 
plant extracts. Triterpene saponins have been shown to exert a wide range of 
pharmacological activities including anti-diabetic, anti-viral, anti-inflammatory, 
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anti-allergic and anti-bacterial effects. The anti-diabetic effect seen with CP may be 
also mediated by these saponins but this is still to be determined.  
Insulin is released from β-cells in vitro in either controlled or uncontrolled 
manners. Regulated or controlled insulin release involves membrane 
depolarization, Ca2+ influx and granule exocytosis, whereas unregulated or 
uncontrolled insulin release usually occurs due to a compromised plasma 
membrane and increased membrane permeability. Most plant extracts contain 
different chemical constituents that may damage the plasma membrane. It has been 
reported that high content of saponins may compromise plasma membranes 
leading to uncontrolled release of insulin. Therefore the effect of CP on plasma 
membrane integrity was determined by Trypan Blue exclusion test. CP extract did 
not compromise plasma membrane viability even at a concentration as high as 1.0 
mg/ml, suggesting that its effects on insulin secretion in our experiments were due 
to an activation of a regulated exocytotic response.  
Data from static incubation experiment using MIN6 cells as monolayers showed 
that CP caused a concentration-dependent increase in insulin secretion. In these 
experiments, I used late passage MIN6 cells (p.39) and it is well-documented these 
late passage cells in static secretion experiments lose their ability to respond to 
various stimuli such as glucose and α-ketoisocaproic acid. The secretory responses 
of MIN6 cells to those stimuli can be largely restored if they configured into three-
dimensional islet-like clusters (pseudoislets), probably because of enhanced β-cell 
to β-cell communication within the pseudoislet structures (Hauge-Evans et al., 
1999). Therefore, for our subsequent perifusion measurements of the effects of CP 
extract on insulin secretion, the MIN6 cells were configured as pseudoislets to 
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ensure maximum insulin secretory responses. Perifusion experiments have the 
additional advantages of measuring the rate and duration of insulin output, which 
facilitate the detection of relatively transient responses of the extract. These 
experiments confirmed the observations obtained using monolayer cells that CP 
extract acutely initiated insulin secretion in the presence of a substimulatory 
concentration of glucose, and further revealed that the effect was transient. These 
observations are in accordance with the lack of effect of CP extract on plasma 
membrane permeability because such damage is associated with irreversible 
leakage of insulin from compromised cells. In addition, CP extract induced an 
insulin secretory response from primary mouse and human islets confirming that 
the extract had a direct stimulatory effect in primary β-cells. Furthermore, the 
direct stimulatory effect of CP extract on mouse islets was not associated with 
increases in insulin expression at either mRNA or protein levels, further supporting 
the results of our perifusion experiments which reported a transient effect of CP on 
insulin secretion.  
The initiation of insulin secretion by CP could not be attributed to the presence of 
high K+ levels in the plant extract since, in a previuosly published report, trace 
element analysis of CP leaves using proton-induced X-ray emission indicated that 
the K+ concentration was only 0.4±0.12g/ml (Jayasri et al., 2008). Thus, CP leaf 
extracts contain, at most, micromolar concentrations of K+ while millimolar 
concentrations are required to stimulate insulin secretion (Wollheim and Sharp, 
1981).   
Although CP slightly potentiated the first, but not the second, phase of glucose-
induced insulin secretion from MIN6 PIs and mouse islets, the increment in insulin 
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secretion did not reach statistical significance. On the other hand, CP did not 
enhance insulin output over the bi-phasic glucose-induced insulin secretion from 
human islets. This may be a consequence of the human islets showing a robust 
glucose-induced secretory response (maximally 18 fold basal) and any small 
changes in insulin secretion that may have been caused by CP are likely to have 
been masked. A supra-physiological glucose concentration (20mM) was used in 
these experiments to preclude an action of the plant extracts through metabolism-
induced generation of ATP. Our observations are in contrast to a recent report that 
aqueous CP extract stimulated insulin secretion above that induced by 20mM 
glucose (Gireesh et al., 2009). The differences in reported effects of CP extracts most 
likely reflect differences in experimental protocols between studies. Our perifusion 
experiments were designed to look at rapid changes in the rate of insulin secretion 
over a minute-to-minute time scale, whereas the previous study (Gireesh et al., 
2009) used a static incubation protocol which found stimulatory effects on glucose-
induced insulin secretion after prolonged (24h) exposure to the extract. 
Many physiological insulin secretagogues act by facilitating the influx of 
extracellular Ca2+, or the release of Ca2+ from intracellular stores leading to 
increased [Ca2+]i and insulin exocytosis. Our measurements of [Ca2+]i in Fura-2-
loaded MIN6 cells demonstrated that the CP extract induced elevations in [Ca2+]i, 
consistent with its effects to initiate insulin secretion. The removal of extracellular 
Ca2+ or blockade of VGCC by nifedipine completely inhibited the CP-induced 
increases in [Ca2+]i, suggesting that CP raised cytosolic Ca2+ levels in β-cells by 
increasing Ca2+ influx through VGCC. The ability of the cells which had been exposed 
to CP to further increase [Ca2+]i in response to ATP further demonstrated that the 
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extract did not impair the ability of the cells to maintain a membrane potential and 
Ca2+ gradient across the plasma membrane, consistent with the Trypan Blue 
measurements of membrane integrity. 
In summary, our in vitro studies suggest that an important mechanism of action of 
Costus pictus extract is through a direct effect on islet β-cells to stimulate insulin 
secretion. Our measurements of [Ca2+]i suggest that CP initiates an insulin secretory 
response by increasing Ca2+ influx through VGCC, consistent with a mode  of action 
similar to that of other depolarizing agents such as sulphonylurea drugs. This ability 
to by-pass glucose metabolism and induce insulin secretion by depolarization-
induced Ca2+ influx offers a mechanism for increasing insulin secretion from 
glucose-unresponsive β-cells in T2DM. 
The data presented here and in previous chapters have shown that the effects of GS 
and CP extract on insulin secretion have distinct characteristics. First, although both 
extracts act directly on β-cells to initiate insulin secretion, the effect of GS was 
maintained throughout the stimulation period. Second, the GS, but not CP, extract 
potentiated glucose-induced insulin secretion. Third, both extracts increase [Ca2+]i 
with similar time course suggestive of a common mechanism of action through Ca2+ 
influx. Finally, the GS extract, but not the CP extract, enhanced PPI mRNA 
expression, consistent with a therapeutic advantage in modulating β-cell insulin 
stores. Overall, when comparing the profiles of both extracts, GS extract may offer 
better therapeutic potential than CP extract. This type of “screening portfolio” 
allows identification of useful plant-based remedies, which will be discussed in 
detail in the General Discussion (chapter 8). 
Chapter 8  General discussion 
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8.1 Introduction 
Diabetes mellitus is a global health problem affecting both developed and 
developing countries. It is defined as a metabolic disorder characterized by an 
elevation of blood glucose concentration leading to chronic hyperglycemia and is 
associated with abnormal metabolism of carbohydrates, fat and protein. The 
prevalence of the disease is increasing and the estimated number of people with 
diabetes will be 440 million by the year 2030, more than double the current 
estimate (Internaional Diabetes Federation, 2009). Ninety-five percent of those 
individuals will have Type 2 diabetes mellitus (T2DM) which is characterized by β-
cell dysfunction and worsening of insulin sensitivity in insulin-sensitive tissues. 
Recent studies have developed the concept that T2DM is associated with a 
progressive loss of the functional β-cell mass, with symptoms appearing when the 
β-cell mass is no longer sufficient to maintain glucose homeostasis. The risk of 
developing macrovascular and microvascular complications increases with 
untreated or poorly controlled T2DM as a result of long-standing hyperglycemia 
and insulin resistance. These complications can involve many different organs of 
the body leading to coronary heart disease, stroke, peripheral vascular disease, 
neuropathy, retinopathy and nephropathy (Defronzo et al., 2004). Therefore, the 
major targets of T2DM treatment are reduction in hyperglycemia and improvement 
of insulin resistance. The current available therapies for the treatment of T2DM 
have been focused on correcting these abnormalities. However, some of these 
therapies are associated with serious adverse effects and complete glycemic control 
is yet far from achievement. Therefore, introducing and developing new drugs 
especially those from plant origin have been an active area of research.     
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There is no doubt that alternative medicine, especially herbal remedies, has 
attracted a lot of attention in the past few decades. This is due to the fact that 
almost 35-48% of people worldwide have used herbal medicine to treat various 
diseases including DM. Metformin, one of the current and effective antidiabetic 
drugs, was originally isolated from Galega officinalis, a plant which has been used in 
managing DM for centuries (Witters, 2001). Thus, identifying novel, effective 
extracts of plant origin to treat DM could offer inexpensive and widely available 
therapeutic options in the developing world.   
More than 800 plants have been claimed to be effective in treating DM (Alarcon-
Aguilara et al., 1998). However, currently there are no defined criteria in the 
phytochemical society for bench-marking identification and screening of plant-
based remedies as potential antidiabetic agents. Therefore, in this thesis I have 
identified certain characteristics which can be used as a screening tool to identify 
potential plant extracts as therapeutic agents for the treatment of DM. 
8.2 Screening for potential plant extracts 
We here suggest specific criteria that can be applied as a “screening portifolio” to 
identify potential therapeutic agents of plant origin. A useful plant extract should 
possess some or all of the following properties: 
 Potentiate nutrient-induced insulin secretion to reduce post-prandial 
hyperglycemia. 
 Stimulate insulin secretion while preserving β-cell insulin stores.  
 Preserve β-cell mass by either stimulating neogenesis and 
proliferation or preventing apoptosis. 
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 Reduce the rate at which glucose enters the bloodstream by 
interfering with glucose absorption in the intestine. 
 Improve diabetic symptoms either by   direct stimulation of insulin 
secretion from β-cells or by reduction of insulin resistance in animal 
models of diabetes and in human subjects. 
8.3 GS and CP as potential antidiabetic agents 
Gymnema and Costus are genera in the family of Asclepiadaceae and Costaceae, 
respectively, containing 100 species among which the species GS and CP have a 
historical use as Ayurvedic medicine in treating various diseases, practically DM 
(Benny, 2004, Porchezhian and Dobriyal, 2003). The therapeutic benefits of GS and 
CP in treating DM reside in their leaves. Extracts of GS and CP leaves have been 
shown to contain many bioactive compounds that are responsible for their 
antidiabetic activities. Saponins and flavonoids have been extracted from CP leaves 
and may possibly contribute to the antihyperglycemic effects of CP extracts (Jayasri 
et al., 2008, Jothivel et al., 2007, Meléndez-Camargo et al.). Triterpene saponins 
including gymnemic acid (GA) have been isolated from GS leaves and are believed 
to mediate some of the effects of GS on DM (Sugihara et al., 2000). GA-containing 
extracts (also known as low molecular weight extracts) have been documented to 
lower blood glucose levels and to increase insulin levels in animal models of DM 
and in human subjects (Balasubramaniam et al., 1988, Baskaran et al., 1990, Gupta, 
1961, Gupta, 1963, Gupta and Variyar, 1961, Khare et al., 1983, Shanmugasundaram 
et al., 1981, Shanmugasundaram et al., 1983, Shanmugasundaram et al., 1988, 
Shanmugasundaram et al., 1990b, Srivastava et al., 1985, Srivastava et al., 1986, 
Sugihara et al., 2000). Most of these studies have used low molecular weight 
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extracts to establish the antidiabetic effect of GS. However, the activity of other 
extracts, especially high molecular weight extracts, has yet to be determined. 
Therefore, in this project I have studied the therapeutic potential of a high 
molecular weight extract named OSA® in a series of in vivo and in vitro 
experiments. 
In this chapter I will compare the potential therapeutic efficacy of OSA® or CP using 
the criteria described above.  
8.3.1 Direct stimulation of hormone release from β-cell line and primary 
islets 
Both OSA® and CP caused concentration-dependent increases in insulin secretion 
from MIN6 monolayers at a substimulatory glucose concentration. The kinetic 
profiles of the insulin secretory responses induced by OSA® and CP were assessed 
in perifusion experiments with MIN6 PIs. At substimulatory glucose concentrations, 
OSA® induced a sustained increase in insulin secretion which was reversible upon 
withdrawal of OSA®. The sustained effect of OSA® should provide a therapeutic 
benefit of long-term control of blood glucose levels and thus reduces the frequency 
of dosage. Unlike OSA®, CP only transiently elevated insulin secretion which 
returned rapidly to basal levels in spite of the continuous presence of CP, suggesting 
that it may be of limited therapeutic efficacy in the face of prolonged hyperglycemia, 
as occurs in T2DM. 
The insulinotropic effects of OSA® and CP were also observed in mouse and human 
islets, indicating a direct action on primary β-cells. In mouse and human islets, 
OSA® and CP initiated insulin secretion which was again sustained in the presence 
Chapter 8  General discussion 
The role of plant extracts on islet function in vivo & in vitro Page | 249  
 
of OSA® but only transient in the presence of CP. Although increasing insulin 
secretion at substimulatory glucose concentrations may increase the risk of 
developing hypoglycemia, SUs, which also stimulate insulin release at 2mM glucose, 
are still used successfully in the treatment of T2DM (Persaud and Jones, 2008), 
suggesting that OSA® and CP may be at least as effective as this commonly used 
class of T2DM drugs. 
In addition to the initiation of insulin secretion, OSA® also potentiated glucose-
induced insulin secretion from MIN6 PIs, mouse and human islets. OSA® increased 
insulin output over 20mM glucose, a supra-stimulatory glucose concentration, 
suggesting that OSA® did not act as a nutrient, nor by enhancing nutrient 
metabolism. The advantage of this effect is that OSA® can bypass glucose 
metabolism and stimulate insulin secretion in glucose unresponsive β-cells, similar 
to exendin-4, a GLP-1 agonist. However, OSA® has the benefit of not being 
degraded in the GI tract, unlike exendin-4, and thus be safe to be given orally. 
OSA®, not only increased insulin secretion at 2 and 20mM glucose, but also 
stimulated insulin secretion at more physiological glucose concentrations (5 and 
10mM). This gives OSA® the advantage of exerting its insulinotropic action 
regardless of glucose levels. In contrast to OSA®, CP did not augment glucose-
induced insulin secretion from the β-cell line nor from primary islets, suggesting 
that CP may have limited use as a therapeutic agent to treat hyperglycemia in 
T2DM.  
OSA® also affected the secretion of other pancreatic hormones. Glucagon secretion 
was stimulated by OSA® in the presence of either 2mM glucose or 20mM arginine. 
Whether OSA® has a direct or indirect action on α-cells is yet to be determined. 
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However, the increase in glucagon secretion is not uncommon for insulinotropic 
agents. SUs, which are still used as a first-line therapy in T2DM treatment, are also 
reported to stimulate glucagon secretion (Bohannon et al., 1982, MacDonald et al., 
2007). 
8.3.2 Maintenance of cell viability 
Any saponin-containing plant extracts may have deleterious effect on plasma 
membrane integrity because saponins have been shown to increase plasma 
membrane permeability through membrane pore formation (Ahnert-Hilger and 
Gratzl, 1988, Schulz, 1990). Neither OSA® nor CP caused any detectable damage to 
the plasma membrane at the therapeutic concentrations used in this thesis as 
demonstrated by the Trypan Blue exclusion test. Cells treated with effective 
concentrations OSA® or CP showed no increase in Trypan Blue uptake indicating 
an intact cell membrane. Maintaining the integrity of plasma membrane is 
important in triggering a regulated exocytosis of insulin. 
8.3.3 Preservation of β-cell insulin stores 
Maintaining insulin stores in β-cells following chronic stimulation of insulin 
secretion prevents β-cell exhaustion (Leibowitz, 2002) and thus prevents the 
gradual loss of secretory responses associated with the continuous use of insulin-
secreting agents over prolonged periods of time. An effective pharmacological 
treatment for T2DM should therefore simultaneously stimulate both insulin 
secretion and insulin biosynthesis, to ensure that β-cell stores of insulin are 
maintained.  The eventual failure of sulphonylureas as a front line therapy for 
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T2DM may be caused by their failure to stimulate insulin biosynthesis, leading to β-
cell exhaustion and the requirement for insulin replacement therapy.   
OSA® seems to fulfill the requirement of stimulating both insulin secretion and 
insulin biosynthesis. Our measurement of PPI mRNA levels indicated that OSA®, 
but not CP, significantly elevated the mRNA expression of PPI in chronically-treated 
mouse islets. In addition, the total insulin content of OSA® treated mouse islets 
remained unchanged as compared to vehicle-treated islets, despite the chronic 
stimulation of insulin secretion induced by OSA®.  
The elevations in PPI mRNA levels without any change in total insulin content seen 
in OSA®-treated mouse islets will act to not only maintain β-cell insulin stores but 
also to prevent overloading β-cells with insulin, suggesting a therapeutic advantage 
of OSA® over some of the currently used insulin-secreting agents such as SUs.  
8.3.4 Activation of crucial steps in stimulus-secretion coupling 
Common intracellular mechanisms of increasing insulin secretion are by elevating 
[Ca2+]i levels and/or activating other second messengers/protein kinases (Howell et 
al., 1994). The insulin secretory responses to both OSA® and CP were associated 
with elevations in [Ca2+]i concentrations in β-cells as assessed by Ca2+ 
microfluorimetry. Both OSA® and CP-induced increases in [Ca2+]i levels were 
inhibited in the presence of EGTA or nifedipine indicating that both OSA® and CP 
increase cytosolic Ca2+ by facilitating Ca2+ entry through VGCC. These results were 
confirmed by perifusion experiments showing that OSA®-induced insulin secretion 
was partially inhibited by nifedipine. 
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The downstream elements of the signaling pathway of the insulin secretory 
response of OSA® were not well understood. The closure of KATP-channels and 
subsequent β-cell depolarization were ruled out as the cause for increasing β-cell 
[Ca2+]i levels because opening KATP-channels by diazoxide did not affect OSA®-
induced insulin secretion. However, protein kinase activation was partially involved 
in the secretory response to OSA® as evident by the inhibition of OSA®-induced 
insulin secretion by staurosporine, a non-selective serine/threonine protein kinase 
inhibitor. The exact nature of the protein kinase responsible for the OSA® effect on 
insulin secretion is unknown.  PKCαβ and CamKII are known to be involved in the 
regulation of insulin secretion but were shown not to be involved in OSA®-induced 
insulin secretion. The ability of OSA® to increase insulin secretion independent of 
[Ca2+]i might suggest an involvement of cAMP in the secretory action of OSA®, 
because cAMP has been reported to increase insulin secretion by sensitizing the 
secretion machinery to [Ca2+]i without altering [Ca2+]i concentration. Interestingly, 
the insulin secretion induced by OSA® was dissociated from cAMP formation 
because OSA® reduced [cAMP]i levels in β-cells in parallel to increasing insulin 
secretion.  
Overall, our current data suggest two possible sites of action of OSA® in the β-cell, 
(as shown in Figure 8.1). The first is after KATP-channel closure and depolarization 
and leads to increased [Ca2+]i, so this may be a direct effect on a plasma membrane 
Ca2+ channel, or an associated receptor. The second site of action is at a late stage in 
the exocytotic pathway, after the activation of protein kinases, which is not 
inhibited by broad spectrum protein kinase activators. This may be a direct effect at 
the site of exocytosis, as has been postulated for some other insulin-releasing 
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agents such as arachidonic acid, or it may be through a receptor which affects 
exocytosis directly, as has been suggested for α-adrenoreceptors.     
Although the precise mechanism(s) of action of OSA® have not yet been defined 
this does not prevent the use of OSA® as a therapeutic agent. For example, 
sulphonylureas were used clinically for many decades before the discovery of KATP-
channels as their site of action. Similarly, metformin has been used in treating 
T2DM for decades despite the fact that its mechanism of action is not yet clear. 
 
8.3.5 Protection of β-cells against harmful insults 
T2DM is associated with chronic elevation of cytokines, glucose and FFAs which can 
precipitate β-cell death through excessive induction of apoptosis via caspase-
dependent and –independent pathways (Cnop et al., 2005, Eizirik and Mandrup-
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Poulsen, 2001, Johnson and Luciani, 2010, Lupi and Del Prato, 2008, Mandrup-
Poulsen, 2001, Poitout and Robertson, 2008, Robertson et al., 2004). Protecting 
against apoptosis may provide an important way to preserve β-cell mass and thus 
prevent the progression of T2DM. One successful example of this type of therapy is 
exendin-4, a GLP-1 agonist, which inhibited IL-1β induced apoptosis in β-cells in 
vitro suggesting a protective role of exendin-4 in β-cells (Ferdaoussi et al., 2008). 
Exendin analogues or DPPIV inhibitors which inhibit the degradation of 
endogenous GLP-1 are now being adopted as an effective therapy for T2DM because 
they have the potential to reduce hyperglycemic by stimulating insulin secretion 
whilst maintaining the β-cell mass (Xu et al., 1999). The data generated in our 
studies suggest that OSA® may act in a similar fashion. Thus, OSA® significantly 
reduced cytokine-induced caspase-3/7 levels in a β-cell line and primary mouse 
islets, consistent with a protective effect against cell loss via apoptosis. This effect 
was further emphasized by the data from the microarray analysis of OSA® and/or 
cytokine treated islets. Cytokines, as expected, elevated caspase-3 mRNA levels. 
Cytokines-treatment was associated with reduced expression of key genes involved 
cell survival and defenses, including AKT and MnSOD. OSA® partially reversed the 
effects of cytokines in mouse islets by reducing the levels of both caspase-3 mRNA 
and protein. In addition, OSA®-treatment of mouse islets in the presence of 
cytokines induced an elevation in some free radical scavengers, including MnSOD, 
suggesting that OSA® may have anti-oxidant activities in β-cells. Our enrichment 
analysis of the microarray data to identify pathways that were influenced by OSA® 
demonstrated that PI3K/AKT pathway may mediate some of the anti-apoptotic 
effects of OSA®. These studies have identified another potentially important 
mechanism through which OSA® may be an effective therapy for T2DM, and the 
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cytoprotective activities of OSA® in addition to its insulin secretagogue activity 
may allow OSA® to be used as an alternative therapy for T2DM. 
8.3.6 Improvement of glycemia in vivo 
Proving the efficacy of a potential antidiabetic drug in animal model of DM and in 
human subjects is a prequisite to use the drug therapeutically. In a small cohort 
study, administering OSA® (1 g/day) for 60 days to patients with T2DM 
significantly improved blood glucose levels pre- and post-prandially. Fasting and 
post-prandial blood glucose concentrations almost returned to normal levels after 
OSA® treatment, with no changes in either body weight or post-prandial glucose 
excursion but with elevations in plasma insulin and C-peptide levels indicating that 
improvement in glycemia by OSA® was not secondary to changes in either glucose 
absorption of food intake but rather secondary to a direct effect of OSA® on β-cells. 
These observations strongly support the use of OSA® as a β-cell-directed therapy 
for T2DM acting as an insulin-releasing agent. 
In our animal study, a single dose of OSA® (500 mg/kg) to ob/ob mice, a T2DM 
model characterized by hyperglycemia, dramatically attenuated the glucose 
intolerance status of these animals during IP glucose tolerance tests. This effect of 
OSA® was not associated with any reduction in glucose absorption or with 
improvement in insulin resistance, again supporting a direct effect of OSA® on β-
cells. The beneficial effects of OSA® seen in our animal and human studies were in 
agreement with the reported antihyperglycemic actions seen with other GS 
extracts. 
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Similar to the effects of OSA®  in our  in vivo studies , our colleagues have reported 
that aqueous CP extracts significantly reduced blood glucose levels and increased 
plasma insulin levels in STZ-treated hyperglycemic rats, an effect which was 
postulated to be due in part to a direct effect on β-cells. 
8.4 Conclusion 
The work described in this thesis highlights the potential importance of plant-based 
remedies in the treatment of T2MD. Certain screening criteria and characteristics 
were devised and applied to identify potential therapeutic agents of plant origin. To 
validate the screening process, two aqueous plant extracts, OSA® and CP, were 
studied using a series of functional endpoints to assess their potential usefulness as 
antidiabetic agents. When the profiles of both extracts were compared, they showed 
distinct characteristics from each other. The GS extract, OSA®, fulfilled almost all 
the criteria chosen for an effective antidiabetic agent,  being an effective insulin 
secretagogue at non-toxic concentrations; inducing a simultaneous increase in 
insulin gene transcription to avoid β-cell exhaustion; having protective effects 
against apoptotic stimuli; being effective at lowering blood glucose in vivo; and 
being effective when delivered by the enteral route. In contrast, the CP extract was 
much less attractive as an antidiabetic agent. Although it was an insulin 
secretagogue, and non toxic, the CP extract would be therapeutically ineffective 
because it only caused a transient increase insulin secretion and was only effective 
under normoglycemic, but not hyperglycemic, conditions. These characteristics 
make it unsuitable for further functional studies as a therapeutic agent for T2DM.    
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In conclusion, these studies have highlighted the therapeutic potential of OSA®, and 
perhaps other GS extracts, as a low cost and readily available alternative therapy for 
the treatment of T2DM. 
8.5 Future work 
The work in this thesis is not yet complete unless the following is considered in 
future projects: 
 OSA® is an alcoholic extract of a mixture of compounds and for OSA® 
to be used clinically it is required to fractionate and purify OSA® to 
isolate and identify the most active ingredient(s) using high 
performance liquid chromorography (HPLC) and mass 
chromotography (MS) techniques. 
 Previous reports showed that crude or low molecular weight GS 
extracts reduced intestinal glucose absoption so the effect of OSA® 
on glucose absorption should also be investigated using in situ gut 
perifusion.   
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Eleven patients (7 female, 4 male) were recruited and consented for an in vivo study 
of the effects of OSA® administration on blood glucose and insulin levels.  The 
mean age of the cohort was 50.1±3 years (female: 50.7±4; male: 49±5, p>0.2) with a 
range from 36 to 70 years. The mean body weight at the outset of the trial was 
58.7±7.6 kg (female: 57.7±3.0; male: 60.5±2.8, p>0.2) with a range from 45 to 70 kg.  
Patients were recruited, following local ethical approval, from Burdwan Medical 
College clinic, West Bengal, and were either newly diagnosed with T2DM, or had 
previously been treated with standard pharmacological regimens. Exclusion criteria 
were pregnancy, pre-existing heart disease, hypertension or respiratory disorders, 
and failure of compliance with the protocol. This study was performed by C.R. 
Maity, S.K. Chatterjee, N. Koley, T. Biswas and  A.K. Chatterji.  
Treatment and analysis 
OSA® was administered orally in a capsule form at a dose of 500mg (2x250mg 
capsules) two times each day before food intake for 60 days, giving a total daily 
dose of 1g OSA®. Blood samples were taken at the start of the trial (day 0) and at 
the completion of the trial (day 60), and body weight was recorded at the start and 
completion of the trial. Blood glucose was estimated by a colorimetric glucose-
oxidase method (Middleton and Griffiths, 1957) and insulin and C-peptide were 
measured in serum samples by radioimmunoassay (RIA) (Claudio and Lagua, 
1995). 
Statistical analysis 
Data are represented as mean ± SEM unless otherwise stated. Differences between 
treatment groups were assessed using analysis of variance (ANOVA) and 
Bonferroni’s T test for multiple comparisons or Student’s paired T test (two tailed), 
as appropriate. Differences between treatment groups were considered significant 
when p< 0.05. 
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Effect of chronic OSA® administration in humans with T2DM  
Daily oral administration of OSA® for 60 days produced significant improvements 
in glycemic control, as shown in Figure 1. Thus, in 10/11 patients OSA® treatment 
was associated with a reduction in fasting blood glucose levels (Figure 1), with a 
mean reduction from 162±23 to 119±17 mg/dl (p<0.005). Post-prandial blood 
glucose levels (Figure 2) also showed significant reductions in 10/11 patients, with 
a reduction from 291±10 to 236±30 mg/dl (p<0.02). OSA® treatment had no 
significant effect on the extent of the post-prandial excursion in plasma glucose 
(day 0, 132±10 mg/dl; day 60, 117±26 mg/dl, p>0.2), nor on body weight over the 
60 day period of the trial (day 0, 58.7±7.6 kg; day 60, 53.9±7.3 kg, p>0.2). One 
patient showed no reduction in either fasting or post-prandial blood glucose levels 
and no change in body weight during the treatment period. 
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The improvements in glycemic control in response to OSA® treatment were 
associated with increased circulating levels of insulin and/or C-peptide in all 
patients, as shown in Figure 3 and 4. Thus 60 days treatment with OSA® induced a 
mean increase in serum insulin (Figure 3) from 24±9 to 32±6 μU/ml (p<0.001), 
with a corresponding increase in serum C-peptide (Figure 4) from 298±42 to 
447±48 pmol/l (p<0.05).  
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Mouse preproinsulin (insulin I & II) 
Insulin I (Ins I)  Gene ID: 16333  mRNA accession #: NM_008386   
Insulin II (Ins II)  Gene ID: 16334  mRNA accession #: NM_008387   
Product size: 125bp 
Forward primer: 5’-CCACCCAGGCTTTTGTCA-3’       
Reverse primer: 5’- TTGTGGGTCCTCCACTTCA-3’ 
Assay conditions:   Activation: 95C° for 10mins 
Cycling:  (melting 95C° for 10 sec; annealing 58C° for 10 
sec; extension 72C° for 10 sec; fluorescence measurement x 40) 
Melt:  65-95C° in 1C° increments 





Marker: PBSII + SK/Hpall (40 ng/µl) 
Standard series: from purified PCR product Linear regression of standard 












Copy number: 108-101 
Slope: -3.02, Efficiency: 2.1 
Islets Marker NC -RT 
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Mouse actin (Actb) 
Gene ID: 11461  mRNA accession #: NM_007393  Product size: 285bp 
  
Forward primer: 5’- ATGAAGTGTGACGTTGACATCCGT-3’  
Reverse primer: 5’- CCTAGAAGCATTTGCGGTGCACGATG-3’ 
 
Assay conditions:   Activation: 95C° for 10mins 
Cycling:  (melting 95C° for 10 sec; annealing 58C° for 10 
sec; extension 72C° for 10 sec; fluorescence measurement x 36) 
Melt:  65-95C° in 1C° increments 






Marker: PBSII + SK/Hpall (40 ng/µl) 
Standard series: from purified PCR product Linear regression of standard 
Series & assay efficiency
NC 
 1       2         3         4 
Copy number: 108-101 
Samples 
NC 
Slope: -3.3, Efficiency: 2.0 
Islets Marker NC -RT 
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